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ABSTRACT 
Blood transfusions are aimed at increasing the cell count to a physiological 
level, in practice to prevent anaemia and to maintain haemostasis in the 
case of red blood cells and platelets, respectively. Besides participating in 
haemostasis, red blood cells and especially platelets are active contributors 
to immunology, and using the powerful arsenal of secreted factors, 
platelets can rapidly influence their surroundings. Many of these functions 
involve extracellular vesicles (EVs), lipid bilayered nanoparticles secreted 
by these cells. In addition to the blood cells, the transfused blood products 
also contain the EVs. 
Currently, EVs are associated with multiple physiological and 
pathological conditions, but further studies to determine the exact EV-
related mechanisms are needed. One major limitation in the current EV 
research is the lack of standardisation and comparability in the diverse 
technologies used to assess EVs. To directly address the repeatability and 
transparency of EV measurements, a biological reference material for EV 
studies compatible with multiple quantification and characterisation 
techniques was developed. This product development project involved an 
extensive literature search, a questionnaire sent to 50 laboratories 
working with EVs, the optimisation of candidate reference material 
production and the characterisation of the said reference material. The 
final reference material chosen in the study, nanoerythrosomes (NanoE), 
were produced by disrupting red blood cells into nanoparticles, which had 
similar physicochemical properties to naturally secreted red blood cell-
derived EVs. The production and distribution of reference material with 
EV-like properties is of paramount importance as the incorporation of 
reference material into EV research would facilitate the inter-laboratory 
comparison of results and even benefit the development of technology. 
As part of the assessment of temporal secretion of EVs in platelet 
concentrate, the potential of EVs as a novel marker for platelet activation 
was evaluated in ageing platelet concentrates. Measuring the EV 
concentration was as sensitive as a marker for platelet activation as the 
previously established platelet activation markers, CD62P exposure of 
platelet surface and the concentration of soluble glycoprotein V in the 
platelet concentrates, when the time-dependent activation of platelets was 
determined. EV concentration also revealed differential activation of 
platelets depending on the storage solution of the platelet concentrates. 
Next, in addition to quantitative differences, compositional differences 
of EVs in platelet concentrates were examined by exploring one 
fundamental aspect of EV-mediated intercellular signalling, the lipidome. 
Platelet-derived EVs were shown to contain an enriched 
glycerophospholipid profile compared to platelets, a variety of pathway 
vii 
 
markers of enzymatically modified fatty acids, and their bioactive forms, 
lipid mediators. Besides transporting phospholipids, pathway markers, 
and lipid mediators to recipient cells, EVs were shown to contain the 
required enzymatic attributes for the production of potent bioactive lipid 
mediators, pivotal for the active role of EVs in intercellular messaging. 
To conclude, this study reports a production method for mass-
producible and widely applicable reference material with EV-like 
properties for EV studies, a critical element of transparent and comparable 
EV research. Secondly, the examination of temporal secretion of platelet 
concentrate EVs demonstrates the value of EVs as a sensitive indicator of 
platelet activation. Finally, the EVs were shown to be a significant 
contributor to the lipid-mediated signalling of platelets. 
NanoE and EVs of blood products are in a crucial position in unravelling 
the EV-mediated cellular functions, as they provide tools for improved, 
detailed research. Moreover, these nanoparticles have wide theranostic 
applicability, therefore they must not be considered mere platelet dust, as 
platelet-derived EVs were designated previously, but rather as the hidden 
pearls of blood products. 
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1 BACKGROUND 
1.1 FROM DONATED BLOOD TO TRANSFUSABLE 
PRODUCTS 
Transfusions of different blood components are carefully premeditated life-
saving medical procedures. The main reason to transfuse red blood cells 
(RBCs) is to maintain sufficient oxygen supply to tissues, in practice to 
treat the loss of iron and RBCs, a status clinically titled anaemia [1]. 
Platelets or plasma are given to patients with problems in bleeding, 
typically caused by decreased platelet count or functionality, for instance 
in the case of cancer, where chemotherapy has eradicated platelets [2,3].  
In Finland, three products, RBC concentrate, platelet concentrate, and 
plasma, can be prepared from a single unit of whole blood if the blood is 
processed within 24 hours of the blood donation (Fig. 1). For the donated 
whole blood, the first step is cell separation, where RBCs, platelets and 
leukocytes, and plasma are separated from each other in a bulk manner, 
resulting in some residual plasma contamination in cell fractions. After 
cell separation, the RBCs undergo leukoreduction, a process of removing 
the majority of residual leukocytes with filtration, and are then combined 
with a buffer solution containing nutrients and electrolytes to extend the 
functionality of RBCs [4]. After preparation, the RBC concentrates are 
stored at +4 °C and are transfusable for 35 days [5] counting from the blood 
donation. 
After removal of RBCs, the remaining cell fraction called the buffy coat 
contains some residual plasma, most of the leukocytes, and platelets. As 
platelets are activated during the cell separation, buffy coats from 
individual donors are maintained at room temperature for a minimum of 
two hours before further processing to platelet concentrates to prevent the 
formation of platelet aggregates. The majority of the platelet concentrates 
in Finland are produced by combining the buffy coats of four ABO RhD-
matched donors, after which the platelets in the buffy coat pool are isolated 
in a process also involving leukoreduction. Similarly to the RBC 
concentrates, platelet additive solution (PAS) is added to prevent platelet 
activation and to extend the platelet functionality [6]. After preparation, 
the platelet concentrates are stored at +25 °C under constant horizontal 
agitation and are transfusable for 5 days counting from the blood donation 
[7]. 
In addition to platelets and RBCs, plasma is separated and delivered to 
be processed into plasma-based medicinal products. The blood-cell derived 
extracellular vesicles (EVs) present in plasma are major contributors to 
the coagulation capacity of the transfused fresh frozen plasma [8], and on 
the other hand, they may explain the adverse transfusion reactions (ATR) 
Background 
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of plasma [9]. For details, see 1.2.1 The significance of red blood cell and 
platelet-derived extracellular vesicles. 
 
Figure 1: The simplified process of blood product preparation from whole blood at the 
Finnish Red Cross Blood Service.  
Background 
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1.1.1 RED BLOOD CELLS, DEDICATED SERVANTS OF GAS 
EXCHANGE 
 
The blood circulation is an extremely efficient logistics system conveying 
oxygen, nutrients, waste products and heat, in addition to maintaining the 
intact blood circulation system and immunological defence system for the 
whole organism. All these functions are sustained by blood, which is a 
complex body fluid composed of plasma and blood cells circulating in the 
vasculature. Plasma accounts for 55% of the blood volume and, besides the 
main component, water, plasma is a rich source of lipids, proteins, ions, 
nutrients, and dissolved gases [10–12]. The remaining 45% of blood volume 
consists of blood cells, namely RBCs, platelets, and white blood cells, with 
a distribution of 94.2%, 5.5%, and 0.2%, respectively [10]. 
RBCs are anucleated cells with a diameter of 7 µm and a typical lifespan 
of 100-120 days in circulation [13]. The production of RBCs, erythropoiesis, 
is induced by erythropoietin secreted from the liver or kidney as a result 
of low oxygen levels in blood [14]. Erythropoiesis initiates from the 
multipotent hematopoietic stem cells in the bone marrow, and during the 
development of the RBC precursors, the cells are saturated with 
haemoglobin crucial for the oxygen transportation [15]. One of the final 
steps of the RBC maturation process involves the expulsion of cellular 
organelles and nucleus, explained either as an effort to maximise their 
haemoglobin transporting capacity [16] or to minimise their size to enable 
them to squeeze through small capillaries [17,18].  
As structural features indicate, the central task of RBCs is the gas 
exchange, where RBCs bind oxygen to the iron in haemoglobin molecules 
and transport the oxygen to tissues. Conversely, RBCs transport 
haemoglobin-bound carbon dioxide from tissues to the lungs to be exhaled. 
Carbon dioxide is also transported dissolved in solution or buffered with 
water as carbonic acid, depending on factors such as oxygen partial 
pressure and pH [19]. Besides maintaining tissues oxygenated, the gas 
exchange also retains the pH of blood and tissues on the desired level 
[20,21]. 
For long, RBCs were considered to be functionally simple cells. 
However, with recent studies the current understanding of RBCs is 
changing. RBCs can influence the haemodynamics by secreting vasoactive 
factors and influencing the rheological properties of blood [20]. RBCs also 
contribute to nitric oxide metabolism and redox regulation [20], and more 
recently, the RBCs of human blood were also recognised as modulators of 
innate immunity, similarly to their counterparts in evolutionarily less 
developed species [22].   
Background 
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1.1.2 PLATELETS, MORE THAN HAEMOSTASIS 
 
Similarly to the RBCs, platelets are produced from common myeloid 
progenitor cells derived from pluripotent hematopoietic stem cells. 
Although platelets and RBCs are both anucleated cells, the maturation 
processes of these cells are very different. Whereas RBC precursors 
actively remove their nucleus and other organelles, platelets have never 
contained a nucleus, as the final step of the thrombopoietin-mediated 
platelet production is the fragmentation of platelets from megakaryocytes 
(reviewed in [23]). Nevertheless, platelets have a limited capability to 
synthesise proteins de novo with their specialized translation apparatus 
[24,25]. Platelets have a diameter of 2-3 µm and a lifetime of up to 10 days 
in the human circulation [26].  
In an intact vasculature, blood is actively maintained as a fluid. When 
the endothelial layer of vasculature is ruptured, procoagulant stimuli 
become exposed, initiating a sequence of cellular and enzymatic actions, 
platelet adhesion and aggregation and the activation of the coagulation 
cascade, which are the essential parts of haemostasis to minimise blood 
loss. Under pathological conditions, these haemostatic processes are called 
thrombosis. Haemostasis, the best-established functional role for platelets, 
consists of primary haemostasis, secondary haemostasis, and fibrinolysis. 
The initial responses to wounds, damaged vasculature, involve the 
constriction of the blood vessel mediated by the underlying smooth muscle 
cells, vasoconstriction [27], and the coverage of the damaged site by the 
incoming (circulating) platelets that adhere and subsequently aggregate, 
forming a temporary plug. To briefly summarise the molecular process, 
platelets become tethered to the immobilised von Willebrand factor (vWf) 
with a complex consisting of glycoprotein (GP) Ib (CD42), GPV, and GPIX 
located on the platelet surface. While the vWf-GPIb-V-IX interactions are 
not stable, platelet adhesion to the ruptured vessel site is then further 
stabilised by platelet interaction with the subendothelial collagen e.g., 
through GPIaIIa(CD49c/CD29)-collagen interactions, and GPVI-collagen 
mediated platelet activation, ultimately resulting in the activation of 
GPIIb/IIIa (or the platelet integrin CD41/CD61), which is the critical 
mediator of platelet aggregate i.e., the thrombus formation. The activation 
of platelets by collagen has several consequences: Firstly, the platelet 
shape changes from discoid to spherical with extensions (pseudopods), 
which facilitates the platelet spreading to form a monolayer plug to 
prevent bleeding at the damaged site. Morphological changes are 
paralleled with further platelet activation, especially via GPVI, resulting 
in the procoagulant transformation of platelets, where the phospholipid 
membrane is reorganised leading to the loss of the lipid asymmetry at the 
platelet plasma membrane and the exposure of negatively charged 
glycerophospholipids (GPL) phosphatidylserine (PS) and 
phosphatidylethanolamine (PE). This facilitates the assembly of 
Background 
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coagulation complexes producing thrombin. Secondly, platelet activation 
also results in the secretion of EVs exposing PS and PE that further 
promote coagulation by facilitating the thrombin production similarly to 
the platelet membranes [28]. Thirdly, α-granules rich in e.g., growth 
factors, haemostatic proteins, and adhesive proteins [29] stored in 
platelets fuse with the plasma membrane, causing stabilisation of the 
interactions between platelets already present at the wound site. As a 
result of α-granule fusion, platelets expose P-selectin (CD62P), a common 
marker of platelet activation [30]. The formation of a platelet monolayer 
creates the basis for the secondary haemostasis, the formation of a more 
stable clot, by secreting activating factors and by providing a contact 
surface for the additional platelets to aggregate at the wound site.  
The secondary haemostasis is largely initiated by tissue factor (TF), 
which is mainly exposed to blood from the injury site, but EVs also 
contribute to the total TF activity by facilitating the production of bioactive 
TF [31]. Also, the role of TF in platelets is controversial, as normal 
platelets are not considered to express TF [32], yet TF is still found in 
platelets, possibly due to the fusion of monocyte or cancer EVs [33,34] or 
an inducible pool of TF messenger ribonucleic acid (RNA) [35], which also 
explains the dissemination of TF with platelet-derived EVs [36]. TF 
activates the more rapid extrinsic pathway of coagulation, resulting in the 
production of insoluble fibrin strands from fibrinogen and in the promotion 
of further thrombin generation that further activates platelets, thereby 
creating an activatory loop. Thrombin-related activation of platelets leads 
to the proteolytic cleaving of 69 kDa soluble part of GPV (a prerequisite for 
the formation of the GPIb-V-IX-complex) [37], which has also been used as 
a marker of platelet activation [38]. Ultimately, fibrin together with the 
activated platelets forms a tight clot, sealing the wound site. The final part 
of haemostasis, fibrinolysis, is the carefully regulated disassembly of the 
fibrin network mediated by plasmin derived from circulating plasminogen 
[39], which enables the tissue remodelling and ultimately wound healing. 
[40] 
The given description of haemostasis above is an oversimplification of 
the intricate process, as for instance the role of platelets in haemostasis is 
more complex. Two distinct platelet populations, procoagulant and 
aggregatory platelets, both contributing differentially to haemostasis, 
exist. The formation of platelets with the procoagulant phenotype is 
thought to require the exposure to collagen (reviewed in [41]), but recent 
evidence also suggests that in trauma patients, the exposure to histones 
induces a platelet phenotype switch towards procoagulant platelet 
phenotype [42]. The common denominator for both signalling routes is the 
elevated cytosolic calcium concentration that will, besides the 
procoagulant response, activate calpain responsible of the procoagulant 
transformation of platelets. Procoagulant platelets are characterised by 
the morphological change called “ballooning”, PS exposure, inactivated 
Background 
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GPIIb/IIIa, and coagulation factor binding [43,44]. Whilst EVs may be 
formed from both types of platelets, especially the changes taking place in 
the procoagulant platelets are critical for EV formation, which are also 
thought to function as a bridge towards inflammation [42]. Haemostasis is 
a carefully controlled sequence of events, where the sum of activating and 
inhibiting signals determines platelet activation, coagulation, and 
fibrinolysis, not forgetting cellular interplay. Thus, opposing signals can 
be secreted even from the same cell type, as e.g., endothelial cells secrete 
TF, but also TF pathway inhibitor, a protein with extensive anticoagulant 
effects [45] and protein C, which inactivates the components of thrombin-
producing complexes and promotes fibrinolysis [46]. However, platelets are 
in a pivotal role in haemostasis, as besides physically forming the clot, they 
are the target for the majority of the signalling molecules and actively 
secrete factors that promote and moderate haemostasis. Platelets produce 
e.g. adenosine diphosphate and thromboxane (Tx)A2, which further 
activate platelets to form a more stable clot and liberate coagulation factors 
from the secretory granules (e.g. factor V and fibrinogen), but also promote 
haemostasis-limiting effects by liberating e.g., TF pathway inhibitor and 
activating protein C [47]. Platelets also contribute to fibrinolysis in 
multiple ways [48–50]. To conclude, as both procoagulative and 
anticoagulative or profibrinolytic and anti-fibrinolytic features are present 
in platelets, the role of platelets in haemostasis is dependent on multiple 
regulating signals, a homeostatic balance, influencing several aspects of 
platelet functionality.  
Platelets also maintain vascular integrity during inflammation [51] and 
facilitate the development and remodelling of the vasculature [52] and 
lymph system [53]. A growing amount of evidence indicates that besides 
being crucial mediators of haemostasis, platelets should be defined at least 
as an extension to the immune system, if not as actual immune cells. The 
active participation of platelets in immune processes is indicated by e.g., 
the expression of functional Toll-like receptors [54,55] capable of pathogen 
detection and secretion of factors contributing to antimicrobial activity, 
inflammation, and tissue healing [56–58]. Platelets also interact with e.g., 
monocytes, macrophages, T cells, neutrophils, and natural killer cells, [59–
63]. Of these, inflammation is a particularly interesting aspect of platelet 
functionality: platelets can directly interact with leukocytes by e.g., 
facilitating neutrophil migration and neutrophil extracellular trap 
formation [62,64], but platelets also secrete cytokines that attract 
leukocytes and immune mediators such as complement factors and 
immunoglobulins [65]. Furthermore, platelets secrete bioactive lipid 
mediators (LM) with either an inflammation-promoting or moderating 
effect [66]. For details, see 1.3 Membrane lipid signalling in platelets. If 
platelet functionality was limited to haemostasis, having such diversity in 
the resources for interaction with various types of cells would not be 
necessary. Therefore, the view of platelets as simple contributors to 
Background 
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haemostasis has been shattered and replaced with an image of 
multifunctional cells contributing to e.g., inflammation regulation, host 
defence, autoimmune diseases, tumour biology, and even neurological 
disorders [67–72]. The highly versatile functions of platelets are relevant 
in blood transfusions, as the transfused blood products may cause ATRs 
ranging in the severity from febrile nonhaemolytic transfusion reactions to 
life-threatening transfusion-related acute lung injury and anaphylactic 
shock [73]. Compared to RBC transfusions, platelet transfusions have a 
higher rate of ATRs [74], underscoring the role of platelets as important 
mediators of immune reactions. 
To better understand the platelet functions in haemostasis, immunity 
and inflammation, it is crucial that the highly versatile mechanisms of 
platelets are determined. Although the role of platelet-derived EVs as 
facilitators of blood coagulation is well established, the fundamental 
function of EVs, intercellular communication, might explain at least partly 
the “non-classical roles” of platelets, such as vasculature maintenance, 
inflammation and infections [75], since platelet-derived EVs have been 
shown to contain nucleic acids [76], proteins [77], and lipid signalling 
components [78] that enable rapid effects on surrounding cells.  
Background 
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1.2 EXTRACELLULAR VESICLES 
The presence of EVs, “an additional thromboplastic fraction” was first 
demonstrated from blood plasma [79], and the procoagulant factor was 
later shown to originate from platelets as “platelet dust” [80]. As 
exemplified already by the early steps of EV research, the gradual 
discovery of EVs with different origins or functions has resulted in diverse 
nomenclature of EVs [81,82], e.g., outer membrane vesicles (EVs from 
Gram-negative bacteria), prostasomes (EVs from prostate gland epithelial 
cell), or tolerosomes (EVs from intestinal epithelial cell), to mention a few. 
The discrepancy in nomenclature has been addressed by the International 
Society of Extracellular Vesicles (ISEV, established 2011), and currently, 
the common term EV is suggested for “particles naturally released from 
the cell that are delimited by a lipid bilayer and cannot replicate, i.e., do 
not contain a functional nucleus”, as ISEV defines EVs [83].  
EVs, the fluid-filled lipid bilayer encapsulated nanosized particles, are 
secreted by most cells from prokaryotes to eukaryotes (extensively 
reviewed in [84,85]). Multiple ways to categorise EVs exist, and the most 
common approach is based on their formation route: EVs of eukaryotic cells 
are classified as exosomes secreted from cells via endosomal route [86], 
microvesicles budding directly from plasma membranes [87], or apoptotic 
bodies produced by multiple mechanisms, including direct budding and 
endosomal route, but having the defining characteristic of being derived 
from an apoptotic cell source [88]. 
In terms of particle size, the majority of the EV population consists of 
particles < 300 nm, consistent with the power-law function [89], but 
exosomes, microvesicles, and apoptotic bodies cannot be separated purely 
based on particle size. Exosomes are considered to be 30-120 nm in 
diameter [90], and microvesicles 50 to 1000 nm [84]. Apoptotic bodies have 
a wider size distribution as first demonstrated by Kerr and colleagues [91], 
and more recently apoptotic vesicles with a diameter of 40 nm have been 
reported [88]. 
Although there are no unique EV markers as such, because of the 
different biogenesis routes, the two most studied EV subpopulations, 
exosomes and microvesicles, have been thought to be enriched in certain 
molecular markers, which is considered as the basis for their classification. 
For example, exosomes are thought to be enriched in cell surface markers 
tetraspanin CD9, CD63, and CD81, and contain tumour susceptibility gene 
101, whereas microvesicles contain cell organelle and surface markers 
from the cell of origin [84,85,90]. Despite the numerous elaborate studies 
reporting EV subpopulation-specific molecular markers, contradictory 
evidence can be readily found, demonstrating that not all exosomes contain 
“traditional exosome markers”, and on the other hand, EVs with the 
molecular characteristics of exosomes have been shown to bud directly 
from the plasma membrane of cells [92–97]. Platelet-derived EVs as a 
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whole make an important exception to these generalisations, as for 
instance CD9 is readily expressed membrane protein in platelets [98] and 
CD63 is an established degranulation marker of platelets [99], resulting in 
their expression in both exosomes and microvesicles derived from 
platelets. 
The reported density of the EV subpopulations vary from 1.01 to 1.30 
g/cm3 [100] and detailed analyses of EV populations with different 
densities have demonstrated that the density variation is due to the 
different molecular composition of EV populations [90,101–103]. Still, the 
natural EV sample cannot be separated to subpopulations in one gradient, 
as exosomes and microvesicles have been shown to have similar densities 
[95]. 
1.2.1 THE SIGNIFICANCE OF RED BLOOD CELL AND PLATELET-
DERIVED EXTRACELLULAR VESICLES 
 
Blood plasma is an especially rich source of EVs due to a high EV content 
and the presence of EVs from blood cells, along with e.g., cancer- and 
neural-derived EVs [104–106], as illustrated in Figure 2. The majority of 
plasma EVs are from RBCs and platelets, both cells contributing 
approximately 25% of whole plasma EVs, depending on the detection 
method [104,107,108]. From the historical perspective, the EVs from 
platelets and the RBC maturation process represent the epitome of 
biogenesis of microvesicles [80] and exosomes [109,110], respectively. 
 
Figure 2: A schematic presentation of the extracellular vesicle (EV) diversity within blood 
plasma illustrating also the formation route of microvesicles and exosomes. Figure 
published in modified form in [111]. 
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The diversity seen in the functional roles of RBCs and platelets can be 
extrapolated to their EVs: RBCs are robust cells refined to maintain the 
gas exchange, and in physiological context, RBC EVs have been shown to 
enable the optimal RBC functionality in different ways. Besides 
maturation from reticulocytes to mature RBCs, RBCs have been reported 
to increase their longevity via EV-mediated liberation of unwanted 
molecular content [112]. Furthermore, RBC EVs transport haemoglobin 
and haem between RBCs and target cells [113]. The role of RBC EVs in 
haemostasis is also recognised [114,115] and one of the mechanisms shown 
involves their exposure of von Willebrand factor [116]. In stored RBC 
concentrates, EVs are partially responsible for adverse proinflammatory 
and procoagulant reactions [117,118]. Also, RBC EVs have been shown to 
mediate enhanced coagulation in patients with sickle cell anaemia [119]. 
In malaria patients, RBC EVs enable the intercellular communication of 
malaria parasites and induce inflammation, which can also influence 
vascular function as infected RBC EVs activate endothelial cells, causing 
cytokine secretion attracting inflammatory cells that further activate 
endothelial cells [120–123].  
Currently, EVs from e.g., RBCs, monocytes, neutrophils, and 
endothelial cells are known to facilitate different phases of the coagulation 
process [114,124], even though this feature was first attributed to platelet-
derived EVs [80]. While the distinct role of negatively charged lipid 
moieties on platelets’ surface and TF in coagulation has long been 
recognised [125], the contribution of EVs has more recently been studied 
in greater detail. Less than 50% of the platelet-derived EVs express PS on 
their outer leaflet of cell membrane [107], which is the main negatively 
charged lipid class responsible for the assembly of coagulation complexes. 
An experiment with platelet-free plasma has shown that PS-exposing EVs 
alone do not initiate coagulation, as also TF is required for the process, and 
PS-exposing EVs promote the process [126]. However, EVs can provide 
both factors. Through the exposure of PS and PE, which can function as 
binding locations for different coagulation factors [127–132], and as 
facilitators of the production of bioactive TF [31], platelet-derived EVs 
have been shown to directly induce thrombin generation [133]. TF-bearing 
EVs, which are detected in different physiological and pathophysiological 
circumstances [34,102,134], such as cancer, can initiate coagulation [33], 
for instance, by fusing into activated platelets. To underline the 
significance of EVs for haemostasis, the lack or deficiency in the 
composition of platelet-derived EVs has been shown to result in bleeding 
disorders, e.g., Scott syndrome and Castaman’s syndrome [135–137], and 
in an experimental murine model, the removal of platelet-derived EVs 
resulted in reduced coagulopathy in mice with a traumatic brain injury 
[138]. Although plasma EVs have fibrinolytic activity, this feature has not 
yet been associated with RBC or platelet-derived EVs and has only been 
linked to leukocyte EVs [139]. 
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Contrary to RBCs, platelets have widely established roles besides 
haemostasis, and EVs are shown to mediate these functions that include, 
but are not limited to, inflammatory or immune-system related functions 
[140,141], showing direct interaction with the cells of innate [142,143] and 
adaptive immunity [144], tissue regeneration [145], and angiogenesis 
[146,147], which can also facilitate cancer progression [148].  
1.2.2 CARGO-BASED SIGNALLING IN EXTRACELLULAR VESICLES 
 
While EVs can be isolated from all body fluids [85], express a vast variation 
in their physicochemical properties [100], and are present in various 
morphologies [107,149], it can be generalised that EVs are an exceptionally 
efficient means of transporting lipids, proteins, nucleic acids, 
carbohydrates, or their metabolites within the vesicles, thanks to their 
stable structure (Fig. 3), not forgetting the cargo carried on the external 
surface of EVs (reviewed in [150]). The molecular cargo includes, but is not 
limited to, growth factors, (anti)thrombotic signals, adhesion molecules, 
apoptotic signals, cytokines, and bioactive lipids (reviewed in [151]). One 
crucial milestone in the EV field was the discovery of EVs’ capability to 
transport RNA, later transcribable to functional proteins in target cells 
[152,153]. Regarding genomic material, the RNA content of EVs has been 
studied more extensively than their DNA content. Extracellular RNA is 
considered to be either EV-associated or present as protein-complexed 
forms, and at least the presence of messenger RNA, long non-coding RNA, 
small non-coding RNA, ribosomal RNA, and microRNA has been 
demonstrated in EVs [154,155]. To summarise the current view, exosomes, 
microvesicles, and apoptotic bodies have been shown to have specific RNA 
and DNA profiles [94,156,157]. EVs can also transfer functional proteins 
to induce bursts of activity locally, for instance, in connection with lipid 
signalling [76,158–162]. As EVs are lipid bilayered particles, lipids are a 
fundamental part of EVs. Besides providing structure, however, lipids as 
signalling molecules have wide downstream effects and lipid signalling can 
be mediated via various mechanisms (see 1.3 Membrane lipid signalling in 
platelets). 
The molecular composition of the EV surface provides the basis for the 
wide range of EV-mediated signalling. As indicated also by the coagulation 
promoting properties, one characteristic component of EVs, the PS-
exposing surface, can directly interact with a variety of cell surface 
proteins, but alternatively it may also require intermediate proteins as 
bridging components for signalling to occur (reviewed in [150]). Besides 
PS-mediated interactions, EVs can adhere to the recipient cells with 
integrins, tetraspanins, proteoglycans, and lectins (reviewed in [163]), and 
via surface receptor-mediated contacts, EVs can act as signalling 
complexes and activate cells. EVs can also interact with cells by bursting 
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their contents to the proximity/into the recipient cell or incorporate e.g., 
lipids, and surface receptors into the plasma membrane of the recipient 
cell by fusing with the cells. Furthermore, EVs can deliver their cargo to 
the cytoplasmic side of cells by penetrating into the recipient cell, or, via 
transcytosis, travel through the cells (Fig. 3).  
 
 
Figure 3: Schematic presentation of the molecular diversity carried by extracellular vesicles 
and the molecular mechanisms for their interaction with cells. 1 = receptor-mediated cell 
stimulation, 2 = delivery of factors to the proximity of / within cells, 3 = incorporation of 
molecules to the plasma membrane of recipient cell, 4 = endocytic, phagocytic, or 
macropinocytic uptake of extracellular vesicles into cell / transcytosis through cell. 
Modified from [164–166], a part of the figure published as a further modified figure in [111]. 
 
With regard to the molecular cargo of EVs, it is debatable whether the 
EV composition is a result of careful processing of EVs or determined by 
pure chance. Although the composition of EVs may be determined to some 
degree by pure chance, results published by various other groups suggest 
that because specific molecular components not required by the cells can 
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be expelled via EVs [109,112,167], and on the other hand, certain desired 
properties can be enriched in the EVs compared to the original cell 
[28,168], the EV composition is a carefully controlled entity. This is 
apparent especially in platelets, in which the composition of secreted EVs 
is activation-dependent: platelets secrete EVs constitutively as a part of 
their normal homeostasis, but when platelets are activated, their EV 
secretion is affected, as the EV number [169,170], composition [169–172], 
and procoagulant activity [173] have been shown to vary according to the 
conditions platelets are exposed to (Fig. 4). However, the mechanisms 
relating to how the EV cargo is regulated, how EVs target cells, how EVs 
are processed in the recipient cells and ultimately, how EVs function in 
health and disease still remain unsolved mysteries of the EV field [174].  
 
Figure 4: Agonist-dependent composition of platelet-derived extracellular vesicles. 
 
Due to their broad molecular range, EVs are considered to be a vital 
part of intercellular communication an extensive spectrum of 
(patho)physiological functions. EVs’ efficiency as molecular messengers 
was underlined by the discovery that EVs also enable interspecies 
communication: the microRNA carried in EVs from nutritional sources 
have been detected in the consumer and even shown to influence the 
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cellular responses of the consumer in animal models, as e.g., ginger EVs 
induce the expression of anti-inflammatory cytokine interleukin-10 in 
macrophages and bamboo microRNA has been detected in the breast milk 
of the giant panda, potentially influencing neuron development of the 
panda cub [175–177]. 
1.2.3 EXTRACELLULAR VESICLE ASSESSMENT 
 
In EV studies, not many established facts have been defined, except for the 
two distinct formation routes of EVs and their remarkable capability to 
transfer various types of molecules. The field is rapidly developing as novel 
technologies emerge, which forces researchers to be alert and constantly 
question the current knowledge. As an example, platelets could be 
classified as megakaryocyte-derived EVs with the current EV definition by 
ISEV. EV assessment in this emerging field is highly method-dependent, 
and as even the current golden standards, e.g., ultracentrifugation in the 
EV isolation, are acknowledged not to serve their purpose properly, 
enormous variance in the methods to isolate, quantify, and characterise 
exist, influencing the reported results [178,179]. To address the variability 
of sample preparation and analysis methods, ISEV has released [180], and 
also updated [83,181], the minimal experimental requirements for EV 
studies to guarantee a certain level of harmonisation in the experimental 
settings and also to increase the transparency and comparability of data. 
The latest requirements are summarised in Table 1. Furthermore, ISEV 
actively participates in the methodological development by publishing 
position papers of current topics in the EV field [182–184]. In addition to 
these milestones, other well-cited reviews [85,185,186], international 
initiatives [187–189], and databases [190–192] have been compiled to 
guide the field and scientists starting their EV careers.  
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Table 1: The latest minimal information for studies of extracellular vesicles for reliable and 
repeatable extracellular vesicle studies. Table modified from [83]. 
Category Recommendation Examples 
EV sample 
preparation 
EV source 
Quantitative description of EV source (cell 
number or volume of body fluid), cell 
culture conditions, anticoagulant 
EV yield 
Quantification of EVs through lipid-, 
protein-, or particle amount and the ratio of 
these to estimate purity the of the sample 
General EV 
characterisation 
One protein from 
class 1, 2, and 3 
 
If EV subpopulations 
are assessed, also 
protein from class 4 
and 5 
Class 1: membrane proteins (tetraspanins) 
Class 2: cytoplasmic proteins capable of 
binding to lipids or proteins in cell 
membrane (TSG101, HSP70) 
Class 3: impurities (negative control: 
lipoproteins, albumin, Tamm-Horsfall 
protein) 
Class 4: proteins (histones, cytochrome C) 
targeting to cellular structures like nucleus, 
mitochondrion, endoplasmic reticulum, 
Golgi apparatus, autophagosome: 
cytoplasm and endosomes excluded 
Class 5: soluble proteins (cytokines, growth 
factors) binding to EV surface receptors or 
demonstration of the presence of 
corresponding receptors 
Single EV 
characterisation 
EV characterisation 
using two 
complementary 
characterisation 
techniques 
Techniques characterising single EVs, e.g., 
atomic force and electron microscopy 
Techniques measuring biophysical 
properties of EVs (size, light scattering, 
fluorescence, chemical composition), e.g., 
nanoparticle tracking analysis, flow 
cytometry, and Raman spectroscopy 
Other 
characterisation 
Cargo localisation 
Determination of protein location within 
EVs, on the EV surface, or outside EVs 
using antibodies or with protease-, 
nuclease-, or detergent treatment 
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1.2.3.1 Isolation of extracellular vesicles 
 
Several aspects have to be considered when choosing the EV isolation 
method, and perhaps the primary deciding factor regarding the EV 
isolation methods is the original sample, more specifically the volume and 
the source of the sample. Several pre-analytical aspects need to be 
considered especially in the case of blood samples [185,193], and getting a 
pure EV sample from cell culture supernatant and blood plasma requires 
different approaches. In addition to the amount of inherent 
contaminations, the starting volume may also dictate what kind of 
isolation methods can be used in the EV purification. Unless EVs are 
produced in bioreactors dedicated to producing vast amounts of EVs [194], 
the use of massive cell cultures consisting of multiple cell culture flasks 
typically results in large starting volumes for EV isolation, which may 
prevent the use of very specific EV isolation methods, and therefore a more 
general EV isolation technique is typically chosen. On the other hand, if 
starting material volume is limited, as it typically is in the case of e.g., 
clinical blood plasma samples, more specific EV isolation approaches can 
be applied, resulting in a very different level of purity of EVs [195], but 
also a lower EV yield [196]. To address the demand for EV isolation 
methods for samples measured in microliters, some of the most common 
isolation methods are also available on the microfluidics platform [197–
201]. 
Besides the limitations set by the sample material, also the down-
stream applications of EV analysis should be considered as they ultimately 
dictate whether the quantity or the specificity of the EV population is more 
important. Typically, it is not feasible to achieve both high quantity and 
specificity unless a substantial amount of time and money is spent on 
sample preparation. For a detailed molecular characterisation of EVs, the 
desired EV sample would ideally contain as little contaminants as possible 
[202]. Especially regarding mass spectrometry, the earlier sample 
requirements were stricter, but as mass spectrometric techniques overall 
have improved, less material is needed for accurate analysis, enabling 
molecular examination of EVs even from scarce sources [202]. If EV 
functionality is assessed by e.g., exposing cells to EVs generated with 
different methods, typically EVs are needed in larger amounts, in which 
case EV sample isolation may be cruder, guaranteeing that the vast 
majority of possible impurities are removed, while as much of the EVs and 
their functionality as possible is retained in the isolation processes [179]. 
The most commonly used EV isolation method is the centrifugation-
based method, which was also the method of choice in the current study. 
In centrifugation-based method different EV subpopulations are typically 
isolated with multiple centrifugation steps using different g-values [203]. 
Several parameters, such as rotor type, centrifugation duration and speed, 
and temperature, influence the particle pelleting [203,204]. Before the 
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ISEV recommendations, various centrifugation protocols were applied to 
EV isolation [205], rendering the comparison of older results especially 
difficult. Differential centrifugation has also been proved to be an 
insufficient method for separating EV subpopulations thoroughly, to cause 
clumping and deformation of EVs [206,207], and also to co-isolate potential 
contaminants to the EV samples [203], which has to be taken into account 
in the consecutive experimental steps. 
To provide a better separation of EV subpopulations, density gradients 
can be applied to ultracentrifugation [90,97,101]. Most commonly 
gradients are prepared with sucrose or iodixanol. As reviewed in [193], 
iodixanol-gradient provides better resolution and is iso-osmotic, inert, 
nontoxic, self-forming, and less viscous, thus requiring shorter 
centrifugation time. With density gradient, the sample particles are 
separated based on their size and density (in top-loaded gradient 
ultracentrifugation) or purely on density (in bottom-loaded gradient 
ultracentrifugation) [193,208,209]. Gradient ultracentrifugation is 
considered to enable EV isolation without contaminant protein aggregates 
and lipoproteins [210] if run for a sufficiently long time to establish 
equilibrium; however, one-step isolation is not sufficient to remove 
lipoproteins [211], as in terms of size (low-density lipoproteins, very low-
density lipoproteins, and chylomicrons) and density (high-density 
lipoproteins), subpopulations of lipoproteins are similar to EVs [212], and 
furthermore, lipoproteins directly associate with EV surface [150,213]. 
EVs can be isolated based on the charge, density, molecular features, or 
size of the particles (Table 2), and along with the centrifugation-based 
methods, other common EV isolation methods include chromatography-, 
filtration-, precipitation-, or immunoaffinity-based methods. Different 
commercial kits, where the exact isolation mechanism is not stated, are 
also available for EV isolation [196,214–216]. 
 
Table 2: Different methods used to isolate extracellular vesicles.  
Isolation criteria Method References 
Charge 
 
Chromatography 
Phase separation 
Precipitation 
[217,218] 
[219] 
[220,221] 
Density Gradient-centrifugation [193,222] 
Molecular features Immunoaffinity [195] 
Size 
Acoustic trapping 
Centrifugation 
Chromatography 
Droplet evaporation 
Field-flow-fractionation 
Ultrafiltration 
[197,223] 
[193,222] 
[224,225] 
[96] 
[226,227] 
[228] 
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To summarise EV isolation, different techniques with their advantages 
and limitations exist (reviewed in detail in [179,193,228–230]), and due to 
the different functioning principles, the isolation technique influences the 
resulting EV population [215,231–233]. Finally, the more the EV sample 
is treated, the bigger the loss of EVs [204,234], and therefore the optimal 
isolation technique or combination of techniques, e.g., size-exclusion 
chromatography together with gradient centrifugation, that may provide 
a clean EV sample without a significant loss or dilution of EVs [225] is 
highly dependent on the starting material and the following down-stream 
analysis of the EV sample. 
1.2.3.2 Quantification and characterisation of extracellular vesicles  
 
Although notable variation exists in the EV isolation methods, even more 
variation in the results is caused by the subsequent analysis of EVs. 
Perhaps the most important factor in EV assessment is accurate 
quantification: regardless of whether the EVs are examined as a cellular 
response to an agonist or subjected to further analyses, accurate 
quantification is an absolute must. Besides meticulous quantification, the 
detailed characterisation of EVs cannot be ignored as it is a prerequisite to 
unravelling the molecular mechanisms and ultimately the biological 
significance of EV-mediated functions. As the EV field is rapidly evolving, 
different techniques are constantly being developed, in addition to the 
currently existing techniques being further refined to better suit the 
analysis of EVs.  
The earliest studies demonstrated the presence of EVs with electron 
microscopy (EM) [79,80]. Compared to light microscopy, where studied 
samples are visualised using visible light and series of lenses, the use of a 
focused beam of accelerated electrons in EM allows the visualisation of 
nanoscale structures [235], including the smallest EVs. Therefore, the 
several different types of EM applications [236] are elementary methods 
even today, as accurate visualisation of EVs is required e.g., to confirm the 
EV isolation process [83]: EM can be used to confirm that the studied 
sample contains EVs and whether contaminants have been co-isolated. 
Additionally, EM also offers a means of characterising EVs, especially 
when using cryo-EM, where the native hydrated state of studied sample 
structures is preserved, since the sample fixing with cryo-immobilisation 
involves sample cooling with liquid ethane, resulting in the vitrification of 
water instead of ice crystal formation. When cryo-EM is combined with 
immunogold labelling, the size, morphology, and phenotype of EVs can be 
analysed in detail [107]. However, EM as a quantification method is being 
replaced by other techniques, mainly due to the laborious protocol involved 
in EM, but also due to inaccuracy, as EV concentration determination is 
affected by the sample preparation e.g., by the variable deposition of EVs 
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on to EM grids [193]. It must also be stressed that from all methods used 
to assess EVs, EM in particular is prone to protocol- and operator-
dependent variation [237]. Initially, the cup-shaped appearance (Fig. 5) 
was thought to be a determining morphological feature of EVs, but 
nowadays the collapsed EVs are known to be artefactual, caused by the 
sample dehydration [186]. 
 
 
Figure 5: Electron micrograph of red blood cell-derived extracellular vesicles, where the 
artefactual cup-shapes are indicated with black arrows. Unpublished figure. 
 
One of the most common methods to quantify and characterise EVs is 
flow cytometry, where the particle detection is based on the detection of 
scattered light or fluorescence. The sample particles carried by the sheath 
fluid are subjected to a laser beam, and the scattered light is collected with 
detectors located in the laser line and perpendicular to the laser line 
(forward scattering light and side scattered light, respectively). If the 
analysed structures are smaller than the wavelength of light, which is the 
case for majority of EV population, they produce more side scattered light. 
Because of this, the cellular analysis using light scatter can be generalised 
so that the forward scattered light corresponds to the size of particles and 
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the side scattered light to the structural complexity (organelles) of the 
sample particles. [238] 
A more detailed characterisation of the molecular composition of the 
sample particles can be achieved by the attachment of fluorescent label to 
lipids, proteins, or RNA. The label is excited with a laser, and the emitted 
light from the label is detected by the optical system of the flow cytometer 
[239]. A clear advantage of flow cytometry in EV characterisation is that it 
is a particle-by-particle analysis as long as the EV sample is prepared in a 
way that prevents swarm detection, the interpretation of multiple small 
EVs as a single EV [240], from occurring. As the hardware and protocols 
develop, more accurate data of EVs can be generated using flow cytometry 
[241,242], resulting in better understanding of EVs and even paradigm 
shift, as demonstrated by the change in the plasma EV composition. 
Previously even 70-90% [243] of the blood EVs were thought to be platelet-
derived purely because the detection limits of first-generation flow 
cytometers tailored for cell analysis enabled only partial detection of the 
EV population [244]. However, with current technologies, the percentage 
has been shown to be significantly lower, approximately 25-40%, 
depending on the detection method [104,107,108]. Besides developing more 
sensitive flow cytometers, also completely new types of flow cytometer 
methods have emerged, combining the advantages of flow cytometer 
sample preparation and assessed particle number with the imaging of 
microscopy that enables, for instance, more detailed investigation of 
particle uptake [245–247]. However, as mentioned previously, any 
labelling-based detection of EVs is cumbersome due to the heterogeneity 
of EVs, physical restrictions regarding antigen expression of EVs [108], 
and micelle or aggregate formation in the case of lipid dyes [242,248]. 
As a clear demand for label-free methods to examine EVs existed, 
dynamic light scattering (DLS) was applied to EV quantification and 
sizing. With DLS, however, the accurate sizing of sample particles can be 
conducted only with samples consisting of monodisperse particles [249], 
and as EV samples are polydisperse, DLS was found to be a suboptimal 
method to analyse natural EV population, and therefore nanoparticle 
tracking analysis (NTA) has largely replaced DLS.  
NTA is currently offered commercially by a few companies [250], and 
the technique is based on sample particle illumination with a laser in a 
measuring chamber, where the number of visible particles in a determined 
dilution is used to calculate the particle concentration in the sample [251]. 
In NTA, the random movement of particles, called Brownian motion, is 
used to deduce the size of the sample particles, as based on Stokes-Einstein 
equation, the Brownian motion and particle size correlate inversely [252]. 
An interesting publication, however, points out, that the protein content of 
EVs might hinder the particle mobility [253]. Furthermore, various 
sources of variability (e.g., type of camera, depth of laser beam, and optical 
alignment) regarding NTA have been identified [254], and one clear 
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limitation of NTA is the rather high detection limit with regard to EVs, 
approximately 70 nm [89]. 
Another method to quantify and size nanoparticles, Tunable resistive 
pulse sensing (TRPS), is also offered commercially by two companies [255]. 
The method is based on Coulter principle, a widely used cell quantification 
technique where sample particles are enumerated and their size is 
determined by detecting a change in the electric current, which is caused 
by the sample particles that move from one electrolyte-filled chamber to 
another via microchannels or pores of the setup. The number of blocks is 
related to the particles passing the pores and in a known volume that can 
be translated into particle concentration. Whereas the concentration is 
determined based on the frequency of the current alterations, the 
magnitude of the resistance in predefined current relates to the size of the 
particle passing the pore [256]. The limitation of TRPS is related to the 
simplicity of the technique: For the particles to be detected, they have to 
pass the pores of the measurement setup. However, sample particle charge 
impact the electrophoretic mobility of the particles and pore passing [257]. 
Additionally, the pores come in predefined sizes, which might prevent 
quantification and characterisation of samples with highly polydisperse 
particles [258]. Upon aging the nanopores also become vulnerable to 
stretching. DLS, NTA, and TRPS are designed for the same task, mainly 
to quantify and determine the size distribution of the sample particles, and 
all three techniques, especially NTA, are widely used in EV studies. 
The molecular composition of EVs can be examined in detail with mass 
spectrometry, where the sample is ionised and typically also fragmented, 
after which the mass-to-charge ratios of fragments are determined and 
used to identify the fragments [259]. The various applications of mass 
spectrometry (reviewed in [259,260]) have been widely applied to examine 
especially the proteome of EVs [95,261,262], but the interest and the 
number of publications regarding EV lipidome [262–264] and metabolome 
[168,194] are constantly growing as EV-mediated signalling is not limited 
only to the protein-based interactions.  
In addition to the described techniques, EVs can be characterised using 
different biochemical analyses, electrochemical sensing, immunoassays, 
Raman spectroscopy, and small-angle X-ray scattering. Techniques that 
can quantify and characterise EVs also include atomic force microscopy 
and interferometric imaging (Table 3). Especially interferometric imaging 
of single particles is an interesting novel development, where the number, 
size, and phenotype of studied EV populations captured to silicon substrate 
using immobilised antibodies can be analysed using digital optical 
detection capable of detecting particles with the diameter of 50 nm [265]. 
Similarly to isolation methods, EVs can also be characterised on 
microfluidics platforms [199,266,267]. 
As a summary, several methods to quantify and characterise EVs exist, 
but the techniques have notable variation, as some are capable of 
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“ensemble” analyses (e.g., mass spectrometry, Raman spectroscopy, DLS) 
whereas others provide “particle-by-particle” analyses (e.g., microscope-
based techniques, flow cytometry, TRPS). Another aspect is the type of 
results the techniques give, which could be classified as “direct 
measurements” (surface marker presence in flow cytometry or diameter 
with TRPS) or “indirect estimates” (diameter estimation in NTA).  
 
Table 3: Techniques used to quantify and characterise extracellular vesicles. Table modified 
from [268]. * = truly quantifying techniques applied for extracellular vesicle quantification. 
 Technique Characterisation References 
C
ha
ra
ct
er
is
in
g 
m
et
ho
ds
 Biochemical analyses Composition [268] 
Electrochemical 
sensing 
Various, mainly 
cargo or surface 
markers 
[269–272] 
Immunoassays Composition [273,274] 
Mass spectrometry Composition [202,275] 
Raman spectroscopy Composition [276] 
Small angle X-ray 
scattering 
Size, structural 
information 
[257] 
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Atomic force 
microscopy* 
Molecule interaction, 
morphology, size, 
surface marker 
[277–279] 
Dynamic light 
scattering* 
Size [249] 
Electron microscopy 
Composition, 
morphology, size 
[236,280] 
Flow cytometry* Composition, size [281] 
Interferometric 
imaging* 
Size, surface 
markers 
[265] 
Nanoparticle tracking 
analysis* 
Size, surface 
marker, zeta 
potential 
[251,254,282] 
Tunable resistive 
pulse sensing* 
Size, zeta potential [257,258,282] 
1.2.4 BEYOND BIOLOGY, TOWARD APPLICATIONS AND 
COMMERCIAL VALUE 
 
The active research to understand the biological significance of EVs, need-
based development and standardisation of EV-based methodology and 
protocols, and substantial efforts to generate EV-based applications have 
resulted in an exponential growth of EV-related publications in recent 
years (Fig. 6). The potential of EVs as tools in therapeutics and diagnostics, 
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with a combined term theranostics [182,283–285], has led to an estimation 
that the market value of EV-related products will reach 2.28 billion USD 
by 2030 with the compound annual growth rate of 18.8% [286]. 
  
Figure 6: Timeline with the number of extracellular vesicle (EV) publications and important 
events of EV field. For further information, see references [79,80,290–
294,109,110,152,153,180,287–289]. Amount of publications confirmed from PubMed on 
3.12.2019. FDA = Food and Drug Administration; ISEV = International Society of 
Extracellular Vesicles; ISO = International Organisation of Standardisation; JEV = Journal 
of Extracellular Vesicles. 
 
Due to their principal role as intercellular messengers and particles 
that are taken up by cells, EVs are also considered to be excellent drug 
carriers. EVs derived from e.g., cell culture supernatants, bovine milk, 
plants, and microbes have been suggested for drug delivery systems [295–
297], but especially RBC EVs have been appraised as mass-producible, 
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safe, and stable candidate for drug delivery vehicle production [298,299]. 
EVs can also function as natural therapeutics due to their specific 
molecular assortment [182]: Ground-breaking work of Kordelas and 
colleagues has demonstrated the value of EVs in the treatment of graft-
versus-host disease [291], and in 2018 Food and Drug Administration 
permitted the initiation of clinical trials of burn wound patient treatment 
with EVs [293].  
EVs are acknowledged as valuable biomarkers, potentially enabling 
earlier diagnosis of e.g., cancer [283,300], and neurological diseases [106] 
through cancer cell-derived EVs and neural EVs, respectively. Also, the 
Food and Drug Administration (US) has recognised the biomarker value of 
EVs, as attested to by the granting of the accelerated review process for an 
EV-based diagnostic application [294]. Increase in the plasma EV 
concentration, and especially platelet-derived EVs, have also been 
suggested to serve as a biomarker for trauma, atherothrombotic disorders, 
autoimmune diseases, and cancer [126,244]. As the composition of platelet-
derived EVs is activation-dependent [169–172], the careful 
characterisation of platelet-derived EVs could result in disease-specific 
molecular biomarkers, which would be a more reliable and repeatable 
basis for diagnosis than EV quantification. 
The first set of minimal experimental requirements in EV studies were 
published only in 2014 [180], three years after ISEV was established, and 
although the lack of standardisation of EV research is a notable issue, 
standardised and certified EV-based diagnostic applications already exist 
[292]. Another aspect concerning especially blood plasma-derived EV 
application in therapeutics is the legislative classification of EVs: while 
Food and Drug Administration considers EVs as biological medicinal 
products, are they regarded as blood products (or as cells and tissues, if 
isolated from other sources), advanced therapy medicinal products, 
“others”, or should they be classified in the yet-to-be-established category 
of EVs [182]? European Medicines Agency has defined EVs from gene-
modified cells as gene therapy, in practice as advanced therapy medicinal 
product, whereas mesenchymal stem cell-derived EVs are not considered 
as advanced therapy medicinal product [301], indicating that the method 
of action is the defining aspect in EV classification.   
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1.3 MEMBRANE LIPID SIGNALLING IN PLATELETS 
Membranes are a fundamental part of every organism since defined 
functional entities such as cells, EVs, and cellular organelles are 
membrane-covered structures [302]. The plasma membrane of the 
mammalian cell consists of phospholipids, cholesterol, and glycolipids, and 
the assembly of lipid bilayer, the central element of plasma membranes, is 
based on hydrophobic interactions: like all lipids, e.g., phospholipids 
consist of nonpolar (hydrophobic) hydrocarbons, typically carbon chain 
attached to a carboxylic acid or fatty acids (FA), and a polar (hydrophilic) 
part, phosphate in the case of phospholipids. The main component of 
plasma membranes in mammalian cells, phospholipids, can be categorised 
as GPLs and sphingolipids, where FAs are linked to (diacyl)glycerol or to 
ceramide, respectively. In addition to the FAs, glycerol or ceramide, and 
phosphate group, phospholipids contain a varying head group, the basis 
for the further classification of phospholipids (Fig. 7A). The main head 
groups of phospholipids are choline, ethanolamine, serine, and myo-
inositol, which correspond in GPLs to head groups of phosphatidylcholine 
(PC), PE, PS, and phosphatidylinositol (PI), respectively (Fig. 7B). In 
mammalian cells, especially PE but also PC can additionally be present as 
plasmalogens, where ether bond to the alkenyl group is present in the sn-
1 position [303]. In contrast to phospholipids, glycolipids consist of 
carbohydrates attached directly to the glycerolipids or sphingolipids, and 
depending on their nonpolar section they are classified as 
glycoglycerolipids or glycosphingolipids, respectively. Glycosphingolipids 
can also be further classified based on their carbohydrate structures. 
Glycolipids account for 2% of mammalian cell plasma membranes and are 
located exclusively at the extracellular surface of plasma membranes, 
mainly at lipid rafts with cholesterol. [304–306] 
Besides providing structure by forming a physical barrier separating 
the cellular contents from their surroundings, lipids offer an evolutionally 
conserved [307], efficient way to preserve energy, due to their high 
reduction state, which can be exploited to power cellular functions when 
required [308]. It is well established that the dietary fats influence the 
cellular lipid membrane composition and functionality [309] and 
furthermore, we have shown that supplementing FAs to human 
mesenchymal stromal cells also influences the lipid composition of EVs 
[310]. 
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Figure 7: [A] General structure of glycerophospholipids where the cleavage sites of 
phospholipase (PL) enzymes are indicated with red, [B] molecular structure of most 
common glycerophospholipid head groups, and [C] the asymmetric lipid membrane of red 
blood cells. Image modified from [260,311]. 
 
Moreover, lipids serve also a vital role in signalling by participating in 
signalling processes via multiple distinct mechanisms. The complexity of 
lipid-mediated signalling can be observed even on the molecular 
interactions on plasma membrane: lipids provide a stable yet dynamic 
environment for other molecules to interact, as demonstrated by the 
presence of carbohydrates, nucleic acids, and proteins on plasma 
membrane [312–314] and the presence of e.g., immunoglobulins, 
coagulation factors, cytokines, and lipoproteins on EV surface [150]. A level 
of complexity is added to this type of participation by lipid rafts consisting 
of (glyco)sphingolipids and cholesterol. These distinctive structural 
microdomains of plasma membrane have been shown to mediate multiple 
different signalling processes, including immunoglobin E signalling and T-
cell receptor signalling (reviewed in [315]). 
Lipids also participate in signalling directly. The asymmetric lipid 
composition of plasma membrane (Fig. 7C) is a carefully controlled entity, 
and the aminophospholipid translocase and phospholipid scramblase-
mediated loss of membrane asymmetry [316], manifested as the exposure 
of PE and especially PS on the extracellular side of cell membrane, is a 
recognised marker of apoptosis, whereas, for platelets, it is a marker of 
cellular activation [317] and a crucial part of haemostasis, as the negative 
charge facilitates the production of thrombin [40]. As a curiosity, the RBC 
membrane is one of the best-characterised membranes [318] due to the 
functional and structural simplicity of RBCs. In platelets, the lipid 
asymmetry is not yet determined to a similar level of detail. 
Lipid signalling can also involve only a certain part of the lipid 
molecule, as secondary messengers can be produced either from the polar 
head group or nonpolar hydrocarbon tails via enzymatic modification [319] 
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or even with spontaneous oxidation processes [320]. Perhaps the best-
known example of the head group-mediated signalling is the PI-signalling 
(reviewed in [321]), which is also an important aspect of exosome secretion: 
PI-signalling is a known regulator of membrane dynamics and vesicular 
transport, and preventing PI-signalling reduces the autophagic 
degradation of multivesicular bodies, possibly due to impaired membrane 
fusion, which results in promoted secretion of exosomes [322].  
Recently, signalling mechanisms involving bioactive metabolites of 
GPL-derived FAs, termed as LMs, have attracted increasing interest due 
to their pivotal role as powerful regulators of inflammation. LMs can 
promote inflammation or have pro-resolving effect, which actively 
dampens the inflammation. Pro-resolving function is a distinct mechanism 
from anti-inflammatory effect: as an example, blocking the neutrophil 
recruitment would be an anti-inflammatory measure, whereas promoting 
macrophage phagocytosis to remove microbes is a pro-resolving measure. 
The functional nature of LMs provides a way to categorise LMs, as they 
are titled proinflammatory LMs (e.g., TxA2) or specialized pro-resolving 
mediators (SPMs, e.g., Resolvins (Rv), Protectins, and Maresins (MaR)), 
and some LMs, such as Prostaglandin (PG)E2, exhibit dual functions [323]. 
Structurally LMs are divided to eicosanoids and docosanoids according to 
the length of the carbon chain (20 or 22 carbons, respectively) of the 
original FA. 
Analogously to EVs, only recent technological advancement has enabled 
an accurate characterisation and assessment of LMs that are bioactive in 
pico to nanomolar concentrations [324]. The novelty of this emerging field 
of studies is underlined by the recent discovery of novel classes of lipid 
mediators [325]. The enzymatic processing of FAs involves a sequence of 
enzymatic steps, initiating from the FA cleavage from the GPL by 
phospholipases (PL) (Fig. 7A). Both the cleaved FA and the participating 
enzymes, which modify the intermediate products (COX, lipoxygenases 
(LOX), and members of cytochrome P450 (CYP) family) influence the 
functions of the produced LM. The diversity is best exemplified with the 
metabolism of arachidonic acid (AA), an FA with a carbon chain consisting 
of 20 carbons and 4 double bonds starting from 6th carbon from the omega 
end, which can serve as a precursor for proinflammatory LMs, SPMs, and 
dual-function LMs (Fig. 8). 
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Figure 8: Simplified representation of lipid mediator production from fatty acids. 
Proinflammatory lipid mediators indicated with red, specialised pro-resolving lipid 
mediators with green, and dual function lipid mediators with teal. For detailed mechanisms 
of lipid mediator production, see [326–330]. COX = Cyclooxygenase, CYP = Cytochrome 
p450, LOX = Lipoxygenase. 
 
LMs have substantial significance in the inflammation, as they have 
been shown to directly exert their proinflammatory or proresolution 
influence on the cells in an inflammatory milieu [331–338]. Currently, the 
role of LMs in several chronic inflammatory diseases, such as rheumatoid 
arthritis, asthma, and atherosclerosis [339] and, on the other hand, the 
survival-promoting effect of SPMs in e.g., lung injury and burn wound 
sepsis with murine model [340] has been well established.  
The diversity of LM signalling can also be seen in platelet function as 
both proinflammatory LMs and SPMs directly influence platelet 
functionality. The most abundant interaction between LMs and platelets 
is the activation-dependent production of AA-derivatives, capable of 
exerting pro- and antithrombotic influence on platelets [341]. For instance, 
TxA2 is a vasoconstrictor and platelet activator [342] with a half-life of 30 
seconds [343]. However, the same AA platelets can also produce LMs with 
opposing effects, such as PGD2 and PGE2. As already stated, the novel 
interesting roles of platelets indicate their active participation in immune 
modulation. Besides propagating platelets’ functions, for instance, the 
secreted TxA2 also activates monocytes and induces T-cell differentiation, 
to mention a few examples of the influences they exert on the surrounding 
cellular milieu. The wide range of effects of TxA2 also partially explain why 
aspirin, a commonly used inhibitor of COX1 producing TxA2 [344], is 
considered as a beneficial treatment in inflammatory and cancer context 
[345]. Aspirin has also been shown to induce SPM production [346].  
Although LM-mediated signalling has not been as extensively studied 
in RBCs as in platelets, curiously a decreased polyunsaturated FA content 
of RBCs has been speculated to associate with Alzheimer’s disease [347]. 
The increased oxidative stress of RBC concentrates, which is related to 
storage time, has also been shown to result in the non-enzymatic 
generation of LMs that influence platelet functionality [348]. 
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2 AIMS OF THE STUDY 
The lack of consistency in EV analysis technologies hinders the comparison 
of EV studies, preventing a detailed understanding of the mechanistic 
aspects of EV functionality, a prerequisite for EV-based theranostic 
applications. To fully unravel the potential of EVs, the conducted research 
should be transparent and traceable, achievable, for instance, with the use 
of widely applied standards. Recognising the significance of EV 
components is crucial, especially with regard to cellular therapy products, 
such as platelet and RBC concentrates, where EVs accumulate in a closed 
system. Besides being indicators of the cellular status and therefore having 
the potential to act as quality control measures, firm evidence exists that 
EVs are major contributors in health and disease. EV-mediated effects also 
involve lipid signalling cascades, which are considered as an especially 
potent immunomodulatory signalling route, but the details of how EVs 
contribute to lipid signalling are still poorly understood. 
  
The overall aim of this study was to improve the comparability of EV 
measurements and to analyse in detail the temporal secretion of EVs and 
accumulation of potent lipid signalling components to EVs in a platelet 
concentrate. 
 
The specific aims of this thesis were 
 
♦ To develop biological reference material compatible with EV 
quantification and characterisation methods based on different 
techniques (Study I) 
 
♦ To evaluate the relationship of platelet activation and platelet-
derived EVs together with sGPV production and CD62P exposure of 
platelets (Study II) 
 
♦ To assess the time-dependent lipidome alteration of platelet 
concentrate-derived EVs (Study III) 
 
♦ To examine the molecular mechanisms of bioactive lipid mediator 
production in platelet concentrate-derived EVs (Study III) 
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3 MATERIALS AND METHODS 
The materials and experimental methods used in this study have been 
described in detail in the original publications (Table 4) and hence only 
brief descriptions of the methods are provided here with references to the 
original publications. 
 
Table 4: Materials and methods used in the thesis project. 
Material or method Study 
Blood products I-III 
Extracellular vesicle isolation I-III 
Reference material production I 
Reference material characterisation I 
Platelet activation assessment II 
Membrane lipid and fatty acid analysis III 
Lipid mediator and pathway marker analysis III 
Flow cytometry I-III 
Nanoparticle tracking analysis I-III 
Western blot III 
Statistical analysis I-III 
3.1 BLOOD PRODUCTS 
The source for nanoparticles in all publications were blood products of the 
Finnish Red Cross Blood Service or Sanquin. In Study I, the 
nanoerythrosomes (NanoE) were prepared from RBCs isolated from RBC 
concentrates and the natural RBC EV population was isolated from the 
respective RBC concentrates produced by Finnish Red Cross Blood Service 
and Sanquin. In Studies II and III, the platelet concentrates produced by 
Finnish Red Cross Blood Service consisted of the platelet pools derived 
from 4 buffy coats of ABO RhD-matched donors. In Study II, the time-
dependent platelet activation and the effect of storage conditions on the 
platelets were assessed by examining platelet concentrates with different 
PAS, the main difference being that PAS-E contains potassium, chloride, 
and phosphate, whereas PAS-B does not (Table 5). In Study III, the 
assessment of lipid signalling in platelets was conducted with platelet 
concentrates with PAS-E.
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Table 5: Compositional differences of platelet additive solution (PAS)-B and PAS-E. Table 
modified from [6]. 
Component (mM) PAS-B PAS-E 
Sodium chloride 116 69 
Sodium acetate  30 30 
Sodium citrate 10 10 
Potassium chloride - 5 
Magnesium chloride - 1.5 
Phosphate - 26 
3.2 EXTRACELLULAR VESICLE ISOLATION 
In all publications, EV isolation was performed by differential 
centrifugation. The isolation of EVs from RBC concentrates (Study I) 
involved a process of concentrate dilution and several low-speed 
centrifugations together with high-speed centrifugation to isolate the final 
EV population. 
When the EVs were isolated from platelet concentrate (Studies II and 
III), a similar protocol with concentrate dilution and low-speed 
centrifugations to remove cellular contamination and high-speed 
ultracentrifugation to isolate the final EV population was applied, but the 
protocol additionally involved the inhibition of platelet activation with 
Apyrase and Anticoagulant Citrate Dextrose before the centrifugations. 
3.3 REFERENCE MATERIAL PRODUCTION 
Before the actual production of the reference material, a literature search 
of available nanoparticles for candidates for the reference material was 
conducted. A questionnaire (Appendix IV) was sent to 50 laboratories 
working with EVs, including questions about the desired properties of the 
reference material and, for instance, the currently used techniques.  
To produce reference material, RBCs were broken down to nanosized 
particles titled NanoE, and three protocols, freeze-thaw cycles, N2 bomb, 
and ultrasonication of RBCs were tested in the production of NanoEs. The 
presumed membrane fragments were washed and sealed with incubation 
at 37 °C. 
3.4 REFERENCE MATERIAL CHARACTERISATION 
To assess the efficacy of different methods to break down RBCs, the 
resulting fragments were fixed, negative stained using uranyl acetate, and 
imaged with transmission electron microscopy. To determine the size 
distribution and stability of NanoEs in storage, they were subjected to NTA 
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measurement. To compare NanoEs to naturally produced RBC EVs, their 
refractive indices were determined, and both CD235a and Di-8-ANNEPS 
positivity was compared using flow cytometry and protein composition was 
analysed using silver-stained SDS-PAGE gels. 
3.5 PLATELET ACTIVATION ASSESSMENT 
The platelet activation was assessed using the CD62P exposure of the 
platelets determined with flow cytometry and the production of soluble 
GPV with a commercial kit, while NTA was used to assess the EV 
production of the platelets and to determine the EV size. 
3.6 MEMBRANE LIPID AND FATTY ACID ANALYSIS  
The FAs of the platelet concentrate were quantified as fatty acid methyl 
esters using gas chromatography. The identification and quantification of 
fatty acid methyl esters were confirmed using authentic standard mixtures 
that were run together with the samples. 
To determine the phospholipid profile alterations of the platelet 
concentrates, platelets, and EVs, the different sample types and time 
points were all isolated from the same 5 platelet concentrates. The lipids 
were extracted and infused into the electrospray ionisation source of triple 
quadrupole mass spectrometer. Phospholipids were detected using specific 
scans, and the quantification was based on known concentrations of the 
internal and external synthetic lipid standards run together with the 
samples. 
3.7 LIPID MEDIATOR AND PATHWAY MARKER 
ANALYSIS 
The LMs were analysed from platelet concentrates and EVs, and similarly 
to phospholipid profile analysis, 5 platelet concentrates were used to 
isolate both sample types. The LM and pathway marker sample 
preparation involved sample spiking with internal standards (the basis of 
the identification and quantification), protein removal by precipitation 
followed by centrifugation, and after the extraction and elution of the LMs 
and their sulfido-conjugates (methyl formate and methanol, respectively), 
the samples were concentrated and injected into a liquid chromatography-
tandem mass spectrometry. The identification of the LMs was based on a 
two-step identification process requiring a matching retention time of the 
sample with the identical synthetic standard and the identification of six 
diagnostic ions, including at least one backbone break, from the MS/MS 
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spectra. The chirality of pathway markers was determined from the 
methyl formate fraction with chiral liquid chromatography-MS/MS. 
3.8 FLOW CYTOMETRY 
In Study I, flow cytometry was used to compare the Di-8-ANNEPS and 
CD235a positivity of the naturally produced RBC EVs and the NanoE, and 
to assess the particle size. Using flow cytometry, a detailed 
characterisation of the cellular sources of platelet concentrate-derived EVs 
was conducted together with the determination of CD62P exposure of the 
platelets in Study II, whereas in Study III, flow cytometry was used to 
confirm that the majority of platelet concentrate EVs were derived from 
platelets.  
3.9 NANOPARTICLE TRACKING ANALYSIS 
In Study I, NTA models LM14C, NS300, and NS500 were compared by 
analysing a NanoE sample using identical sample preparation and 
software settings for data analysis. Data capture settings were 1:10000 
dilution of the sample with particle-free phosphate-buffered saline, camera 
level 8 or 15, and capture of 3 × 90 second videos, which had been 
determined as optimal for the LM14C. 
In Studies I-III, the EVs were quantified and their size was determined 
with NTA. The samples were diluted with particle-free (as verified with 
NTA) phosphate-buffered saline or Hepes to a dilution of 10-50 
particles/frame to assure a reliable particle quantification and size 
determination. If feasible, similar EV samples (e.g., day 1 samples from 
different platelet concentrates in Studies II and III) were prepared with 
the same dilution to more reliably assess real differences between 
concentrates rather than the artificial variation possibly generated by 
sample dilution. Unless stated otherwise, platelet EVs were measured 
with the camera level 14, and RBC EV samples or NanoE were measured 
with the camera level 8. For the analysis, 3 videos of 90 seconds each were 
captured for each sample and the sample was manually mixed in between 
the videos. 
3.10 WESTERN BLOT 
In Study III, the characterisation of the EV fraction, as well as the 
detection of the enzymes responsible for processing GPLs to bioactive LMs 
was conducted with Western blot. To acquire a sufficient amount of EVs, a 
separate sampling was conducted, where all sample types, platelet 
concentrates, platelets, and EVs, were isolated from two different platelet 
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concentrates on day 1 and day 8. An equal quantity of samples, 25 µg of 
protein, was loaded together with protein size standards to wells of 
commercial gradient gels. After running the sample front until the end of 
gel, the proteins were blotted to nitrocellulose membranes using a semi-
dry blotting machine. After the confirmation of successful blotting, the 
membranes were blocked with milk proteins. 
EV samples were examined for the presence of apolipoproteins, platelet 
marker CD41, and EV markers CD9 and CD63, and the presence of 
different members of PLA, LOX, COX and CYP family enzymes in all 
sample types was assessed with an overnight primary antibody incubation 
at +4 °C. After washes, an hour of secondary antibody incubation at a room 
temperature, and addition of the enhanced chemiluminescence reagents, 
the antibody-specific chemiluminescence was captured. 
3.11 STATISTICAL ANALYSIS 
In Study I, the differences in the Di-8-ANNEPS lipid dye labelling and the 
CD235a-labelling of RBC EVs and NanoE was determined using paired 
two-tailed t-test. 
In Study II, the significance of the alterations in the assessed platelet 
activation markers within one PAS were determined using Kruskal-Wallis 
test together with Dunn’s multiple comparison test. The differences 
between PAS on day 5 samples were assessed using single Mann-Whitney 
test together with Bonferroni correction for each platelet activation 
marker. 
In Study III, the significance of EV accumulation to platelet 
concentrates and time-dependent alteration of the EV size profile were 
determined using Friedman’s test with Dunn’s multiple comparison test. 
The significance of the variation in the relative quantities of phospholipids 
and pathway markers or LM quantities was assessed using Friedman’s 
test with Dunn’s multiple comparison test. The differences in phospholipid 
profiles of platelet concentrate, platelets, and EVs were analysed using 
principal component analysis (PCA) in Study III. In all experimental 
settings, p-values < 0.05 were considered statistically significant. 
Statistical analysis was conducted using GraphPad Prism (GraphPad 
Software, San Diego, CA, USA), PCA visualisation was done using 
Metaboanalyst [349]. 
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4 RESULTS 
4.1 NANOERYTHROSOMES AS A REFERENCE 
MATERIAL 
As the synthetic reference materials are comparable to EVs only in certain 
aspects, e.g., nominal diameter, and many of their properties, e.g., the 
refractive index, which is crucial in flow cytometry, do not resemble EVs, 
a biological reference material was developed to improve the comparability 
and traceability of EV studies. The development of the biological reference 
material was initialised with a thorough literature search to map 
candidates categorised as naturally occurring particles (EVs, lipoproteins, 
viral particles, coccoid-shaped organisms (Table 3 in Study I)) and as 
particles requiring some production or manufacturing steps (disrupted 
cells or lipid constructs (Table 4 in Study I)).  
Based on the query conducted during the Study I in 2014, the most 
commonly used technique in EV studies was flow cytometry, and as 
polystyrene and silica beads are commonly used in flow cytometry, over 
50% of the responders indicated the use of synthetic reference materials in 
their EV studies. On the basis of the questions about biological reference 
material, the most appreciated properties of biological reference material 
were stability and biochemical composition reminiscent of natural EVs, 
and 80% of the replies indicated the need for phospholipid membrane and 
proteins. If safety could be guaranteed, 60% of the respondents indicated 
readiness to use plant viruses or marine bacteria as the reference material 
for EVs (Fig. 2 in Study I). 
To fulfil the desired requirements, the reference material was prepared 
from disrupted cells. The tested methods to produce nanoparticles from 
cells varied greatly in their efficacy to break down the cells, as evident by 
EM. Freeze-thaw cycles did not disrupt the RBCs but only made the cells 
leaky, as the visibly red haemoglobin content could be washed away, 
resulting in colourless pellet contrary to red pellet after the sonication of 
RBCs. The N2 bomb disrupted the cells completely to membrane fragments 
of various sizes, but these fragments could not be resealed to form spherical 
particles (Fig. 3 in Study I). Ultrasonication of isolated RBCs resulted in 
nanoparticles morphologically similar to RBC EVs (Fig. 9A and B). Further 
comparison of NanoEs and RBC EVs proved that the particles were similar 
in terms of size and refractive index, as approximately 80% of the particles 
were 100-300 nm in diameter and approximately 70% of the particles had 
a refractive index of 1.35-1.37 (Fig. 9C and D). However, molecular 
differences were also apparent, as differences in CD235a expression, Di-8-
ANNEPS positivity, and general protein composition could be observed 
between NanoE and RBC EVs (Fig. 9E and F).
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Figure 9: Comparison of nanoerythrosomes (NanoE) and red blood cell-derived 
extracellular vesicles (RBC EV) showing transmission electron microscopy micrographs 
from [A] NanoE and [B] RBC EV, [C] size distribution, [D] refractive index distribution, [E] 
CD235a and Di-8-ANNEPS positivity, and [F] silver-stained SDS-PAGE gel of NanoE and 
RBC EV. Columns represent mean and bars standard deviation, n = 3 [D], 6 [E], or 18-20 [C]. 
*p ≤ 0.05, ***p ≤ 0.001 using paired t-test. Figure compiled from the Figures 4-6 in Study I. 
 
Currently, EVs are assessed with various methods and alarmingly, 
even with a single technique, NTA, using three different models with 
similar hardware and identical sample preparation, measurement 
settings, and data analysis, the sample quantification analysis might 
result in completely different results, as shown in Figure 10.  
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Figure 10: [A] Particle concentration and [B] size distribution of identical nanoerythrosome 
samples measured with Nanoparticle Tracking Analyser models LM14C, NS300, and NS500 
using either the camera level (CL) 8 or 15. Columns represent mean and bars standard 
deviation, n = 3. Figure modified from Figure 7 in Study I. 
 
The result indicates that despite the seemingly identical measurement 
settings and samples, the determined particle concentration and size 
distribution differed solely due to the used instrument: sample analysis 
with LM14C resulted in the highest particle concentration, as 
approximately a 10-fold higher particle concentration was observed 
compared to sample analysis with NS300 and NS500. However, the 
detected size distribution of the particles was similar with all the 
measurements. When the NanoE sample was analysed with NS500 using 
more optimal settings for the given sample, the camera level 15 in the case 
of this instrument, a particle concentration closer to the LM14C 
measurements was obtained (unpublished result). Still, the determined 
size distribution measured with the optimal settings for NS500 differed 
from the results for the other measurements, as the relative amount of 
particles with the diameter less than 100 nm was notably increased and 
consecutively larger particles were detected less.  
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4.2 EXTRACELLULAR VESICLES AND PLATELET 
ACTIVATION 
Platelets secrete EVs as part of their homeostasis, and upon activation, the 
EV production is increased. As part of the study, the EVs of ageing platelet 
concentrates were quantified and characterised to determine how the 
storage of platelets influences the EV population in the platelet 
concentrates. Besides the effect of the ageing of platelets, the effect of 
storage conditions on the EV secretion of platelets was assessed by 
comparing the EV populations isolated from platelet concentrates with 
different PAS.  
A significant increase in the platelet activation status was observed 
with all the assessed platelet activation markers (CD62P exposure of 
platelets, sGPV, and EV count) by day 5 in platelet concentrates with PAS-
B (Fig. 11A-D). In PAS-E concentrates, a significant increase in the 
platelet activation status was detected starting from day 5 with the sGPV 
and EV count. However, using CD62P exposure, a significant increase in 
the platelet activation was detected only in day 8 samples. The analysis of 
day 5 platelet concentrates indicated that platelets stored in PAS-E 
containing potassium, magnesium, and phosphate are activated to a lesser 
degree, which was also indicated by the lower CD62P exposure of PAS-E 
platelets. Temporal change in the EV numbers of the platelet concentrate 
was shown to serve as an accurate biomarker for platelet activation since 
the fresh and expired platelet concentrates and even concentrates with 
different PAS could be differentiated based on the EV concentration. Most 
importantly, a change in EV concentration correlated with changes in the 
established platelet activation markers, underlining the feasibility of 
applying the EV concentration as a marker of platelet activation (Fig. 2 in 
Study II). 
In addition to the EV count, the platelet storage conditions also 
influenced the size distribution of the secreted EVs: EVs with a larger 
diameter were secreted from platelets stored in PAS without magnesium, 
potassium, and phosphate compared to the platelets stored in PAS with 
aforementioned components (Fig. 11E), as the modal size class of EVs was 
changed from < 100 nm EVs to 101-200 nm EVs by day 8. 
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Figure 11: Quality control markers used for the evaluation of platelet activation during 
storage of platelet concentrates with platelet additive solution (PAS) B and PAS-E. Time-
dependent changes in the CD62P exposure of platelets, when compared to [A] thrombin-
activated positive control or [B] isotype control, [C] soluble glycoprotein V (sGPV) 
production of platelets, [D] concentration and [E] size distribution of particles in the 
extracellular vesicle samples isolated from platelet concentrates. Statistical difference 
within a given PAS is indicated with black and grey stars for PAS-B and PAS-E platelet 
concentrates, respectively, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 compared to day 
(d)1 using Kruskal-Wallis test with Dunn’s multiple comparison. Statistical difference 
between PAS-B and PAS-E platelet concentrates on d5 is indicated with a red star, *p ≤ 0.05 
using Mann-Whitney test with Bonferroni correction. Bars represent mean with standard 
deviation in A-D, columns present mean and bars standard deviation in E. Data were 
acquired in 3 independent experimental settings, n = 4-5 [PAS-B in all figures, PAS-E in A 
and B] or 10 [PAS-E in C, D, and E]. Figure reproduced from Study II with permission from 
Karger AG. 
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4.3 LIPID-MEDIATED SIGNALLING OF 
EXTRACELLULAR VESICLES  
One crucial milestone of the EV field was the discovery of EVs’ capability 
to transport RNA later transcribable to functional proteins in target cells. 
Although this significant finding revealed a new dimension of intercellular 
communication, it is only one mode of communication in the multifaceted 
interaction skills of EVs. In Study III, EVs’ potential contribution to the 
platelet function via lipid-mediated signalling was assessed in the specific, 
isolated environment of platelet concentrates. 
The assessment of the compositional changes in EVs from platelet 
concentrates demonstrated a time-dependent alteration on phospholipid 
class level (Fig. 12, unpublished data), a significant time-dependent 
decrease in the relative amount of PC is reflected by the increase in the 
relative amount of PS, PE, PE plasmalogens, and lysoPC. 
 
Figure 12: Time-dependent phospholipid class level alterations of the extracellular vesicles 
from 5 platelet concentrates on days (d)1, d2, d5, and d8. Columns represent median and 
bars interquartile range. *p ≤ 0.05, **p ≤ 0.01 using Friedman’s test with Dunn’s multiple 
comparisons test. PC = phosphatidylcholine, PS = phosphatidylserine, SM = 
sphingomyeline, PE = phosphatidylethanolamine, PEp = phosphatidylethanolamine 
plasmalogen, PCa = phosphatidylcholine alkyl-acyl, LPC = lysophosphatidylcholine. 
 
When the lipidome of EVs was examined in more detail at the 
phospholipid species level, it could be observed that initially, platelets 
secreted EVs with relatively short and highly unsaturated PE, PE 
plasmalogen, and PS, but upon storage, the type of EVs secreted by the 
platelets changed. In practice, EVs with an increased relative amount of 
AA-containing species became dominant, which was particularly evident 
in the PE and PS classes (Fig. 13). Although alterations in the relative 
phospholipid profile were observed at both class and species level of EVs, 
virtually very little time-dependent alteration was observed in the FA 
profile of the platelet concentrates (Supplementary Fig. 2 in Study III). 
Results 
41 
 
 
Figure 13: Relative abundance of phosphatidylcholine (PC), phosphatidylserine (PS), 
phosphatidylethanolamine (PE), and phosphatidylethanolamine plasmalogen (PEp) species 
of extracellular vesicles from 5 platelet concentrates on days (d)1, d2, d5, and d8. Columns 
represent median and bars interquartile range. *p ≤ 0.05 **p ≤ 0.01, using Friedman’s test 
with Dunn’s multiple comparisons test. Figure compiled from the Figures 2-4 and 
Supplementary Figure 3 from Study III. 
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When the phospholipid profile alterations were visualised using PCA, 
the time-dependent compositional changes of EVs were also apparent, as 
the day 1 and 2 samples, as well as day 5 and 8 samples, formed their 
separate subpopulations. Such variations were not observed in the tightly 
clustered populations of platelet concentrate and platelet samples. 
Moreover, the phospholipid profiles of EVs were different from the 
phospholipid profiles of whole platelet concentrate and isolated platelets, 
as the confidence intervals of different sample populations did not overlap 
(Fig. 14).  
 
Figure 14: Visualisation of principal component analysis of phospholipid composition in the 
platelet concentrates, platelets, and extracellular vesicles. All quantified phospholipid 
species were used as loadings. Samples were assigned codes consisting of the sample 
type (PlaC/Platelets/EV), platelet concentrate number (1-5), and the sampling day (d1, d2, 
d5, or d8); shaded areas represent 95% confidence intervals. Figure reproduced from Study 
III with permission from Elsevier.   
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Interestingly, EVs were further shown to contain the required 
enzymatic machinery to produce bioactive LMs (Fig. 15A): Especially in 
the day 8 samples with the highest EV content (Fig. 1 in Study III), 
cytosolic and secretory PLA2, but also 12-LOX, 15-LOX2, COX1, (CYP)1A1, 
and CYP5A1 enzymes were detected by Western blot. The increased CD41 
in the EV samples is in line with the results observed in Study II showing 
temporal EV release in the platelet concentrate. A similar increase was not 
detected in EV markers CD9 and CD63, and the lipoprotein contamination 
in EV samples also remained stable. The functionality of enzymes in 
platelet concentrates was verified indirectly through the examination of 
the chirality of pathway markers showing the prevalence of either S or R 
configuration of the pathway markers (Fig. 15B). 
 
Figure 15: [A] Enzyme detection from the platelet concentrates, platelets and extracellular 
vesicles by Western blot and [B] chirality analysis of monohydroxy pathway markers. 12-
lipoxygenase (LOX), 15-LOX1, 15-LOX2, cyclooxygenase (COX)1, COX2, cytochrome p450 
(CYP)1A1, CYP2J2, CYP5A1, cytosolic phospholipase 2 (cPLA2), secretory phospholipase 
2 (sPLA2), CD41, apolipoprotein (Apo)A1, and ApoB were detected from the platelet 
concentrates, platelets and extracellular vesicles. Samples were isolated from two different 
platelet concentrates on day (d)1 and d8. The size of detected proteins is indicated on the 
right side of the figure, STD = molecular weight standard. Figure reproduced from Study III 
with permission from Elsevier. 
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Besides FAs and enzymes for processing FAs to bioactive LMs, EVs also 
contained proinflammatory LMs (TxB2 and PGD2) and pathway markers 
(12-hydroxyeicosatetraenoic acid (HETE)), dual-function LMs (PGE2) as 
well as SPMs (17R-RvD1) and proresolution pathway markers (14-
hydroxydocosapentaenoic acid (HDPA)) in quantifiable amounts. The EV 
fraction also contained LMs unique to the EV fraction (SPMs RvE3, RvD3, 
and MaR1). Some LMs and pathway markers (e.g., TxB2 and 4- 
hydroxydocosahexaenoic (HDHA)) were steadily expressed in EVs, 
whereas the amount of some (e.g., PGE2 and 12-HETE) clearly 
demonstrated a time-dependent accumulation in the EV fraction (Fig. 16; 
Supplementary Table 2 in Study III). 
 
Figure 16: Accumulation of lipid mediators and monohydroxy pathway markers in the 
extracellular vesicles of 5 platelet concentrates during storage. Results are expressed as 
pg / 2.0 × 108 platelets. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 vs. day 1 using Friedman’s test with 
Dunn’s multiple comparisons test. HDPA, hydroxydocosapentaenoic acid; HETE, 
hydroxyeicosatetraenoic acid; Mar, maresin; PG, prostaglandin; Rv, resolving; Tx, 
thromboxane. Figure compiled from Figure 8 and Supplementary Table 2 from Study III. 
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5 DISCUSSION 
5.1 ON THE ROAD TO TRACEABLE EXTRACELLULAR 
VESICLE ASSESSMENT 
In the vigorously developing EV field, optimal golden standards regarding 
isolation, quantification or characterisation remain to be developed and 
disseminated, and in the meanwhile, EVs are assessed with various 
techniques. The results of this study underscore the instrument 
dependency of even simple EV quantification and particle sizing, as 
already with one type of a device the sample analysis may result in e.g., a 
10-fold variation in particle concentration. An important question then 
arises: how to compare any EV results analysed by different techniques 
and laboratories? To construct an accurate understanding of how EVs are 
involved in intercellular communication on a molecular level, results from 
multiple sources achieved with various techniques need to be compared. 
Only a thorough comprehension of the mechanisms behind EV functions 
will enable further exploitation of EVs in various theranostic applications, 
therefore repeatable and comparable experiments are of paramount 
importance.  
If the pitfalls in sample isolation are excluded, then a thorough answer 
on how to address measurement-based discrepancy of EV results can be 
divided into three parts. Firstly and maybe most importantly, method 
development should aim to produce techniques addressing the entire EV 
population, and not only part of it, by taking into account the 
physicochemical properties that are currently understood the best e.g., the 
low refractive index of EVs compared to synthetic particles and the small 
diameter of EVs. Although this sounds simple, the task is not that easy to 
carry out, therefore for the time being EV quantification and 
characterisation will continue to be conducted with combinations of 
different kinds of techniques that are currently available.  
Secondly, one cannot stress enough the importance of a thorough 
comprehension of the used technique and especially its shortcomings: with 
NTA, the measurement settings reported in previous publications should 
not be used as a point of reference in the measurements, as this study 
points out that even the outcome of identical measurements with similar 
instruments differ. Strikingly the variation in the detected particle 
concentration was 10-fold, but the determined sample size distribution was 
similar with all instruments. As the same sample dilution was used 
throughout the measurements, the particle count during the data 
acquisition was approximately 10 times lower in measurements conducted 
with NS300 and NS500 compared to LM14C. Such a low particle count is 
inadequate for reliable sample analysis as it is below the linear range  
Discussion 
46 
 
of the technique [254], influencing the determination of both particle 
concentration and size distribution [250]. Indeed, when the sample 
analysis was conducted using NS500 with optimal settings for it, the 
particle concentration was more similar to the particle count detected with 
LM14C using its optimal conditions. However, the particle size 
distribution detected with NS500 using optimal settings differed from the 
size distribution obtained with the camera level 8 setting (regardless of the 
instrument model) as notably more < 100 nm particles were detected in 
relation to other particles. The result demonstrates that the same sample 
is perceived differently even by the same technique and seemingly 
identical hardware, as it seems that with optimal measurement settings, 
NS500 detected small particles with better efficacy than LM14C. Since the 
data analysis was conducted with the same software version, these results 
pinpoint one crucial source of variation in the EV studies performed with 
NTA (Nanosight). 
To minimise measurement errors, measurements should be conducted 
with individually tailored conditions ideal for the particular sample type 
to assure that the sample analysis is performed in the best possible 
manner given the known limitations of the technique. In practice, with 
regard to NTA (Nanosight), this may even require separate measurements 
for the optimal determination of particle concentration and size 
distribution, as high particle count during data capture results in more 
reliable determination of size distribution, while possibly leading to 
erroneous determination of particle concentration due to particle masking 
[254], which can be detected by measuring a dilution series of the sample 
[350].  
The third part of the answer is to improve the comparability of the 
results by creating a common denominator for the measurement results, a 
reference material. International Vocabulary of Metrology defines 
reference material as “material, sufficiently homogeneous and stable with 
reference to specified properties, which has been established to be fit for 
its intended use in measurement or in examination of nominal properties” 
[351]. For instance, in another popular method for EV characterisation 
which may be applied to quantification, flow cytometry, synthetic 
references, typically polystyrene or silica beads, have commonly been used 
to estimate the size of a target population, either cells or EVs [352]. 
However, the use of synthetic reference material may lead to 
underestimation of the EV size and even assessment of wrong particle 
population (because cellular debris could be interpreted as EVs), as the 
refractive indices of polystyrene (1.59) and silica (1.45) notably differ from 
the refractive index of EVs (~1.39) [254,353], and EVs would have to be 
notably larger than synthetic beads to scatter a similar amount of light 
and to be detected with gating of the synthetic reference materials [352]. 
Due to this and the relatively high detection limit of older generation flow 
cytometers [352], together with swarm detection of EVs, erroneous 
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interpretations of EVs have been made. For example, the impression that 
platelet-derived EVs constitute the majority of plasma EVs [243] is 
predominantly due to the gating of EVs that are much larger than what is 
currently known to be the size of the major pool of EVs, < 300 nm.  
From the perspective of physicochemical properties, ideal reference 
material for EV studies would be comparable to EVs and characterised in 
detail with a metrologically traceable method. Metrological traceability is 
defined as “the result should be related to a reference through a 
documented unbroken chain of calibrations, each contributing to the 
measurement uncertainty” [351]. Such reference material would enable a 
reliable point of comparison for multiple different techniques (and with 
different instrument models), ensuring complete transparency and 
comparability of experiments. A biological reference material similar to 
EVs would benefit the EV field in many ways: importantly, as EV research 
is a rapidly developing and highly method-dependent field, in the area of 
technology development, the optimisation of instrument settings would 
benefit from a standard reference material with EV-like properties [354]. 
Another way to universally apply reference material to EV quantification 
is to use it as a calibrator of a method [254,355]: After carefully quantifying 
the reference material by a metrologically traceable method, the accuracy 
of different quantification techniques, instruments, and quantification 
measurement rounds can be determined by comparing whether the 
measured concentration of reference differs from the concentration of the 
well-characterised reference material concentration achieved with a 
metrologically sound method, enabling a calibration factor to be calculated 
and applied to the obtained results.  
Ultimately, EV measurements need to be metrologically traceable if the 
use of EVs in e.g., theranostics is desired. To properly represent EVs, a 
close similarity to EVs is required from the reference material in terms of 
physicochemical properties: Most importantly, the reference material 
should be safe to use. An ideal reference material for EV studies should 
consist of monodisperse particles with a similar size to the major 
population of naturally occurring EVs, approximately 300 nm, and EV-like 
refractive index of 1.38. Regarding structural requirements, the reference 
material should contain surface proteins and genomic material. For the 
reference material to be widely applied, it should be either affordable to 
acquire or otherwise accessible by e.g. mass-production of stable lots of 
particles (Fig. 17). 
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Figure 17: Desired properties of reference material applicable for multiple techniques in 
extracellular vesicle studies. Reproduced from Study I with permission from Elsevier. RI = 
refractive index. 
 
However, as long as the differences between the standard and a sample 
are known, and the limitations of the measuring techniques are 
acknowledged, a simpler standard can still be utilised for a limited number 
of applications. For example, if an EV reference is developed to address 
only one EV quantification or characterisation technique, e.g., flow 
cytometry, fewer physicochemical properties of particles need to be taken 
into account, and a more optimal reference for a specific technique could 
be used or developed de novo. Examples of such reference materials for 
flow cytometry include monodisperse hollow silica particles or engineered 
retroviruses [255,356], which do not resemble EVs in most 
physicochemical properties, but from the perspective of light scattering 
and monodispersity they fulfil the criteria of a good reference material 
tailored for flow cytometry. 
 Keeping these caveats and aspirations in mind, an attempt was made 
in this study to genuinely increase the comparability of EV results by 
investigating the properties required of a biological reference material and 
by generating a candidate that would be suitable for multiple EV 
quantification and characterisation techniques. After careful consideration 
(via a questionnaire and a literature search), a decision was made to 
generate the candidate from RBCs because of the readily available 
material and the robustness of structurally simple and well-characterised 
RBCs. One crucial property of RBCs as a source for reference material is 
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their exclusive expression of CD235a [357], providing trackability for the 
reference material [355], as CD235a expression enables reference material 
identification from a pool of natural EVs (excluding RBC EVs), which may 
enable a more complex use of the reference. EV sample spiking with 
reference material expressing CD235a could be applied to the 
determination of e.g., the effectiveness of an EV isolation procedure 
[185,355] or to the relative quantification of EVs using flow cytometer by 
mixing a known amount of reference material to EV sample and 
determining the ratio between CD235a-positive particles and the original 
EV sample particles. Especially the biochemical similarity and stability 
were also considered to be desired properties for a reference material in 
the questionnaire sent to 50 laboratories working with EVs.  
Then, the mass production of reference material was assessed and as a 
result, NanoEs were produced from RBCs via sonication and the method 
was optimised. A major advantage of NanoE as a reference material, 
compared to isolated subpopulations of EVs, is the production cost: in a 
tube of blood, approximately half of the volume consists of RBCs, and the 
NanoE production utilises the entire lipid membrane of RBCs. In practice, 
this means that from 10 mL of whole blood, one can prepare a 4-5 mL pellet 
of NanoEs in a matter of hours with only basic laboratory equipment. 
Isolating the same amount of plasma EVs would require litres of blood and 
countless hours of centrifugation, or alternatively, if cell line-derived EVs 
were sought for, multiple high-yield 3D bioreactors [358,359] with high 
initial costs, and weeks of EV harvesting, not forgetting the additional task 
of EV isolation. As another evident advantage of the simple production 
method and readily available materials, NanoEs could be reproducibly 
generated in different laboratories independently in contrast to the highly 
variable results of EV isolation. 
Besides NanoEs’ potential as biological reference material, their 
production concept offers an interesting opportunity to study in detail the 
molecular enrichment in EVs through comparison of naturally produced 
particles and manufactured particles from the same source. As NanoE 
production is a relatively straightforward mechanical procedure involving 
the breakdown of RBCs to smaller particles, the molecular composition of 
NanoEs should resemble the natural distribution of lipids, proteins, and 
carbohydrates of the RBC membrane, but on a nanoscale. The EV 
composition differs from the natural composition of cells [360,361], as also 
shown by the results of this thesis (Fig. 14), and furthermore, the 
composition is, at least in the case of platelets, activation-dependent [169–
172]. Analogously, the NanoEs, a miniature representation of plasma 
membrane, were not identical to naturally produced RBC-derived EVs. As 
the protein and lipid composition of NanoEs was different from that of RBC 
EVs, the differences are most likely applicable to the molecular 
composition in general. These results also indirectly indicate the specific 
cargo loading to EVs, and the compositional differences are presumably 
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also reflected in functional differences. Therefore, a detailed molecular 
characterisation of RBC EVs and NanoEs, together with the comparison of 
different functional aspects, such as cellular uptake, may facilitate the 
identification of the moieties responsible for different functions. With a 
similar method, platelet-derived nanoparticles could also be produced 
[362], and therefore it can be deduced that cell disruption using 
ultrasonication can be applied to various cell types, enabling a detailed 
pair-wise comparison of natural EVs and nanoparticles produced from 
corresponding cells. As a curiosity regarding platelet-derived EVs, calcium 
ionophore induces EVs shown to be unlike natural platelet-derived EVs 
[169], therefore the comparison of nanoparticles produced by platelet 
sonication and calcium ionophore-induced platelet-derived EVs would be 
highly interesting. With this approach, the unique cell type-specific EV 
functionality could be examined accurately, allowing the identification and 
comprehension of such moieties better, which would ultimately facilitate 
the development of different EV-based applications. 
As a clear limitation of Study I, only a superficial analysis of the 
lipidome and proteome was conducted, and the RNA content of NanoE was 
not assessed at all, therefore the further detailed characterisation of 
NanoE is necessary. As indicated in the questionnaire, the presence of 
genomic material was considered to be a desired property for reference 
material. As RBCs contain RNA [363], it could be presumed that NanoE 
produced with the method described in Study I may contain some RNA, 
which would enable further applications of the reference material, e.g., the 
determination of whether RNA is intact after general sample treatment, 
such as sample isolation or extended storage of samples. The minor 
difference in the refractive index of NanoE and RBC EVs can most likely 
be resolved by washing the contents, e.g., haemoglobin, of the visibly red 
NanoE (when produced with the method reported in Study I): After initial 
RBC isolation the cells should be subjected to three freeze-thaw cycles. As 
the freeze-thaw treatment does not break down the RBCs (Fig. 3A in Study 
I), but render the RBCs leaky, the freeze-thaw treatment of RBCs enables 
the RBC content washing, after which ultrasonication could be used to 
break down the washed RBCs to NanoE. Since the contents of particles 
also influence the total refractive index of the particle [255], arguably 
preparation of NanoE from the emptied RBCs in aqueous solution with a 
lower refractive index would result in NanoE having a lower overall 
refractive index and therefore an even closer resemblance to RBC-derived 
EVs. Another significant way to improve NanoE as a reference material 
would be to further modify the NanoE manufacturing protocol for instance 
by applying different ultracentrifugation protocols to especially isolate 
smaller particles or by adding phospholipids before sonication to influence 
the diameter of particles formed as a result of ultrasonication [364]. A 
proper reference material should contain monodisperse populations of 
particles, and with NanoEs this is could be achieved by applying simple 
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filtration or latest isolation techniques, such as asymmetric-flow field-flow 
fractionation [227], to crude NanoE preparation. Given the mass 
production possibility of NanoEs, even commercial amounts of 
preparations with particle populations of specific sizes could be prepared 
without problems. Ideally, EV reference material would consist of particles 
covering the size range of the majority of the EV population, and for 
example, with NanoE, the preparation of particle subpopulations with the 
diameter of 100, 200, and 300 nm would be possible.  
To summarise, RBC-derived NanoEs represent an accessible, 
affordable, and mass-producible reference material that is safe to use. The 
characterisation of NanoEs proved that the produced particles were 
similar to naturally produced RBC EVs in many physicochemical aspects 
and stable over extended storage, therefore it can be concluded that in 
many ways RBC-derived NanoEs fulfil the criteria for a good reference 
material for EV studies (Fig. 17), or that they can be further refined to 
meet these criteria. After minor improvements and detailed 
characterisation to formally assess the level of similarity to naturally 
occurring EVs, NanoEs could enable metrologically traceable EV 
measurements, on condition that the reference material is accessible to the 
EV field and incorporated routinely into EV measurements. The NanoE 
represents an important advance in the standardisation of the EV field 
and, at the time of starting this thesis project, similar studies had not been 
published. Recently, however, another alternative for a biological reference 
material, recombinant EVs, has also been published [355]. 
Finally, even if a perfect reference material enabling metrologically 
sound assessment is developed for EV studies, rather than remove the 
shortcomings between different techniques or the differences in measuring 
sensitivity, it would make the results comparable and point out the 
variance between methods. Therefore, the EV field would benefit most 
from a methodology with more uniform detection of EVs. However, having 
a well-characterised EV reference material such as NanoE may also 
facilitate method development and optimisation.  
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5.2 THE EXTRACELLULAR VESICLES OF PLATELET 
CONCENTRATES: THE GOOD, THE BAD, OR THE 
UGLY? 
Blood transfusions are aimed at restoring the platelet and RBC counts to 
the physiological level, which is an effective countermeasure against 
anaemia and bleeding. However, simultaneously EVs are also transfused 
to patients. Previously, the EVs of blood concentrates were mostly 
overlooked, but more recently the possible roles of EVs in transfusions 
have also become better recognised (reviewed in [365,366]): the EVs of 
platelet concentrate have been hypothesised to contribute to haemostasis 
and influence the functionality of the other cells in the circulation, which 
adds a level of complexity to consider, particularly in the transfusions of 
older blood products containing more EVs (Studies II and III) with the 
potential to rapidly influence the blood cells e.g. via lipid-mediated 
signalling (Study III).  
It is fascinating to think that even though the platelets and leukocytes 
constitute less than 6% of the cells in circulation [10], approximately 30% 
of the plasma EVs are derived from these cells [104]. By now, it has been 
well established that EVs are not senseless bubbles randomly floating 
around, but rather messengers with a purpose, and the logical next step 
also in the transfusion field is to try to understand how to translate the 
important messages conveyed by EVs with current quantification and 
characterisation methods.  
In platelet concentrates, the EV count was found to be a sensitive 
measurement for determining platelet activation, with sensitivity 
comparable to that of the currently existing platelet activation markers 
widely used in transfusion clinics. Also, using EV concentration, the 
assessed platelet concentrates with different PAS could be differentiated 
based on the extent of platelet activation on day 5, the last day when the 
concentrate is still transfusable to patients, underlining the sensitivity of 
platelets and their reactivity to the exposure to different conditions. The 
difference in platelet activation in PAS-B and PAS-E concentrates on day 
5 was equally well demonstrated with all examined readouts (EV count, 
sGPV production, and CD62P exposure of platelets). Taken together, these 
results on platelet-derived EVs are in line with previous experiments 
showing the effect of platelet-activating conditions on secreted EVs [169–
172], the time-dependent increase in EV content of platelet concentrates 
[367–369], the time-dependent activation of platelets in platelet 
concentrates [30,38], and the relationship between the composition of PAS 
and platelet activation [370–372]. As EVs are a fundamental part of 
platelet functionality, EVs genuinely are a valuable indication of the 
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platelet status and provide information that complements the currently 
existing platelet activation markers.1 
A good, upscalable quality control marker for blood products would be 
such that it requires minimal sample preparation and does not need 
immediate analysis after sampling, and the quantitative parameter should 
be determinable with an automated and standardised system requiring as 
little hands-on time as possible [38]. CD62P fulfils these criteria in many 
ways, as only a small (unprocessed) sample from platelet concentrate is 
needed, a positive control can be prepared, and the sample labelling and 
processing are simple, but as a downside samples have to be processed fast 
to prevent unspecific artificial platelet activation [30]. Another possible 
source for variation is the cleavage of CD62P from the platelet surfaces to 
soluble form [373]. The use of sGPV as a platelet activation marker 
requires moderate sample preparation to get a platelet-free supernatant, 
but the samples are stable in extended storage and the platelet activation 
state can be determined accurately using a positive control or the known 
amount (12 000 copies/platelet) of the receptor on a platelet and total 
amount of platelets in the sample [38]. However, a clear pitfall of the sGPV 
determination is the actual quantification performed with an enzyme-
linked immunosorbent assay, as previously the commercial kit was 
available only from one manufacturer. Platelet activation can also be 
determined from other soluble components (reviewed in [374]), and one 
option would be the quantification of soluble CD62P [373]. Similarly to 
sGPV, approximately 13 000 copies of CD62P are expressed on the platelet 
surface [375], but the major drawback of soluble factors is that the sample 
preparation involves the preparation of platelet-free and also EV-free 
supernatant, as platelet-derived EVs express CD62P [373]. 
EVs, on the other hand, require extensive sample preparation. From 
the practical perspective, as it is, the method in Study II, involving the 
isolation of EVs with several centrifugation steps before determining EV 
concentration with NTA, would be difficult to translate and upscale for the 
needs of quality control of hundreds of samples a day. Additionally, varying 
information on EV storability exists, as stability in short-term storage at 
4 °C or room temperature [376–378] has been indicated by some studies, 
while other publications suggest that EVs are unstable in these conditions 
and recommend either storing EV samples at -20 °C or colder [208,379] or 
analysing the samples immediately [380]. Another limitation is the 
preparation of a reliable positive control, as different activators result in 
different amounts of EVs from platelets [169,170] and inter-individual 
variation in the platelet reaction capability towards stimuli [169]. 
Moreover, the definition of absolute working range EV values for platelet 
concentrates with activated platelets would be difficult due to the 
heterogeneity of the platelet concentrates. Typically, buffy coats (and 
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residual plasma) from 4 donors are used to produce a single platelet 
concentrate, which results in varying baseline EV populations that may 
interact with the components of the blood product, even further activating 
the platelets [381,382]. Furthermore, as shown by us previously, the EV 
count is not a definitive indicator of an altered platelet status, as platelets 
can secrete EVs with different compositions while the number of secreted 
EVs remains unchanged [169]. Despite these limitations, several other 
publications indicate the value of EVs as a blood product quality control 
marker, and from practical perspective, the standardised determination of 
platelet-derived EVs with nano flow cytometry capable of detecting EVs 
[367], dynamic light scattering-based applications [383,384], or 
microfluidics [385] might offer better pipelines for high-throughput EV 
quantification. 
Based on these factors, EV quantification as a quality marker has 
limitations. However, besides quantification, with the composition of 
platelet-derived EVs being activation-dependent, the characterisation of 
platelet-derived EVs could provide a better insight into the conditions 
platelets in the concentrate are exposed to: in this study also the size 
distribution of produced EVs was influenced by the storage conditions. 
Therefore, albeit more laborious, the compositional differences rather than 
the quantity of EVs should be analysed to gather more relevant 
information about the original cells and overall effects of the transfused 
unit in patients. As an example of critical information, the coagulation 
potential of the transfused unit could be assessed through the 
determination of the TF activity of EVs [386], although the TF 
measurement alone is problematic, and even more so when the 
standardised measurements of EV and TF are combined (reviewed in 
[387]).  
Another crucial signalling pathway that EVs mediate is the lipid 
signalling. The time-dependent lipidome alteration of EVs was apparent 
at the level of phospholipid classes, and more importantly, from the 
perspective of LM production, at the species level. In this study, the 
relative amount of PS and PE in EVs was increased at the expense of PC. 
As LDL and HDL contain mostly PC [388], the result most likely reflects 
the increased EVs-to-lipoproteins ratio (Fig. 15A). The influence of the 
increased EVs-to-lipoproteins ratio was also observed on the GPL species 
level, as the relative amount of the most prominent PC species in 
lipoproteins, PC 34:2 [388], was decreased. However, as very little PS and 
PE are present in lipoproteins [388], the findings in these classes are due 
to the EV fraction of the concentrates. On GPL species level, the EV 
fraction initially contained EVs with relatively short and highly 
unsaturated PE, PEp, and PS, GPL species with a high efflux propensity 
[389], promoting their rapid exit during the early budding of EVs from the 
plasma membrane. Upon storage, the ageing platelets secreted EVs of a 
different type, which was manifested as an increase in the relative amount 
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of AA-containing species, especially observable in the PE and PS classes, 
and the respective decrease in the relative amount of GPL species with 
high efflux propensity. The results of the GPL examination are well in line 
with previous publications [264,390,391]. Finally, the phospholipid profile 
of EVs differed from that of platelets and platelet concentrates, indicating 
that certain types of lipids became enriched in EVs. Similar conclusions 
have also been made by others, showing enrichment of sphingolipids, PE 
plasmalogen and lysoPC species in EVs of platelet concentrates [392]. In 
the assessed aging platelet concentrate samples, the efflux propensity of 
GPL species most likely explains the altered GPL composition of EVs, but 
other mechanisms cannot be excluded. Knowing the activation-dependent 
(protein) composition of platelet-derived EVs, it could be extrapolated that 
exposure to different antagonists could influence the lipidome of EVs, 
indicating also the involvement of other factors, such as preference of 
cellular location of EV production. However, this assumption is purely 
speculative and deserves further assessment. Taken together, the results 
demonstrate the spatiotemporal secretion of EVs: the type of EVs that 
platelets secrete are dependent on the age, storage conditions, and 
activation status of platelets, however, their molecular composition is not 
dictated by the composition of the platelets.  
One noteworthy remark on result interpretation in Study III concerns 
the units: as the results of Figures 12 and 13 are expressed as molar 
percentages, a relative measure of quantity, it does not take into account 
that the EV content of platelet concentrate increases during the storage, 
as shown by us (Studies II and III) and others [367–369]. In the study in 
question, the particle concentration in EV samples increased 3-fold by day 
8, therefore as absolute quantities, the increase of the AA-containing 
species is even greater, as the relative amounts of e.g., PE 38:4 and PS 38:4 
increase from 25 to 45 mol% and from 15 to 45 mol%, respectively (Fig. 13). 
In conclusion, notable quantities of especially AA are stored within the EV 
fraction for lipid-mediated reactions, either to be transferred to the target 
cell or to be enzymatically modified to bioactive molecules in EVs. 
The compositional changes of EVs from fresh to aged platelet 
concentrate may translate to functional differences: in practice, the 
increased EV count with an enriched PS and PE profile may lead to 
increased procoagulant potential in platelet concentrates due to increased 
assembly sites for procoagulation complexes [393,394], which is an effect 
curiously reversed by the presence of high-density lipoproteins [395]. As 
stored platelet concentrates contain more activated platelets and EVs 
compared to fresh platelet concentrates, the procoagulant potential is 
increased via two different mechanisms. Also, the potential role of EVs in 
ATR has been speculated before [396–398],2 supported by the observation 
that washing the platelets with PAS, which removes plasma and EVs from 
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concentrates, results in fewer incidences of ATR [399–402], but does not 
dramatically influence the platelet functionality [403,404]. 
When the interplay of composition and functional effects of EVs is 
examined further, the signalling potential of EVs will be better 
understood. Additionally to the enriched phospholipid profile compared to 
original cells, EVs contained PLA2, the enzymatic requirement for cleaving 
FAs from the membrane of EVs [405], and COX, LOX, and CYP enzymes 
for the further processing of FAs into either proinflammatory or pro-
resolving LMs. In this study, the enzymatic activity was indirectly 
assessed from platelet concentrates proving that the majority of pathway 
markers are a direct result of enzymatic processing rather than oxidation, 
as enzymatic processing typically produces pathway markers with defined 
chirality [406,407], and due to auto-oxidation or hindered enzyme 
functionality the ratio of two different chiralities between enantiomers 
approaches 1:1 [408,409]. Although the enzymatic activity in EV fraction 
was not assessed directly, compelling evidence exists suggesting that the 
enzymes transported within EVs are active and capable of processing FAs 
[76,158–162]. The GPL composition and the presence of various enzymes 
indicate that EVs do not participate solely in proinflammatory or 
proresolution signalling, but rather represent dynamic and homeostatic 
means of influencing the surrounding environment.  
Although more prominent in platelet concentrate samples, it could also 
be seen in the EV fraction that the alterations in the relative frequency of 
precursor FAs were not translated to changes in the produced pathway 
markers, for instance 12-LOX products. The observation underlines that 
there are preferences to what FAs the enzymes process [410], and further, 
this finding indicates that the regulating step in the process of producing 
bioactive LMs from GPLs is enzymatic activity.  
More pathway markers than bioactive LMs were detected in EVs, most 
likely because the bioactive LMs are required only in pico to nanomolar 
concentrations to exert their function [324] and thus their detection in the 
EV fraction is technically difficult. Additional challenge in the LM 
detection during the storage of platelet concentrate is their short-lived 
presence in a bioactive form. The finding supports the role of EVs as mobile 
units transferring pre-processed material for further enzymatic 
modification when needed. Considering the EVs in plasma, and their 
massive lipid signalling potential, it can be concluded that EVs are an 
efficient and crucial extension of the lipid-mediated intercellular signalling 
of platelets, underlined also by the detection of LMs unique to EVs (SPMs 
RvE3, RvD3, MaR1). Platelet concentrates have been shown to contain 
residual EVs from different cellular sources, as shown by us (Table 1 in 
Study II) and others [411], but as the platelet concentrates are closed 
systems, the massive increase in LMs and pathway markers in the EV 
fraction can only be explained with newly secreted EVs contributing to the 
lipidome of the sample. Based on this study, a direct answer to the question 
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of what factors influence the LM and pathway marker content of EVs 
cannot be given, but it can be speculated that the composition is the result 
of the combined effect of random/specific packaging of GPLs, LM, pathway 
markers, and the enzymes, and on the other hand, the enzymatic activity 
of EVs, which could process the available GPLs, FAs, and pathway 
markers. Enzymatic activity within EVs has been demonstrated in cancer 
cell-derived EVs [412] and hepatocyte-derived EVs [413], and this could 
explain also the highly enriched molecular composition of EVs compared 
to cells, as also demonstrated by us previously [168]. In this experimental 
setting, the EV number increased only 3-fold, whereas the 12-HETE 
increased approximately 200-fold in the EV fraction. As the pathway 
marker accumulation is not explained purely by the increased EV number, 
the result more likely points towards enriched packaging and/or enzymatic 
activity within EVs. What factors influence enzyme loading, and more 
importantly, enzymatic activity within EVs and to what extent these 
aspects explain the molecular enrichment of platelet-derived EVs remain 
to be clarified by future studies. 
As a limitation of LM quantification, every time point studied 
represents only a snapshot of the current EV population within the sample, 
and the dynamic interactions between cells and EVs can only be 
speculated. As EVs are crucial part of intercellular communication, one 
could also hypothesise that EVs are absorbed by other cells in the 
concentrate or expel their contents, which impacts the detected LM and 
pathway content of the EV fraction. 
As at least 68% of EVs in platelet concentrates are from platelets (Table 
1 in Study II), this study, together with others, confirms that platelet-
derived EVs have several ways to influence the recipient cells from the 
perspective of lipids.3 First of all, EVs have a specific phospholipid profile 
that can be incorporated into the plasma membrane [33,414] for starting 
material of the synthesis of bioactive LMs. Regarding LMs, EVs can 
transfer (unique) bioactive LMs or pathway markers to the proximity of 
the cells or into the recipient cell, where they are further processed. 
Finally, EVs contain a wide selection of active enzymes related to lipid 
signalling, which can be transferred to other cells, enabling even the 
synthesis of new types of eicosanoid-derivatives [78]. Based on this study, 
the mechanisms of LM-signalling cannot be explained in detail and need 
to be further assessed, however it has been indicated that 12-HETE, which 
strongly accumulated in the EV fraction, promotes the internalisation of 
platelet-derived EVs by neutrophils [76]. Rather than being passive 
transportation shuttles, it is tempting to speculate that EVs are an active 
extension of the intercellular signalling of platelets, “metabolic machines” 
capable of processing their GPLs or pathway markers into bioactive LMs, 
both proinflammatory and SPMs, upon need using the cargo EVs carry.  
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The lipid-mediated signalling of platelets and their EVs is a potent way 
to influence the surroundings [78,415]. In murine model, the foreign EVs 
are removed from blood circulation in a matter of minutes to the spleen, 
liver, lungs, and kidney [416], but it is noteworthy that RBCs and platelet-
derived EVs have been shown to directly interact with e.g., monocytes 
[417,418]. The LMs present in platelets reinforce their role as immune 
cells, as proinflammatory LMs and SPMs are defined through their 
immune-mediating action. Indeed, platelets have also been shown to 
influence the surrounding cells through LM-mediated signalling [260]. 
As EVs are the main focus of this thesis dissertation, the lipoprotein 
contribution to intercellular messaging was not addressed in this study, 
although lipoproteins are an essential element of plasma and therefore 
also of transfused RBC and platelet concentrates. Besides the influence 
described in the results (Fig. 12 and 13), it has to be acknowledged that 
the lipoproteins can also interact with blood cells [419–421] and EVs 
[150,213], adding yet another layer of complexity to the multifaceted 
interactions occurring in the bloodstream. 
This study, together with others, suggests that EVs of blood products 
can provide vital information on the cells and could be harnessed to 
function as part of the rigorous quality control monitoring of blood products 
[367–369,422]. However, EVs are even more valuable for quality control of 
blood products, as EV assessment would not only help to understand 
platelets better, but would also provide a complete picture and better 
overall comprehension of the whole transfused unit, including cells, EVs, 
and residual plasma. This study indicates that a fresh platelet concentrate 
on day 1 differs notably from an old platelet concentrate in terms of lipid 
composition, EV content, and platelet activation (Studies II and III). Still, 
as demonstrated by others as well, even the 5-day storage of a similarly 
prepared platelet concentrate fulfils the release criteria of safe blood 
product and does not result in a dramatic effect on platelet functionality, 
as measured by platelet activation (CD62P exposure), apoptosis or cell 
death (PS exposure), and metabolism (lactate production) [372]. However, 
the possibility to extend blood product storage has been studied by the 
means of cold-storage of platelet concentrates, improved PASs, and 
pathogen inactivation, resulting in promising conclusions [423–425]. If 
platelet concentrate storage is extended to minimise the number of platelet 
concentrates going to waste, the contribution of EVs to the outcome of 
transfusion will have to be reconsidered.  
By thoroughly understanding the different components of blood 
products, their safety could be evaluated on a detailed level, enabling safer 
transfusions. From another perspective, the time-dependent tailoring of 
the platelet concentrate composition could be exploited by offering 
different kinds of concentrates for different types of patients: patients with 
cancer could benefit from platelet concentrates with fresh platelets that 
would not be removed immediately from circulation, whereas older platelet 
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concentrates with activated platelets ready to aggregate and possibly with 
procoagulant EVs might be better suited to the treatment of massive 
bleeding [369]. Transfusion medicine is considered to be the first example 
of personalised medicine, but based on this study and others, the 
personalisation could be taken even further by analysing and matching the 
EVs of blood products with the needs of the patients [369,426]. To 
summarise, EVs of a platelet concentrate not only provide a means of 
assessing platelet functionality, but also offer a way to rapidly influence 
their surroundings through their LM-related signalling potential. 
Therefore, the traceable, accurate assessment of EVs of platelet 
concentrates, in particular, is crucial for determining the overall effects of 
blood transfusions, for possibly evaluating the applicability of blood 
products to different transfusion needs, and ultimately for conducting 
safer transfusions by preventing ATR.  
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5.3 FUTURE PERSPECTIVES 
Aside from the role of especially lipid-based EV-mediated cellular 
functions in platelets, to which this study also adds, it is tempting to 
speculate about the possibilities offered by EVs to theranostics. The 
concept of applying platelet-derived EVs as a marker for platelet activation 
is encouraging and immediately summons up the thought of extrapolating 
the finding to diagnostics. However, EV quantification, even from a 
specified cellular source, can only provide useful information in a carefully 
defined context, such as the quality control processes of blood products. 
Even if the current technical limitations, e.g., detection limits of 
techniques and lack of standards, hindering the accurate determination of 
the EV count were ignored, the application of (platelet-derived) EV number 
as a clinical diagnostic marker presents challenges. Determining a 
(patho)physiological status of patients based on the quantification of 
plasma EVs would be problematic, as in addition to the intra- and inter-
individual variation, age, and gender [427–429], also multiple 
physiological conditions such as menstrual cycle and exercise [430–435] 
and on the other hand pathological conditions such as trauma, smoking, 
and physical inactivity [244,436,437] influence the EV levels of plasma. 
Due to these reasons, the determination of the physiological plasma EV 
count, similar to physiological blood cell count [238], which would serve as 
a vital point of comparison, is difficult. Furthermore, connecting an 
increased or decreased EV count to any relevant or irrelevant phenomena 
is problematic and even if such parameters could be developed, the inter-
individual variation in the cellular response to different agonists makes it 
challenging to identify the correct reason for the possibly altered plasma 
EV counts. Therefore, it is unlikely that EV quantification even from one 
cellular origin in a different medical context could be used as a definitive 
diagnostic tool, but it could act as an indication of irregularity, which 
requires further studies. 
However, also the findings of this study demonstrate that platelet-
derived EVs have the potential for broader clinical application, as, besides 
the inherent structural diversity [438], the composition of platelet-derived 
EVs is agonist-dependent [169–172]. Presuming that these molecular 
indications can be reliably isolated, detected and deciphered, platelet-
derived EVs have the potential to become biomarkers for different 
conditions, resulting in improved tools for diagnosis and prognosis. As the 
interplay between cancer and platelets has been demonstrated on the 
cellular level [439–444], it is not farfetched to consider that cancer 
progression could be monitored using circulating platelet-derived EVs 
[445–447]. Another interesting concept would be to address the 
relationship between cardiovascular diseases and platelet-derived EVs 
[448–450]. 
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As blood products are a generous source of different kinds of 
nanoparticles that can be either naturally derived (EVs) or mass-produced 
(NanoE) from cells. Blood concentrate-derived nanoparticles could be 
utilised in therapeutics: one way to use EVs, especially specific 
subpopulations of platelet-derived EVs with desired characteristics [100], 
would be to exploit their natural characteristics and to apply them as 
natural drugs in different applications, such as wound healing [451], 
bleeding [28,114,452] or to modulate immunological reactions based on 
their lipid mediator content [76,159,453–457]. 
Another alternative is to chemically engineer EVs or other blood 
product-derived semisynthetic nanoparticles, such as NanoEs, to contain 
preferred therapeutic components [195,298,458–461] and use them as a 
drug delivery system. A particularly interesting feature of EVs is their 
ability to pass the blood-brain barrier [462–465], indicating that EVs have 
potential as drug delivery systems in the treatment of different 
neurological diseases. The EV targeting and uptake is not yet completely 
understood as preferential cellular uptake of EVs from the same cellular 
source has been demonstrated [466], but also evidence of non-selective 
incorporation of EVs to recipient cells using cell-type specific uptake 
mechanisms exists [467]. Our own unpublished results demonstrate a 
differential uptake of RBC and platelet-derived EVs into cancer cells, 
which indicates that certain types of EVs may contain molecular 
characteristics facilitating the cellular uptake process. It is important to 
carefully analyse the composition, and particularly the lipid composition, 
of different populations of EVs to determine how the compositional 
differences influence the uptake and whether such entities could be 
replicated in semisynthetic alternatives, such as NanoEs or liposomes 
[468]. NanoEs have been used in drug delivery before [469,470], and 
supportive evidence for the use of semisynthetic drug delivery systems 
over EVs shows that natural EVs could have counterproductive effects, as 
especially blood product-derived EVs may enhance pro-inflammatory 
responses [117,471] and coagulation [28,114]. 
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6 FINAL CONCLUSIONS 
The details of EV functionality still remain to be determined and to fully 
comprehend these curious little particles, methods and measurements in 
the rapidly developing, highly method-dependent field of EVs need to be 
standardised. To improve the comparability of measurements, a biological 
reference material similar to EVs and applicable to multiple EV 
quantification and characterisation techniques was produced and 
confirmed to be similar to naturally produced EVs in many aspects. 
Through the transparency and comparability of results, the role of EVs in 
a physiological and pathophysiological context can be understood better, 
which leads to the possibility of capitalising the knowledge of EVs in the 
development of different applications: in the very specific context of 
platelet concentrates, EV quantification already provides substantial 
information about the platelets, as platelet concentrate EVs might be 
useful as a marker of platelet activation. 
Besides preventing anaemia and maintaining haemostasis, RBCs and 
especially platelets have more complex functions than initially appears, as 
these cells actively participate in the modulation of immune reactions in 
yet poorly understood ways. As EVs are shown to facilitate and even 
mediate these reactions, the accurate assessment of EVs and their 
molecular composition, especially in lipid signalling, in relation to the cell 
functions was the focal point of this thesis work. This thesis demonstrates 
that lipid-mediated signalling in platelets is a complex entity carefully 
regulated by enzymatic activity. As also EVs met the molecular 
requirements for lipid-mediated signalling, they can be regarded as an 
integral part of intercellular signalling of platelets able to transfer pre-
processed lipid frames and active enzymes to cells. More interestingly, EVs 
may even be active participants in lipid-mediated signalling capable of 
reacting to different conditions by producing bioactive LMs locally when 
needed.  
Several interesting questions remain for future examination, for 
instance, regarding EV-mediated lipid signalling, it is critical to dissect 
whether certain types of LMs and pathway markers are associated 
specifically with different subpopulations of EVs and to determine the 
specific mode of action of EVs in lipid signalling (active participation or 
passive transporter of material). The role of particular LMs and pathway 
markers, e.g., such that do not show time-dependent accumulation in the 
EV fraction, and LMs unique to EVs (SPMs RvE3, RvD3, MaR1), and on 
the other hand the mechanism regulating enzymatic activity of PLA, COX, 
LOX, and CYP enzymes, deserve more attention in future as they could 
mediate ATR in platelet concentrates.
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The vast molecular capacity of EVs to influence surroundings is the 
basis for their (patho)physiological effects, therefore the mechanisms 
involving EV-mediated intercellular signalling need to be understood 
thoroughly, which requires standardised measurements and protocols. 
When the EV-mediated cellular functions are understood better, novel 
aspects of EV assessment may require new types of techniques, possibly 
requiring novel method development. When the relationship between EV 
composition and functionality is understood better, this knowledge can be 
exploited to develop valuable tools for diagnostics and therapeutics from 
EVs or to develop other similar semisynthetic options for e.g., drug delivery 
based on the critical properties of EVs. However, the methodology for e.g., 
current drug delivery systems may not be applicable to EVs, therefore the 
methodology behind EV-based applications may also require some 
development. Then the EVs, either natural or chemically modified, or 
semisynthetic EV-like derivatives could provide a means of influencing 
cellular functionality (in e.g., cancer treatment or wound healing) or of 
assessing the cellular status of an individual by exploiting EVs as a 
valuable biomarker for different conditions (Fig. 18). 
 
Figure 18: The three cornerstones of EV studies and their intertwined relationship, a 
prerequisite for the translation of EVs from bench to bedside. 
 
To summarise, besides their biological significance in intercellular 
messaging, blood product EVs have enormous applicability in quality 
management of blood products. Building our understanding of EV-
mediated functions using blood product EVs as a model could ultimately 
lead to the active incorporation of EVs into the clinical context as EV-based 
diagnostics or even therapeutics. When the added value of NanoE as 
reference material and potential as a drug delivery system is included, it 
can be concluded that blood products contain hidden treasures, pearls, in 
the form of these nanoparticles. 
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Extracellular vesicles (EVs) mediate normal physiological homeostasis and pathological processes by facilitating
intercellular communication. Research of EVs in basic science and clinical settings requires both methodological
standardization and development of reference materials (RM). Here, we show insights and results of biological
RM development for EV studies. We used a three-step approach to ﬁnd and develop a biological RM. First, a lit-
erature searchwas done to ﬁnd candidates for biological RMs. Second, a questionnairewas sent to EV researchers
querying the preferences for RM and their use. Third, a biological RMwas selected, developed, characterized, and
evaluated.
The responses to the survey demonstrated a clear and recognized need for RMoptimized for the calibration of EV
measurements. Based on the literature, naturally occurring and produced biological RM, such as virus particles
and liposomes, were proposed as RM. However, none of these candidate RMs have properties completely
matching those of EVs, such as size and refractive index distribution. Therefore, we evaluated the use of
nanoerythrosomes (NanoE), vesicles produced from erythrocytes, as a potential biological RM. The strength of
NanoE is their resemblance to EVs. Compared to the erythrocyte-derived EVs (eryEVs), NanoE have similar mor-
phology, a similar refractive index (1.37), larger diameter (70% of the NanoE are over 200 nm), and increased
positive staining for CD235a and lipids (Di-8-ANEPPS) (58% and 67% in NanoE vs. 21% and 45% in eryEVs,
respectively).
Altogether, our results highlight the general need to develop and validate new RMwith similar physical and bio-
chemical properties as EVs to standardize EV measurements between instruments and laboratories.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Extracellular vesicles (EVs) are lipid bilayer surrounded particles
that contain proteins, lipids, metabolites, and nucleic acids (Yanez-Mo
et al., 2015). EVs are produced by most cells, including bacteria and
plant cells, making cross-kingdom communication possible (Samuel et
al., 2015). EVs have active physiological and pathophysiological roles
and they are functional components of intercellular communication,
thereby offering possibilities in the development of therapy and diag-
nostics, or collectively, theranostics (Fais et al., 2016). EVs are often clas-
siﬁed into exosomes and microvesicles based on size and the route of
formation, but increasing data have revealed this to be an oversimpliﬁ-
cation, since the isolated populations are heterogeneous and have
overlapping properties including size, density, and molecular markers
(van der Pol et al., 2016).
The molecular content and concentrations of EVs in human body
ﬂuids have raised increasing interest for their use as biomarkers (Fais
et al., 2016). A biomarker based on EVs has not yet been realized, partly
due to the lack of standardization. Standardization is difﬁcult because
the calibration of instruments, the interpretation and validation of re-
sults, and the comparison ofmeasurements require a referencematerial
(RM) with physical properties equal to EVs. One of the most analyzed
property of an EV sample is the concentration. However, the measured
EV concentration depends on the physical properties of EVs, such as the
size distribution and refractive index (RI), complicating the analysis, as
explained below.
EVs smaller than 300 nm constitute the majority of EV population
(Aatonen et al., 2014; Arraud et al., 2014; Dragovic et al., 2011, 2013;
Gercel-Taylor et al., 2012; Varga et al., 2014; Yoshioka et al., 2013).
Typical size distributions of EVs start at ~30 nm, show a peak at a
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diameter b100 nm, and follow a decreasing power-law function or ex-
ponential function for diameters N100 nm (Fraikin et al., 2011; van
der Pol et al., 2016). With the exception of transmission electron mi-
croscopy (TEM), none of the current analytical methods are able to de-
tect the entire population of EVs (van der Pol et al., 2016). The inability
to detect the smallest EVs leads to both differences and underestimation
of the determined concentration. Consequently, the reported number of
EVs in normal humanplasma ranges from104 to 1012mL−1 (vander Pol
et al., 2014a). This 8 orders of magnitude difference in EV concentra-
tions emphasizes the need for standardization.
In ﬂow cytometry, which is one of the most commonly used
methods in EV studies (Lacroix et al., 2010), particle detection is often
based on light scattering. Because the RI of silica (1.45) and polystyrene
beads (1.61) is higher than the mean RI of naturally occurring EVs (~
1.39), applying a gate on the scatter signals of silica or polystyrene
beads will result in erroneous estimations of EV size and concentration
(van der Pol et al., 2012, 2014b). For example, a lower size gate set with
200 nm polystyrene beads, which scatter the same amount of light as
EVs of ~500 nm (Chandler et al., 2011), leads to the exclusion of EVs be-
tween 200 and 500 nm (van der Pol et al., 2014b). Since the concentra-
tion of EVs decreases with increasing diameter, a polystyrene size gate
generally leads to an underestimation of the actual EV concentration.
With nanoparticle tracking analysis (NTA) the Stokes–Einstein
equation is used to derive the hydrodynamic diameter of EVs from
their Brownian motion (Dragovic et al., 2011). Although in NTA, the RI
of EVs does not affect the measured diameter, the EV size distribution
and RI do affect the measured concentration (Filipe et al., 2010), be-
cause the measured concentration depends on the brightness of the
scattering particle.
Altogether, these examples emphasize the urgent need to develop
RM with a similar RI and size distribution, but preferably also with a
morphology (for TEM) and zeta potential (for tunable resistive pulse
sensing, TRPS) similar to the studied EVs. Ultimately, also other RM
properties wouldmatch those of EVs, including surfacemolecules or in-
ternal cargo. This is challenging because the development of an optimal
RM for EV studies and the analytical methods for their detection are de-
pendent on each other. Further, the different analytical techniques de-
pend on different properties of EVs (Table 1). In this study, we took a
three-step approach to develop RM for EV studies: a literature search
was performed to ﬁnd candidates for biological RM, and then EV re-
searchers were asked for the preferences for RM and their use. Finally,
we took a step forward and developed an erythrocyte-derived EV-RM,
nanoerythrosomes (NanoE), and evaluated its usability.
2. Materials and Methods
2.1. Literature Search
The task of discovering a potential biological RM for EV studies was
initiated through discussions with various professionals of “Metrologi-
cal characterization of micro-vesicles from body ﬂuids” (METVES;
www.metves.eu) program. Based on the discussions, the initial catego-
ries of RM were determined and a literature search was conducted in
Google and PubMed using terms such as “erythrocyte ghost”, “RBC car-
rier”, “outer membrane vesicles”, “nanobacteria”, “viral particle”, “coc-
coid bacteria”, “liposome”, “cell organelle”, “stability”, production”,
and “preparation” to elaborate the properties of potential RM. Initial in-
clusion criteria for potential RM were submicron size and organic com-
position. To further investigate the beneﬁts of the selected RM, experts
from the EV ﬁeld were consulted regarding the properties of potential
RM from the literature search. Candidates were excluded if the particles
contained infection risk, did not express sufﬁcient physical and bio-
chemical resemblance to EVs, or were poorly storable. The literature
search and expert consultation was conducted from 10/2014 to 11/
2014.
2.2. Survey of RM and Their Use in EV Studies
A questionnaire (Appendix 1) was designed to collect the following
information: methods in use for the characterization and quantiﬁcation
of EVs, current use of RM, desired andminimal physical and biochemical
requirements of RM, and opinions of other potential RM. The question-
nairewas sent to 14 stakeholders from theMETVES program and32 col-
laborators from the Laboratory of Experimental Clinical Chemistry
(Academic Medical Center, Amsterdam, Netherlands) working with
EVs. Replies were collected from 11/2014 to 12/2014.
2.3. Preparation of RM from Erythrocyte Concentrates
Standard leukocyte-reduced erythrocyte concentrates were used to
produce NanoE. Outdated concentrates were obtained from Sanquin
(Amsterdam, The Netherlands) and the Finnish Red Cross Blood Service
(Helsinki, Finland). Concentrates were handled anonymously, and only
concentrates that could not be administered clinically were used as ac-
cepted by the Finnish Supervisory Authority for Welfare and Health
(Valvira, Finland).
To isolate erythrocyte-derived EVs (eryEVs), 25 mL of the concen-
trate was diluted with 25 mL of 0.22 μm ﬁltered calcium- and magne-
sium-free 1× phosphate-buffered saline (PBS [Sigma-Aldrich, St. Louis,
MO, USA]) and centrifuged for 20 min at 1560×g, room temperature
(RT)without brake (Centrifuge 5810R, Eppendorf, Hamburg, Germany)
(Varga et al., 2014). Supernatant was transferred to new tubes and cen-
trifuged 3 times under the same settings. The obtained supernatant was
centrifuged for 1 h in 100,000×g at 4 °C (Optima™MAX-XPUltracentri-
fuge with rotor TLA-55, k-factor 66, Beckman Coulter, Brea, CA, USA),
after which the pellet was washed with similar ultracentrifugation. Fi-
nally, the pellet was suspended with PBS to the initial volume and
aliquoted to 100-μL aliquots for storage at−70 °C (Fig. 1A).
NanoE production was initiated by separating the erythrocytes from
the concentrate: 25 mL of concentrate was diluted with 25 mL cold (+
4 °C) PBS and centrifuged at 300×g for 10 min at 4 °C without a brake
(Centrifuge 5810 R). The pellet was suspended to an equal volume of
cold PBS, centrifuged 1560×g for 20 min at 4 °C without a brake (Cen-
trifuge 5810 R). The washing was repeated 2 more times. Next, three
different disruption methods were evaluated to produce NanoE:
Freeze-thawing: 500 μL aliquots of erythrocytes were treated with 3
consecutive freeze–thaw cycles of 5 min in liquid nitrogen and 5 min
in 37 °C water bath.
N2 bomb treatment: 5mL of erythrocytes were diluted with 10mL of
PBS in 50 mL Falcon tube to facilitate nitrogen access to the cells. The
tubes were placed in N2 bomb (Parr Cell Disruption Bomb, Moline, IL,
USA). A pressure of 75 Psi was created using nitrogen and after
Table 1
Dependency of the different detection techniques on EV properties and EV sample
properties.
AFM DLS FCM NTA SAXS TEM TRPS
Adhesion + − − − − + −
Buoyancy − − − − − − ±
Charge − ± − ± − − +
Concentration + + + + ++ + +
Membrane proteins ± − ± ± − ± −
Monodispersity − ++ − ± ++ − −
Refractive index − + ++ + − − −
Size − + + + ++ − +
Spherical shape − ++ ++ + + − ++
Stiffness + − − − − + −
Abbreviations: AFM: atomic force microscopy; DLS: dynamic light scattering without
charge option; FCM: ﬂow cytometry; NTA: nanoparticle tracking analysis without charge
option; SAXS: small-angle X-ray scattering; TEM: transmission electron microscopy;
TRPS: tunable resistive pulse sensing.
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30 min, the pressure was gently released and the sample was collected
in a 50 mL Falcon tube.
Ultrasonication: 15 mL of erythrocytes were sonicated in an ice bath
with either Branson digital sonicator 250-D (Branson Ultrasonics, Dan-
bury, CT, USA) equipped with microtip using continuous sonication,
60% power and 30 or 45 s sonication, or Bandelin Sonopuls
ultrasonicator (BANDELIN electronic GmbH & Co. KG, Berlin, Germany)
equipped with MS73 microtip and 30 s continuous ultrasonication.
After disruption, the suspensions containing membrane fragments
were diluted with an equal volume of cold PBS, and centrifuged for
1560×g at 20 min and +4 °C without brake (Centrifuge 5810 R) to re-
move remaining cells and larger fragments. Remnants were washed by
transferring 500 μL aliquots of supernatant to Eppendorf tubes, diluting
the suspension 1:1 with cold PBS and centrifuging 10 min in 20,000×g
for 10 min and +4 °C without brake (Mikro 200R, Andreas Hettich
GmbH & Co. KG, Tuttlingen, Germany). Remnants were washed 3
times by suspending the pellet in 1 mL of cold PBS. The washed pellet
was suspended in 100 μL of +37 °C PBS and transferred into 10× vol-
ume of +37 °C PBS to allow the resealing process at +37 °C (water
bath) for 1 h. After the resealing process, the NanoE were aliquoted to
100 μL aliquots and stored in−70 °C.
2.4. Transmission Electron Microscopy
Samples were ﬁxed 30 min in 0.1% (weight/volume, w/v) parafor-
maldehyde (Electron Microscopy Sciences, Hatﬁeld, PA). Next, a 200-
mesh EM copper grid with formvar coating (Electron Microscopy Sci-
ences) was placed on top of a sample (10 μL), and incubated for 7 min
at RT. The grids were transferred to 1.75% uranyl acetate (w/v) for neg-
ative staining. The grid was imaged using a Tecnai 12 transmission elec-
tron microscopy (TEM, FEI Company, Eindhoven, The Netherlands),
operated at 80 kV.
2.5. Nanoparticle Tracking Analysis
The same NanoE samples were measured with the instruments
LM14C, NS300, and NS500 using the same settings (camera level 8, 3
videos of 90 s, 10,000-fold dilution). Analysis of the acquired videos
was performedwith threshold 5 and gain 10. The usedNTA instruments
and their speciﬁcations are listed in Table 2. LM14C was also used to
study how storage affects the size distribution and the concentration
of NanoE. NanoE samples were ﬁrst measured with NTA immediately
after preparation and then up to 10 weeks with biweekly measure-
ments (Supplementary Fig. 1).
2.6. Flow Cytometry
NanoE and eryEVs were characterized using Apogee A50 micro
(Apogee Flow Systems, Hertfordshire, UK) equipped with a 405 nm
laser for measuring scatter and a 488 nm laser for measuring ﬂuores-
cence. Fluorescence light was spectrally ﬁltered by bandpass ﬁlters
(525/50, 575/30), and a long pass ﬁlter (650 nm). Particles were labeled
with a FITC-labeled anti-CD235a antibody (clone 11EB-7-6, Beckman
Coulter, Brea, CA, USA) and a lipid dye Di-8-ANEPPS (Invitrogen, Wal-
tham, MA, USA). For CD235a, the NanoE and eryEVs concentration
was ~108 mL−1 as determined by NTA (LM14C). The labeling volume
was 100 μL. Possible antibody aggregates were removed before use by
centrifuging for 5 min at 18,890×g and 20 °C without brakes, and
10 μL of the antibodywas used for each sample. After 30min incubation
in the dark, the labeling reaction was stopped by adding 900 μL of
0.22 μm ﬁltered PBS. IgG1-FITC was used as an isotype control (clone
MOPC-21, BD Pharmingen, San Jose, CA, USA). For the Di-8-ANEPPS la-
beling, 1 μL of 12.5× Di-8-ANEPPS lipid dye preparation (1 μL Di-8-
ANEPPS, 6.25 μL pluronic acid (product code#P3000MP [ThermoFisher,
Waltham, MA, USA)], and 5.25 μL mQwater) was added to 200 μL sam-
ples of eryEVs and NanoE at a concentration of ~107 mL−1. As free Di-8-
ANEPPS aggregates in the buffer, the amount of Di-8-ANEPPS-positive
particles in the buffer without EVs was deducted from samples in data
analysis. Samples were incubated for at least 30 min, RT, covered from
light. For sample detection, large-angle light scattering or small-angle
light scattering was used as a trigger and used voltages and thresholds
were 320 and 31 for large-angle light scattering and 295 and 14 for
small-angle light scattering, respectively. Samples were injected at
4.5 μL/min, datawas collected for 120 s for each sample and threewash-
ing cycles were performed between the samples. NanoE and eryEVs
were additionally compared to bead mixture of silica and polystyrene
beads (Apogee Flow Systems).
2.7. SDS-PAGE
The protein compositions of eryEV and NanoE samples were studied
by loading equal amounts of 0.3 μg of protein (determinedwith μBCAkit
[Thermo Fisher Scientiﬁc]) together with Multicolor broad range pro-
tein ladder (Thermo Fisher Scientiﬁc) to commercial Mini-Protean
TGX 10% gels (BioRad, Hercules, CA, USA). The gels were run with
180 V for 1 h in 1× Tris/glycine/SDS buffer (BioRad). The gelwas ﬁxated
(30% ethanol, 0.5% acetic acid [Merck, Kenilworth, NJ, USA]) for 1 h, after
which it was rinsed for 10min in 20% ethanol and 10min in water. The
gel was sensitized using freshly prepared sodium thiosulphate (0.02 g/
100 mL [Sigma-Aldrich]) for 1 min. The gel was rinsed twice in water
for 20 s and stained in freshly prepared silver nitrate (0.1 g/50 mL
Fig. 1. A step-by-step protocol for harvesting EVs from erythrocyte concentrate (A) and schematic of the production of nanoerythrosomes (B).
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[Merck]) for 30 min. The gel was rinsed in water for 10 s, after which it
was developed using freshly prepared development solution (70 μL of
37% formaldehyde [Merck], 3 g of potassium carbonate [Sigma-Aldrich],
1 mg of sodium thiosulphate [Sigma-Aldrich], and added to 100 mL of
water) for 4 min. The development was stopped with incubation in
stopping solution (50 g/L Tris base [Merck], 2.5% acetic acid [Merck])
for 1 min, after which the gel was stored in water. The Western blots
were prepared as mentioned before (Aatonen et al., 2014).
2.8. Determination of Refractive Index
The RI of NanoE and eryEVs were determined by independently
measuring the diameter and the light scattering power of individual
particles with NTA and solving the inverse scattering problem with
Mie theory (van der Pol et al., 2014b).
2.9. Statistics
Statistical signiﬁcance was determined by using two-tailed t-test
(GraphPad Prism v.5.0.1.)
3. Results
3.1. Literature Search
Although several studies have characterized anddescribed the use of
monodisperse (Lacroix et al., 2010; Chandler et al., 2011; Maas et al.,
2015) and bimodal (Nicolet et al., 2016) synthetic RM, the reported
use of biological RM is limited (van der Pol et al., 2012; Anon., n.d.-a).
The following literature search describes potential, naturally occurring
or “produced” RM, which could be further developed for EV analyses.
3.1.1. Naturally Occurring Sources for Biological RM
Submicron particles with physical and biochemical properties simi-
lar to EVs can be isolated from naturally occurring sources. These may
include 1) isolated EV populations from, e.g. cell cultures, 2) plasma li-
poproteins, plant and marine viruses, and 3) small spherically shaped
(coccoid) bacteria, or picoplankton (Table 3).
(1) Potential EV sources are in vitro cell cultures (Lazaro-Ibanez et al.,
2014), cultures of Dictyostelium discoideum (Tatischeff et al.,
2012), therapeutic clinical grade erythrocyte (Varga et al.,
2014) and platelet (Black et al., 2015) concentrates, urine (van
der Pol et al., 2014a), and outer membrane vesicles produced
by bacteria (Biller et al., 2014). Here, the speciﬁc advantage is
that the obtained RM have enhanced physical and biochemical
similarities, including the molecular contents, with actual EVs.
These EV sources are also fairly accessible and safe. Thus, well-
characterized EVs would also be the perfect EV-RM candidates.
(2) Lipoproteins and viral particles from plant and marine sources
are suitable as EV-RMbecause they have a size distribution over-
lapping with the bulk of EVs (Aatonen et al., 2014; Arraud et al.,
2014; Dragovic et al., 2011; Dragovic et al., 2013; Gercel-Taylor
et al., 2012; Varga et al., 2014; Yoshioka et al., 2013; Anon.,
n.d.-b, n.d.-c; Oster, 1950; van Antwerpen et al., 1999; Sawle et
al., 2002; McFarlane et al., 2005) and they do have a relatively
small variation in size (van Antwerpen et al., 1999; Sawle et al.,
2002; McFarlane et al., 2005; Salpeter and Zilversmit, 1968;
Colhoun et al., 2002). However, amajor drawback of lipoproteins
and viral particles is that the RI of these particles is higher than
the RI of EVs, due to their high protein content, a prominent
problem especially of protein-enveloped viruses. Another issue
of using viral particles is their biosafety, which could be
circumvented by producing virus-like particles, i.e. particles lack-
ing the viral genome. The mass production of virus-like particles
is possible in plant or insect cells (Machida and Imataka, 2015;
Santi et al., 2006).
(3) Another possible source of biological RM are non-pathogenic
bacteria and picophytoplankton, i.e. aquatic organisms of both
prokaryotic and eukaryotic origin ranging between 600 nm and
2000 nm in diameter (Anon., n.d.-d). Several non-pathogenic
marine bacteria and picophytoplankton strains exist (personal
communication with representatives of Roscoff Culture Collec-
tion; Roscoff, France) and can be purchased for culturing. The
beneﬁt of cultures of non-pathogenic bacteria and
picophytoplankton is that the cultures could be harnessed into
mass production to provide twopopulations of particleswith dif-
ferent size distributions. Bacteria can be used as larger particles
(N600 nm) and the corresponding bacteria-derived outer mem-
brane vesicles can be used as smaller particles (b250 nm) (Biller
et al., 2014). As outermembrane vesicles have comparable phys-
ical and biochemical properties as the bacteria (Biller et al.,
2014), the main difference would be their size. By maintaining
cultures, the biological RM would be essentially self-generating
with affordable and effortless maintenance depending of the
used strain. A literature search for non-pathogenic bacteria spe-
cies, which could be used as biological RM based on their size,
suggested several spherically shaped (coccoid) bacteria with re-
ported diameters of b1000 nm (Bae et al., 1972; Balkwill and
Casida, 1973; Barbier et al., 1999; Lai et al., 2000; Osburn and
Amend, 2011).
3.1.2. Production of Biological RM
Besides harvesting EVs as RM from naturally occurring sources, sub-
micron particles with EV-like properties can be produced from various
sources. Here, we included particles produced only from biological ma-
terials including disrupted cells and different lipid constructs (Table 4).
Biological RM can be produced by disrupting cells to produce small
vesicles from the fragments yielding particles with varying diameters
(Marchesi and Palade, 1967; Heidrich and Leutner, 1974; Lin and
Macey, 1978; Yoon et al., 2015; Jo et al., 2014). The main advantage of
using such materials is that the physical and biochemical properties of
the obtained RM would better resemble EVs compared to synthetic
RM (Yoon et al., 2015; Jo et al., 2014). Erythrocytes are theoretically
Table 2
Speciﬁcations of the NTA instruments and software.
NTA
instrument Laser Camera
Software version in data
collection
Software version in data
analysis
LM14C Violet laser: 405 nm, 70 mW (Malvern Instruments
Ltd., Malvern, UK)
sCMOS camera (Hamamatsu Photonics K.K.,
Hamamatsu, Japan)
3.0 3.1
NS300 Violet laser: 405 nm, 65 mW (Malvern Instruments
Ltd.)
sCMOS camera (Hamamatsu Photonics K.K.) 3.1 3.1
NS500 Violet laser: 405 nm, 45 mW (Malvern Instruments
Ltd.)
EMCCD camera (Andor Technology, Tokyo,
Japan)
3.1 3.1
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ideal materials to use, since their cell membrane composition is well-
characterized and they are devoid of intracellular membranes
(Virtanen et al., 1998). Additionally, erythrocytes are structurally stable
during extended storage (Chaplin, 1982) and are an easily accessible
material. For these reasons, erythrocytes from clinical surplus concen-
trates were used to produce an RM for testing and evaluation. Different
Table 4
Produced biological reference materials (RM). RM were categorized according to size, polydispersity, refractive index (RI), and the resemblance to the EVs.
RM
Diameter
(nm) Polydispersity (CV) RI
Resemblance to
EVs Considerations References
Disrupted cells
Preparation method A b200 N20% – 4 – Marchesi and Palade (1967)
Preparation method B 200–700 N20% – 4 – Heidrich and Leutner (1974)
Preparation method C 100–5000 N20% – 4 – Lin and Macey (1978)
Preparation method D 100–300 20%–35% – 5 – Yoon et al. (2015)
Preparation method E 100 – – 5 – Jo et al. (2014)
Lipid constructs
Liposomes 100 ~5% 1.363–1.392 3 – Lapinski et al. (2007), Matsuzaki et
al. (2000)
Liposomes (commercially
available*)
100 and
500
b20% for smaller
particles,
N20% for bigger
particles
Varies with used
buffer
3-5 Can be stored at least 12
months
Anon., (n.d.-f)
Lipoparticles** 191 13% – 3-4 Can be stored for 18
months
Anon. (n.d.-g)
Oil droplets*** b100 b20% Engineered to
preferred RI
1 Can be stored at least 12
months
Anon. (n.d.-h, n.d.-i),
Resemblance to EVs was scored from 1 to 5 points depending on whether the RM has (1) no resemblance, (2) proteins and genomic material but no lipid membrane, (3) phospholipid
membrane, (4) phospholipid membrane containing proteins, or (5) phospholipid membrane containing proteins and genomic material. * = Liposomes from Excytex, Zeist, The Nether-
lands; ** = lipoparticles from Integral Molecular, Philadelphia, PA, USA; *** = oil from Apogee Flow Systems, Hertfordshire, UK or Cargille Laboratories, Cedar Grove, NJ, USA.
Table 3
Naturally occurring potential biological reference materials (RM).
RM
Diameter
(nm)
Polydispersity
(CV) RI
Resemblance
to EVs Considerations References
EVs from
Cell lines 30–1000 N20% ~1.38 5 EVs stable for months when
stored−80 °C
Lazaro-Ibanez et al. (2014)
Dictyostelium discoideum 50–300 35%–70% – 5 – Tatischeff et al. (2012)
Erythrocyte or platelet
concentrates
10–350 N20% – 4/5 EVs stable for months when
stored−80 °C
Varga et al. (2014), Black et al. (2015)
Lyophilized exosomes* 30–100 N20% 1.37–1.39 5 Commercially available, can
be stored for months
Anon. (n.d.-e)
Outer membrane vesicles from
(marine) bacteria
10–350 – – 5 – Biller et al. (2014), Li et al. (1998), Kadurugamuwa
and Beveridge (1997), Schooling and Beveridge
(2006), Beveridge (1999)
Urine 45–500 35%–40% 1.37 5 EVs stable for months when
stored−80 °C
van der Pol et al. (2014a, 2014b), Tatischeff et al.
(2012)
Lipoproteins
High-density lipoproteins 6–15 ~5% 1.45−1.6 4 Must be stored under nitrogen
or argon, if stored in +4 °C.
Can be stored at−80 °C for
months
van der Pol et al. (2014b), van Antwerpen et al.
(1999), Sawle et al. (2002), McFarlane et al. (2005),
Salpeter and Zilversmit (1968), Colhoun et al.
(2002), Perusse et al. (2001), Wood et al. (2006)
Low-density lipoproteins 18–25 b10%
Intermediate-density
lipoproteins
30 ~1.5%
Very low-density lipoproteins 30–80 ~20%
Chylomicrons 200–600 N20%
Viral particles from
Marine virus species 110–130 b20% – 2 Can be stored for months in−
80 °C. No safety restrictions, if
particles do not contain
genomic material
Anon. (n.d.-d)
Plant virus species 20–85 b20% 1.52–1.57 2 van der Pol et al. (2014b), Anon. (n.d.-b, n.d.-c)
Oster (1950)
Coccoid-shaped organisms
Aquatic
bacteria/pico(phyto)plankton
300-1000 – 1.35-1.47** 5 Can be stored for months in−
80 °C. No safety restrictions, if
particles do not contain
genomic material.
Biller et al. (2014), Anon. (n.d.-d), Lai et al. (2000),
Ackleson and Spinrad (1988), Spinrad and Brown
(1986), Kuo et al. (2014), Hashemi et al. (2011)
Nanobacteria from soil 200–1000 – – 5 Bae et al. (1972), Balkwill and Casida (1973)
RMwere categorized according to size, polydispersity, refractive index (RI), and the resemblance to the EVs. Resemblance to EVswas scored on 1–5 points depending onwhether the RM
has (1) no resemblance, (2) proteins and genomic material but no lipid membrane, (3) phospholipid membrane, (4) phospholipid membrane containing proteins, or (5) phospholipid
membrane containing proteins and genomicmaterial. *= Exosomes fromHansaBiomed, Tallinn, Estonia. **=Values based on the references and the refractive index ofwater at 488 nm.
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methods for erythrocyte disruption were compared, and a method for
NanoE production was developed (Fig. 1B). An additional advantage of
using erythrocytes is that they can be used to produce two types of bio-
logical RM for comparison: 1) by disrupting the erythrocytes NanoE are
formed, and 2) by harvesting the spontaneously shed eryEVs.
Biological RM can also be obtained from lipid constructs such as lipo-
somes that are extensively used as delivery vehicles (Allen and Cullis,
2004; van der Meel et al., 2014) and their production methods are
well known. Liposomes of a desired size can be prepared by
ultrasonication or extrusion of the starting material through polycar-
bonate ﬁlters of a set pore size (Lapinski et al., 2007; Akbarzadeh et
al., 2013). As the liposomes are produced from bulkmaterial, their com-
position is well characterized. Especially, liposomes with a small diam-
eter (~70 nm) prepared by extrusion have b20% variation in size (CV,
ratio of the standard deviation to the mean, expressed as percentage)
(Garcia-Diez et al., 2016). An advantage of liposomes is that their RI
can be manipulated during the production (Fenzl et al., 2015). Another
type of RM resembling liposomes are non-infectious virus-like particles
called lipoparticles, which consist of a lipid membrane constructed on
top of a protein core. These lipoparticles have a well-deﬁned diameter
of ~190 nm with a narrow size distribution (CV = 13%), and they are
stable during storage. On request, additional proteins could be attached
to the lipoparticle surface, whichwill increase their biochemical similar-
ity to EVs.
Finally, as a non-biological exception, we include oil droplets as one
option of a produced RM because they would offer close similarity with
EVs regarding the size and RI. As with liposomes, extrusion can be used
to prepare oil droplets of a speciﬁc size from oils of commercial pro-
viders. The advantage of using oil droplets is that the RI can be designed
exactly, thus improving their resemblance to EVs (personal communi-
cation with Oliver Kenyon, CEO of Apogee Flow Systems, Hertfordshire,
UK and representatives of Cargille Laboratories, Cedar Grove, NJ, USA).
3.2. Survey
The literature search revealed several different types of RM, which
had varying beneﬁts and drawbacks. Therefore, the opinions of labora-
tories working with EVs were surveyed through a questionnaire to dis-
cover the requirements of biological RM by the end-users. A
questionnaire (Appendix 1) was sent to 46 laboratories and the re-
sponse rate was 44%. Flow cytometry was indicated as the most com-
mon method for EV studies (90% of the responders; Fig. 2A),
Fig. 2. Results from 46 EV laboratories based on a questionnaire asking (A) which techniques were in use for EV studies (multiple choices allowed); (B) currently used RM; (C) preferred
properties for optimal RM; (D) minimal requirements for a RM; and (E) willingness to use plant viruses/marine bacteria as RM. Values represent mean ± S.D. Published previously (in
www.metves.eu), reproduced with permission. NTA = nanoparticle tracking analysis; PCR = polymerase chain reaction.
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underlining the need for a RMwith a size and RI distribution resembling
EVs. Besides using functional assays (50%), dynamic light scattering/
NTA (35%), electron microscopy (25%), and Western blotting (25%)
were listed as the most commonly used techniques for EV studies (Fig.
2A). When laboratories were asked whether they have used an RM in
their studies, the majority reported using synthetic RM (58%), 5% used
biological RM, and 16% used both. However, 20% used no RM in their
EV studies (Fig. 2B).
The laboratories were asked to rank the order of importance regard-
ing the desired properties, i.e. the biochemical composition,
monodispersity, price, refractive index, and safety. The biochemical
composition (average rank of 4.33/6) and stability (average rank of
4.25/6) were indicated as the most important properties (Fig. 2C).
Next, price, RI, and safety were listed with an almost equal importance
(average ranks of 3.13/6, 3.21/6, and 3.20/6, respectively), whilst
monodispersity was considered as the least important property (aver-
age rank of 2.90/6) (Fig. 2C). Regarding the requirements for the struc-
tural properties, 50% of the laboratories working with EVs would be
satisﬁed if the RM would contain a phospholipid membrane, 30%
would additionally require proteins, and 20%would require a phospho-
lipidmembrane and the presence of both proteins and genomicmateri-
al (Fig. 2D). Finally, 60% would be willing to use plant viruses and
marine bacteria as RM, provided that their biosafety can be assured
(Fig. 2E).
3.3. NanoE Production
NanoE were selected as a biological RM candidate, based on the lit-
erature review and the survey responses. Three erythrocyte disruption
methods (freeze–thaw cycles, N2 bomb, and ultrasonication) were test-
ed in the NanoE production. Freeze–thaw cycles did not break down the
erythrocytes sufﬁciently, as seen in TEM micrographs (Fig. 3A), al-
though the treatment made the erythrocytes leaky, resulting in white
erythrocyte ghosts. Furthermore, the number of submicron particles
was almost non-existent (Fig. 3B). Disruption using an N2 bomb result-
ed in either intact or completely shattered erythrocytes (Fig. 3C), and
similar to the freeze–thaw treatment, submicron particles were almost
non-existent (Fig. 3D). Finally, ultrasonication disrupted erythrocytes
almost completely (Fig. 3E), producing a concentration of submicron
particles higher than the application of freeze–thaw cycles or an N2
bomb (Fig. 3F). Despite using different ultrasonicators, the size distribu-
tion proﬁle of the produced NanoE was similar (data not shown). Ex-
tending the length of the ultrasonication treatment from 30 s to 45 s
decreased the ﬁnal particle concentrationwithout affecting the size dis-
tribution (Fig. 3G and H). Based on the results, an additional washing
step was included in the ﬁnal protocol to remove any remaining intact
cells and larger cell fragments, seen especially in freeze–thaw cycle
and N2 bomb disruptions.
3.4. EryEVs vs. NanoE
To examine the usability of NanoE as RM, their physical and bio-
chemical properties were compared with the naturally occurring
eryEVs from the same concentrate. The morphology of eryEVs and
NanoE was similar as inspected by TEM (Fig. 4A and B). Also, the RI dis-
tribution and mean RI (1.37) measured by NTA were similar for eryEVs
andNanoE (Fig. 4C). The protein content of NanoEwas considerably dif-
ferent from eryEVs as shown by SDS-PAGE (Fig. 4D). Enriched proteins
inWestern blotting of NanoE vs. eryEVswere, e.g. hemoglobin and Band
3 (data not shown). The size of NanoE was slightly greater than that of
eryEVs: 66% of the NanoE population was larger than 200 nm, and the
main population (58%) was between 200 and 400 nm, whereas only
b30% of eryEVs were larger than 200 nm when determined by NTA
(Fig. 4E). The difference in size distribution was also observed in ﬂow
cytometry, where a majority of NanoE were found in the same area as
180 nm silica beads in contrast to the smaller eryEVs (Fig. 4F).
Next, ﬂow cytometry was used to determine the fraction of Di-8-
ANEPPS positivity and CD235a antigen density of eryEVs and NanoE.
Lipid labeling of NanoE by Di-8-ANEPPS showed a higher percentage
of labeled particles compared to the eryEVs (67% vs. 45% respectively,
p b 0.05, Fig. 5). Similarly, the CD235a labeling was signiﬁcantly higher
for NanoE than for eryEVs (58% vs. 21%, respectively, p b 0.0001, Fig. 6,
ﬂuorescence intensity 68.3 ± 21.6 vs. 40.5 ± 13.0).
3.5. Application of NanoE as a Biological RM to Standardize EV
Measurements
To demonstrate the relevance of using a biological RM for the stan-
dardization of EV measurements, NanoE was analyzed using three dif-
ferent NTA instruments. The same batch of NanoE was measured
using the same settings optimized for the LM14C instrument, which
were then applied during measurements with NTA models NS300 and
NS500. The size distribution of the detected particles was similar
Fig. 3. Representative transmission electron microscope micrographs of erythrocytes
disrupted by three consecutive freeze–thaw cycles (A and B), by an N2 bomb (C and D),
by a 30-s ultrasonication (E and F), and by a 45-s ultrasonication (G and H).
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among the used NTA instruments, with themajority of particles (~60%)
ranging from 200 to 400 nm in diameter (Fig. 7A). However, although
the same NanoE concentrations were expected to be measured, the ob-
tained NanoE concentrations varied ~40-fold among the different in-
struments (Fig. 7B).
4. Discussion and Conclusions
The development of RM for EVs is tightly intertwined with the de-
velopment of the EV analysis methods as both feed each other's ad-
vancement. Although progress has been made with different sizes of
monodisperse nanoparticles (van der Pol et al., 2014b; Wang et al.,
2008), the analyses of complex mixtures of polydisperse particles are
challenging (van der Pol et al., 2016). The EuropeanMetrology Research
Program has initiated important standardizationwork in anticipation of
the rapid momentum of the EV research ﬁeld and therefore funded
METVES, a program focused on metrological characterization of EVs
from body ﬂuids. In collaboration with METVES, this study was per-
formed by a national EV research platform funded as an initiative of a
Finnish industry- and university-driven research program SalWe-GID,
throughwhichmultiple end-users are interested in the EV standardiza-
tion for their improved utilization. The progress inMETVES on synthetic
RMand the applicablemethods for their analysis encouraged us to try to
foresee the further needs for biological EV-resembling RM. In order to
Fig. 4. Comparison of erythrocyte-derived EV (eryEVs) and nanoerythrosomes (NanoE) showing transmission electron microscopy micrographs from (A) eryEVs and (B) NanoE; (C)
refractive index measurements; (D) silver-stained SDS-PAGE gel of NanoE and eryEV samples; (E) size distribution measured by nanoparticle tracking analysis; and (F) polystyrene
and silica bead mixture, unlabeled eryEVs, and unlabeled NanoE as detected with ﬂow cytometer. Gate 1 = 180 nm silica beads; gate 2 = 240 nm silica beads; gate 3 = 300 nm silica
beads; gate 4 = 590 nm silica beads; gate 5 = 800 nm silica beads; gate 6 = 1300 nm silica beads; gate 7 = (ﬂuorescent) 110 nm polystyrene beads; gate 8 = (ﬂuorescent) 500 nm
polystyrene beads. Values represent mean ± S.D., n= 3 (C) or 18–20 (E).
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gain information on these, a survey was launched. Based on the survey,
ﬂow cytometry and synthetic RMwere indicated as themost used com-
bination in EV studies, which underpins the problems of RM develop-
ment. Especially with the ﬂow cytometers, the use of synthetic RM
leads to the selection of particles within the size range of cells (van
der Pol et al., 2012; Chandler et al., 2011), thereby affecting the conclu-
sions of EV studies particularly from clinical samples such as plasma.
Biochemical resemblance to EVs and stability were the most crucial
properties for a biological RM according to the laboratories who partic-
ipated in the survey. As more unusual sources, e.g. plant viruses or ma-
rine bacteria, were also acceptable as RM, a wide range of possibilities
worth investigating were listed from the literature, if they matched
the basic criteria set for RM.
Based on previous results (Anon., n.d.-a), the survey, and the litera-
ture review, NanoE was chosen for further development and evaluation
as a candidate for biological RM. The optimized method of NanoE pro-
duction required ultrasonication to disrupt erythrocytes, a method pre-
viously used to produce submicron particles from lipids (Lapinski et al.,
2007). Upon resealing, the produced particles resembled eryEVs regard-
ing their morphology and RI. The larger size and the enhanced CD235a/
Di-8-ANEPPS labeling of NanoE vs. that of eryEVs may be beneﬁcial for
their use as EV-RM. Thus, NanoE represents a reasonable option to EV-
dedicated ﬂow cytometers and possibly also to earlier models of ﬂow
cytometers, which are able to detect 300–700 nm single particles with
EV-like RI (van der Pol et al., 2012). The enhanced CD235a positivity
may be explained by the instantaneous disruption of erythrocytes,
where no selection of surface proteins occurs compared to natural EV
budding (Dragovic et al., 2013). This was also supported by the differ-
ences of the total protein composition of NanoE and EryEVs. A drawback
of NanoEmay thus be that since they do not expose common EV surface
markers such as CD9, CD63, or CD81 (Yoshioka et al., 2013; Andreu and
Yanez-Mo, 2014) nor signiﬁcant amounts of genomicmaterial, theywill
not be applicable as RM for methods using these properties as the basis
of the analysis. However, the lack of typical EV markers and expression
of erythrocyte-speciﬁcmarker CD235awould enable spiking of EV sam-
ples with NanoE, which might be useful in the quantiﬁcation of EVs
from different sources. As such, NanoE can already be utilized as an
RM for NTA, TRPS, and ﬂow cytometry.
Comparing the properties of NanoE with those indicated by the sur-
vey, NanoE have a matching RI and contain phospholipid membrane
and proteins; criteriawhich fulﬁl the needs of themajority of the partic-
ipating EV laboratories. Furthermore, NanoE are relatively stable, safe,
and cheap to produce in large quantities from surplus clinical grade
erythrocyte concentrates. Although theNanoE population cannot be de-
scribed as monodisperse, out of the desired properties, monodispersity
was ranked as the least important. Monodispersity could be substantial-
ly improved by additional preparative steps, thereby allowing the isola-
tion of populations with a narrow size range using different ﬁltration
(Zinsser and Tang, 1927), chromatographic (Boing et al., 2014),
microﬂuidics (Ashcroft et al., 2012; Lee et al., 2015), or ﬁeld-ﬂow frac-
tionation (Petersen et al., 2014; Agarwal et al., 2015)methods. Provided
that a monodisperse biological RM could be produced in the future, fur-
ther characterization by methods such as small-angle X-ray scattering
could be, at least hypothetically, used to generate “traceable measure-
ments”, i.e. measurements that could ultimately be related to the SI
unit (in this case “metre”) through an unbroken chain of comparisons
with knownuncertainties (Varga et al., 2014).More realistically, the fol-
lowing step in the development of similarly equivalent standards with
NanoEwould be themechanical disruption of platelets or cells from im-
mortalized cell cultures to produce biological RM that would better re-
semble multiple EV properties, including EV surface markers and
internal cargo, and could then be utilized by multiple analytical
approaches.
To demonstrate the relevance of biological RM for the standardiza-
tion of EV measurements, we measured the same batch of NanoE
using the same settings on different NTA instruments. The size
Fig. 5. (A) Apogee A50 dot plots showing the Di-8-ANEPPS labeling of erythrocyte-derived EVs (eryEVs) and nanoerythrosomes (NanoE) compared to negative controls; (B) datagram
showing the Di-8-ANEPPS labeling of eryEVs and NanoE compared to negative control; and (C) comparison of Di-8-ANEPPS labeling of eryEVs and NanoE. Values represent mean ±
S.D., n= 6, * = p b 0.05.
12 S. Valkonen et al. / European Journal of Pharmaceutical Sciences 98 (2017) 4–16
distribution of the detected particles was similar, but the obtained
NanoE concentrations varied ~40-fold among the NTA instruments,
which emphasizes the importance of using an EV-RM. The particle con-
centration measured by NTA is assumed to be proportional to the mean
number of scattering particles in the ﬁeld-of-view of the microscope,
whichdepends on the intensity andwavelength of the illumination, col-
lection angles of the objective, the sensitivity of the camera with the
applied settings (Maas et al., 2015; Gardiner et al., 2013), the analysis
software, and the brightness of the scattering particles, which in turn
depends on the particle size, refractive index, and concentration (due
to multiple and dependent scattering). The differences in the particle
concentrations obtained with similar NTA instruments are caused by
an inappropriate calibration factor between the mean number of scat-
tering particles in the ﬁeld-of-view and the provided concentration
Fig. 6. (A) Apogee A50 dot plots showing CD235a-labeling of erythrocyte-derived EVs (eryEVs) and nanoerythrosomes (NanoE); (B) a datagram showing CD235a-labeling of eryEVs and
NanoE; and (C) comparison of CD235a-labeling of eryEVs and NanoE. Values represent mean ± S.D., n= 6, *** = p b 0.0001.
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and a lack of knowledge on the diameter of the smallest detectable EVs.
Once the concentration of the NanoE can be measured in a traceable
way, NanoE can be used to calibrate NTA instruments, i.e. relating the
mean number of scattering particles in the ﬁeld-of-view of NTA to the
traceably measured concentration, and deﬁning the smallest detectable
EV diameter. In analogy to NTA, other instruments can be calibrated
with NanoE to improve themeasurement quality within each laborato-
ry. Despite the challenges, EV quantiﬁcation by particle enumeration is,
in most cases, a more accurate way of comparing samples than any in-
direct EV quantiﬁcation method such as determination of protein con-
tent. The protein content of an EV sample may be independent of the
particle number and can vary with the cell activation (Aatonen et al.,
2014), the used cell line (Lazaro-Ibanez et al., 2014), and the method
bywhich the protein content ismeasured (Okutucu et al., 2007). There-
fore, direct particle measurements should be favoured in the case of EV
quantiﬁcation and the expressed concentration should be coupled with
the knowledge of the detection limits of the instruments/method.
A summary of the optimal properties of a biological RM is presented
in Fig. 8, based on the collected information gathered during this study.
However, although desirable, it is unlikely that one biological RMwould
be applicable, not to mention optimal, for all different measurement
techniques due to the vast variation in the detection methods (Table
1). Therefore, the search for an optimal biological RM should be
approached from a technical perspective, research focus, and consider-
ing the EV material. Still, the development of such materials will not be
easy.
As the research on EVs progresses, and the use of EVs is pursued in
clinical assays and for theranostics, it is crucial to develop various RM
to enable precise and reproducible measurements. This will most likely
beﬁrst achieved by the use of synthetic RM in ﬂow cytometry and in the
techniques for EV enumeration. However, the simultaneous develop-
ment of biological RM would clearly provide additional beneﬁts to the
ﬁeld. Where synthetic RM could be useful for instrument calibration,
biological RM could be used for validation of EV measurements. By
spreading the RM for common use, the repeatability of studies and the
reliability of datawill be increased,which in turnwill increase the trans-
parency of EV research and improve standardization. Since the discov-
ery of new biological RM for EV studies is a laborious task, it requires
the united work of all laboratories and openness. Research networks
such as the MEHAD (Extracellular Vesicles in Health and Disease,
COST Action BM 1202) and metrological initiatives such as those con-
ducted by METVES, are in a crucial position to take this endeavor to
the next level, but ultimately, it is the interest and responsibility of all
EV researchers to make this possible.
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Abstract
Novel analytical measures are needed to accurately monitor 
the properties of platelet concentrates (PCs). Since activated 
platelets produce platelet-derived extracellular vesicles 
(EVs), analyzing EVs of PCs may provide additional informa-
tion about the condition of platelets. The prospect of using 
EVs as an auxiliary measure of platelet activation state was 
investigated by examining the effect of platelet additive so-
lutions (PASs) on EV formation and platelet activation during 
PC storage. The time-dependent activation of platelets in 
PCs with PAS-B or with the further developed PAS-E was 
compared by measuring the exposure of CD62P by flow cy-
tometry and the content of soluble glycoprotein V (sGPV) of 
PCs by an immunoassay. Changes in the concentration and 
size distribution of EVs were determined using nanoparticle 
tracking analysis. A time-dependent increase in platelet ac-
tivation in PCs was demonstrated by increased CD62P ex-
posure, sGPV content, and EV concentration. Using these 
strongly correlating parameters, PAS-B platelets were shown 
to be more activated compared to PAS-E platelets. Since the 
EV concentration correlated well with the established plate-
let activation markers CD62P and sGPV, it could potentially 
be used as a complementary parameter for platelet activa-
tion for PCs. More detailed characterization of the resulting 
EVs could help to understand how the PC components con-
tribute the functional effects of transfused PCs.
© 2019 S. Karger AG, Basel
Introduction
Platelet concentrates (PC) are manufactured for pa-
tients with hemostatic problems, e.g., excessive bleeding 
or thrombocytopenia in cancer. The average life span of 
a platelet in blood circulation is 10 days [1], and the stor-
age time of PC is typically 5–7 days [2] mainly due to an 
increased risk of bacterial contamination during extend-
ed storage at room temperature (RT) [3]. Efforts are made 
to increase the storage time of PCs by developing platelet 
additive solutions (PASs), improving protocols in PC 
preparation, pathogen inactivation, and by more detailed 
quality control [4–6].
A crucial aspect of the quality control of PCs is the de-
termination of platelet activation state. One widely used 
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marker of platelet activation is P-selectin (CD62P) expo-
sure of platelets. CD62P is transferred to the platelet plas-
ma membrane through the fusion of α-granules upon ac-
tivation [7]. Another platelet-specific marker is the solu-
ble form of glycoprotein V (sGPV), which is released 
from activated platelets through proteolytic cleavage [8]. 
The transmembrane form of glycoprotein V is located on 
the platelet surface as part of a complex with glycopro-
teins Ib and IX, which is the major receptor for von Wil-
lebrand factor [9], and it also participates in thrombin 
[10] and collagen [11] binding. Other current quality 
control assays of PCs include the quantification of platelet 
metabolites (glucose, lactate, pH) and dissolved gases 
(pO2, pCO2) as well as the determination of platelet func-
tion using the extent of shape change and hypotonic 
shock response. Also, different platelet parameters, such 
as the mean platelet volume and platelet count, are com-
monly monitored to examine the quality of platelets [6].
Besides the platelets’ main role in regulation of hemo-
stasis, they have been shown to influence immune respons-
es [7], which is an aspect to consider when PCs are admin-
istered to patients. During storage of PCs, platelets liberate 
a large variety of bioactive components that have been pro-
posed to relate to adverse proinflammatory effects ob-
served in storage lesion [12, 13]. Although several different 
markers for measuring storage lesion have been suggested, 
a gold standard to evaluate the usability of PCs for transfu-
sion has not yet been established [6]. Therefore, novel 
markers are needed to assess the condition of platelets in 
more detail.
Besides platelets, the PCs contains extracellular vesi-
cles (EVs), which in their majority are derived from plate-
lets, but which also originate from red blood cells and 
leukocytes residually present in the plasma fraction of 
PCs [14]. One of the first functions in which platelet-de-
rived EVs were shown to participate was hemostasis [15, 
16], implemented by the interaction of coagulation fac-
tors on the phosphatidylserine surface of the EVs [17]. 
Additionally, EVs are considered to be biomarkers of 
thrombotic and inflammatory diseases as well as cancer 
[18, 19], and in general EVs have already been shown to 
mediate several (patho)physiological processes [20, 21]. 
Furthermore, EVs have been suggested to contribute to 
adverse transfusion-related reactions [22], underscoring 
the need to understand the possible effector functions of 
EVs in transfusion. In addition to the possible effects of 
the transfused EVs in patients, EV generation during the 
storage of PCs could be considered as auxiliary parameter 
to monitor the activation state of platelets, since the gen-
eration of platelet-derived EVs is dependent on the aging 
and activation status of platelets [23, 24].
In the current study, EVs of PC were quantified to see 
whether the EV content could be utilized as a parameter 
of the activation state of platelets in PCs together with the 
recognized platelet activation markers, CD62P exposure 
of platelets, and sGPV content. This was investigated by 
examining the platelet activation state in aging PCs with 
different PASs.
Materials and Methods
Sample Collection
Standard leukocyte-reduced PCs, each derived from buffy 
coats of four ABO RhD-matched whole blood donations with 
PAS-B or PAS-E, were obtained from the Finnish Red Cross Blood 
Service (Helsinki, Finland) and handled anonymously, as accepted 
by the Finnish Supervisory Authority for Welfare and Health (Val-
vira, Helsinki, Finland). The exact compositions of PAS-B and 
PAS-E, also known as PAS-2 and modified PAS-3 [25], respec-
tively, have been reported elsewhere [26].
Sterile sampling was done using 50-mL syringes (Henke-Sass; 
Wolf GmbH, Tuttlingen, Germany) and 18-gauge needles (Teru-
mo, Tokyo, Japan). Before sampling, the contents of the storage 
bag’s tube were emptied into the storage bag and the PC was mixed 
by gently turning it from side to side five times. This procedure was 
repeated three times to obtain a representative sample. After ex-
tracting 20 mL of sample via the storage bag’s tube, the tube was 
resealed. The sampling days (d) were d1, d2, d5, and d8 counting 
from the blood donation (d0), d1 being the production day of PC. 
The d1 sampling was performed within 2 h once the PCs were 
available from the production line, approximately at 3 p.m., where-
as the d2–d8 samplings were performed at 9 a.m. PCs were stored 
at 22  ° C under constant horizontal agitation.
Determination of CD62P Exposure of Platelets
The CD62P expression on the platelet surface was determined 
by flow cytometry using 1 mL of PC sample. PC samples were di-
luted 1: 100 (to approximately 1 × 107/mL) using a diluent consist-
ing of the same PAS used for PC production (either PAS-B or PAS-
E; SSP or SSP+ [Macopharma, Tourcoing, France]) with 0.5% w/v 
bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA). Fifty 
microliters of diluted PC sample were labeled using 2 µL of fluores-
cein isothiocyanate (FITC)-coupled anti-CD41 (FITC mouse anti-
human CD41, clone HIP8 [Becton Dickinson, Franklin Lakes, NJ, 
USA]) and 5 µL of phycoerythrin-cyanine 5 (PE-Cy5)-coupled an-
ti-CD62P (PE-Cy5 mouse anti-human CD62P, clone AK-4 [Becton 
Dickinson]). For each sample an isotype control sample (50 µL of 
diluted PC sample labeled with 5 µL of PE-Cy5 mouse IgG1 κ iso-
type control, clone MOPC-21 [Becton Dickinson]) and a throm-
bin-activated positive control sample with maximum CD62P ex-
pression (50 µL of diluted PC sample labeled with 2 µL of CD41-
FITC and 5 µL of CD62P-PE-Cy5 and activated with 1 IU/mL 
thrombin [Roche, Basel, Switzerland]) were prepared. Samples and 
controls were labeled and analyzed in BD TruCount tubes (Becton 
Dickinson) containing a known number of fluorescent beads. Sam-
ples were analyzed in singlicates since previously the CD62P mea-
surements had been found well repeatable [27]. After labeling sam-
ples were mixed, incubated for 20 min at RT in the dark, further 
diluted with 500 µL of diluent, and stored in the dark until analysis.
The samples and controls were analyzed with a Navios flow 
cytometer (Beckman Coulter, Brea, CA, USA) at “high-flow” 
speed. The forward (FS) and side scatter detectors’ (SS) volt and 
gain settings had been adjusted such that the platelet population 
was centered in the FS-SS dot plot (at around 101) and the fluores-
cence detectors’ FL1 (FITC) and FL4 (PE-Cy5) settings such that 
the detected fluorescence signals were well within the displayed 
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ranges for all samples. The TruCount beads were gated based on 
their fluorescence in FL1, FL2, and FL3 channels and a platelet gate 
had been defined in the FL1-SS dot plot. For each sample 5,000 
bead events were acquired, corresponding to about 60,000 platelet 
events. The gated platelet population was used to calculate the per-
centage of CD62P-positive platelets, defined as:
• Based on the isotype control, a threshold was set to include 1% 
of all events with the highest fluorescence in the FL4 channel. 
All events with FL4 fluorescence above this threshold were de-
fined as CD62P-positive in comparison to the isotype control.
• Based on the positive control, a threshold was defined to in-
clude 95% of the thrombin-activated platelet population with 
the highest fluorescence. All platelets with FL4 fluorescence 
above this threshold were considered CD62P-positive in com-
parison to the positive control.
Platelet activation state was expressed in relation to both iso-
type and positive control as percentage of gated platelet population 
above the respective CD62P positivity threshold.
Quantification of sGPV
The quantification of sGPV was performed as reported previ-
ously [6]. Briefly, 1 mL of the PC was centrifuged (Biofuge 13; He-
raeus Sepatech, Hanau, Germany), first at 3,600 g at RT for 15 min 
and the supernatant again at 11,000 g at RT for 5 min (Biofuge 13). 
The supernatant was transferred to new tubes in 500-µL aliquots 
and stored at –70  ° C until sGPV quantification with a commercial 
kit (Asserachrom; Diagnostica Stago, Asnières sur Seine, France). 
For the measurement, samples were diluted 1: 80–1: 640 using 
phosphate buffer provided with the kit, and the amount of sGPV 
was expressed as pmol/109 platelets.
Isolation of EVs
A total of 17 mL of PC was used for EV isolation. To prevent 
platelet activation, Anticoagulant Citrate Dextrose Solution pH Eur 
Solution A (Terumo BCT, Lakewood, CO, USA) and Apyrase (Sig-
ma-Aldrich) were added to the final concentrations of 4.25% v/v 
and 2 U/mL, respectively, and the PC was diluted 1: 4 with phos-
phate-buffered saline (PBS) (Thermo Fisher, Waltham, MA, USA). 
The diluted PC was centrifuged at 650 g at RT for 7 min (Eppendorf 
centrifuge 5810R; Eppendorf, Hamburg, Germany) without brake, 
and the supernatant was centrifuged at 1,560 g at RT for 20 min 
(Eppendorf centrifuge 5810R). The residual platelet content of the 
supernatant was reduced to 1 × 106 platelets/mL, as confirmed with 
Coulter Cell Counter T-540 (Beckman Coulter). To extract the 
whole EV population from the PC, the supernatant was ultracen-
trifuged at 100,000 g at 4  ° C for 1 h (MLA-50 rotor, k-factor 92; 
Beckman Coulter). The supernatant was carefully decanted and re-
maining supernatant was removed with a pipette, after which the 
EV sample was resuspended into 200 µL of PBS and stored in Pro-
tein LoBind tubes (Eppendorf) at –70  ° C until analysis.
Quantification and Size Determination of Particles  
in EV Samples
The concentration and size distribution of particles in EV sam-
ples was determined using nanoparticle tracking analysis. The 
LM14C model used was equipped with a 70-mW violet (405 nm) 
laser (Malvern Instruments Ltd., Malvern, UK) and a sCMOS 
camera (Hamamatsu Photonics K.K., Hamamatsu, Japan). Data 
were captured using camera level 14, and three videos of 90 s were 
recorded, manually mixing the sample between measurements. 
EV samples from PAS-B PCs were diluted 1: 1,000, 1: 2,000, 1: 5,000, 
and 1: 10,000 with filtered (0.2 µm) PBS on d1, d2, d5, and d8 sam-
ples, respectively, and EV samples from PAS-E PCs were diluted 
1: 1,000, 1: 2,000, 1: 5,000, and 1: 5,000–1: 10,000 on d1, d2, d5, and 
d8 samples, respectively. Data analysis was performed with thresh-
old 5 and gain 10. Data were recorded and analyzed with Nano-
Sight software version 3.0 (Malvern Instruments Ltd.). The data 
were reported as EV concentration of the PC on the sampling day 
by calculating the particle content of the EV sample using the de-
termined particle concentration and taking into account that the 
particles were isolated from a 17-mL sample, considered as a rep-
resentative sample of PC.
Staining and Characterization of EV Samples on 
ImageStream®X Mark II
EV samples from PAS-E were labeled with Alexa Fluor 488 C5 
maleimide (Invitrogen, Carlsbad, CA, USA) for 60 min at RT as de-
scribed previously [28]. Excess maleimide was removed by using exo-
some resin spin columns (Invitrogen) which were prepared accord-
ing to the manufacturer’s instructions. Maleimide labeling without 
EVs was performed in a parallel fashion to confirm the dye retention 
by columns and to get “mock” controls for the experiments.
Different fluorescent stains for further characterization of EVs 
were used according to the manufacturer’s instructions. Antibod-
ies were: CD41a AF647 (clone HIP8; BioLegend, San Diego, CA, 
USA), CD45 PerCP-Cy5.5 (clone 2DI; BioLegend), CD63 BV510 
(clone H5C6; BD BioScience, San Jose, CA, USA), and CD235a 
Pacific Blue (clone HI264; BioLegend). Apolipoprotein A contam-
ination was surveyed with ApoA1 PerCP (BioSite, Täby, Sweden). 
Antibodies were incubated for 30 min at RT in the dark in PBS.
Maleimide 488 and fluorescent-positive EVs were detected us-
ing a 12-channel Amnis® ImageStream®X Mark II (EMD Milli-
pore, Burlington, MA, USA) imaging flow cytometer. Samples 
were acquired at 60× magnification with low flow rate/high sensi-
tivity. The integrated software INSPIRE® (EMD Millipore) was 
used for data collection. The instrument and INSPIRE software 
were set up as follows: excitation lasers 488, 642, and 785 and chan-
nel 01 (Ch01) and Ch09 (bright field), Ch06 (scattering channel), 
plus fluorescence channels Ch02, Ch05, Ch07, Ch08, and Ch011 
were activated for signal detections.
At least 10,000 events for each sample were acquired. Positive 
events for maleimide 488 were gated based on the intensity values 
and used for further analysis. Single-color controls were used for 
compensation and unlabeled EVs were used to determine the au-
tofluorescence. Buffers with and without antibody/maleimide 488 
molecules were used to determine the background noise. Compen-
sated data files were analyzed using image-based algorithms avail-
able in the IDEAS® statistical analysis software package (version 
6.2.188.0).
Statistical Analysis
Kruskal-Wallis test together with Dunn’s multiple comparison 
test to take into account the effect of multiple testing was used to de-
termine the significance of the results within PASs, and p values 
< 0.05 were considered significant. To determine the significance be-
tween PASs on d5 sample Mann-Whitney test together with Bonfer-
roni correction was used. Spearman correlation coefficient and re-
lated p value together with R2 value of the standard curve was used 
to determine the correlation between the different platelet activation 
parameters. All statistical analyses were performed using GraphPad 
Prism v. 6.07 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
CD62P Exposure of Platelets
A statistically significant, time-dependent increase in 
CD62P exposure was observed during the 8-day storage 
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period. The exposure of CD62P in the PAS-B stored 
platelets increased from 8.5 to 78% (p = 0.0226 and p = 
0.0002 on d5 and d8, respectively) when compared to 
the positive, thrombin-activated control (Fig.  1A). In 
PAS-E platelets, the average CD62P exposure increased 
from 3.6 to 71% (p = 0.0028 on d8) compared to the 
positive control (Fig. 1A).
When CD62P exposure was determined by compari-
son to the isotype control, the CD62P exposure of PAS-B 
platelets increased from 36 to 70% (p = 0.0177 and p = 
Fig. 1. Quality control markers used for the evaluation of platelet 
activation during storage of PCs with PAS-B and PAS-E. A, B 
Time-dependent changes in the CD62P exposure of platelets when 
compared to a positive (A) or an isotype control (B). C sGPV pro-
duction of platelets. D, E Concentration (D) and size distribution 
(E) of particles in the EV samples isolated from PCs. Statistical dif-
ference within a given PAS is indicated with black and grey aster-
isks for PAS-B and PAS-E PCs, respectively. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared to d1 using Kruskal-Wal-
lis test with Dunn’s multiple comparison. Statistical difference be-
tween PAS-B and PAS-E PCs on d5 (Bonferroni-adjusted p < 0.05 
using Mann-Whitney test with Bonferroni correction is indicated 
with a red asterisk). Bars represent mean with standard deviation 
in A–D; columns present mean and bars standard deviation in E. 
Data were acquired in three independent experimental settings, 
n = 4–5 (PAS-B in all figures, PAS-E in A and B) or n = 10 (PAS-E 
in C–E). d, day; EV, extracellular vesicle; PAS, platelet additive so-
lution; PCs, platelet concentrates; sGPV, soluble glycoprotein V.
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0.0005 on d5 and d8, respectively) and from 24 to 53% 
(p = 0.0117 on d8) in the PAS-E platelets (Fig. 1B).
Regardless of the CD62P exposure determination 
method, on d5, the last day when the PC can be transfused 
to patients, platelets in PAS-B PCs exposed more CD62P 
than platelets in PAS-E PCs (Bonferroni-adjusted p = 
0.0016 for both) (Fig. 1A, B).
sGPV Content in PCs
The sGPV content of PAS-B PCs increased from the 
average of 2.1 to 24.5 pmol/109 platelets during storage 
(p = 0.0225 and p = 0.0002 on d5 and d8, respectively) 
(Fig. 1C). Also in the PAS-E PCs, the increase in sGPV 
was statistically significant, but more subtle, as the sGPV 
concentration increased from 1.8 to 12.1 pmol/109 plate-
lets (p = 0.0224 and p = 0.0002 on d5 and d8, respective-
ly) during the 8-day storage (Fig. 1C). The sGPV content 
of PCs was significantly higher in PAS-B PCs than PAS-
E PCs on d5 (Bonferroni-adjusted p = 0.0158) (Fig. 1C).
Concentration and Size Distribution of Particles  
in EV Samples
The particle concentration in EV samples of PAS-B 
PCs significantly increased during the 8-day storage pe-
riod from 1.1 × 1010 particles/mL on d1 to 1.3 × 1011 par-
ticles/mL on d8 (p = 0.0292 and p = 0.0021 on d5 and d8, 
respectively) and in the PAS-E PCs from 7.9 × 109 parti-
cles/mL on d1 to 3.7 × 1010 particles/mL on d8 (p = 0.0019 
and p < 0.0001 on d5 and d8, respectively) (Fig. 1D). Both 
the PAS-B and PAS-E PCs initially had similar particle 
concentration in EV samples, but from d2 onwards the 
particle concentration in EV samples of PAS-B PCs was 
higher compared to PAS-E PCs (Bonferroni-adjusted p = 
0.016 on d5) (Fig. 1D).
The size distribution of particles in EV samples 
changed significantly during aging only in the PAS-B 
PCs (Fig. 1E). Initially, 61% of the particles were < 100 nm 
in diameter, but after 8 days of storage, the percentage of 
particles < 100 nm had decreased to 27% (p = 0.0070). 
Consequently, the percentage of particles with a diame-
ter of 101–200 nm was initially 31%, which increased to 
56% on d8 (p = 0.0484). In contrast to PAS-B, no signifi-
cant alteration in the size distribution of particles in EV 
samples was observed in PAS-E PCs (Fig. 1E).
Characteristics of EVs Isolated from PCs
From all the maleimide-positive particles in the EV 
samples, the majority expressed CD41, indicating that the 
EVs isolated from the PCs are mainly derived from plate-
lets. Also, the EV marker CD63 was abundantly present, 
and the number of CD41- and CD63-positive particles 
Fig. 2. Correlation analysis of the three different markers for plate-
let activation. A Particle concentration in the EV samples and 
sGPV production of platelets. B Particle concentration in the EV 
samples and CD62P exposure of platelets when compared to a pos-
itive control. C sGPV production and CD62P exposure of platelets 
when compared to a positive control. The figure was compiled us-
ing data from both PAS-B and PAS-E PCs acquired from three 
independent experimental settings. EV, extracellular vesicle; PAS, 
platelet additive solution; PCs, platelet concentrates; sGPV, solu-
ble glycoprotein V.
Table 1. Frequency of surface markers identified from maleimide-
positive particles of extracellular vesicle samples isolated from 
platelet concentrate on days 1 and 8
Day 1 Day 8
ApoA1 0.8% 1.4%
CD41 68.7% 88.0%
CD45 0.6% 2.6%
CD63 29.0% 57.7%
CD235a 5.1% 2.1%
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increased during the 7-day storage. Besides the platelet-
derived particles, minute amounts of leukocyte- and 
erythrocyte-derived particles and ApoA1 were detectable 
in the EV samples (Table 1).
Correlation of EV Sample Particle Concentration with 
CD62P Exposure and sGPV Content
A strong positive correlation was observed between the 
particle concentration of EV samples and the sGPV con-
tent of PCs (R2 = 0.7639, Spearman r = 0.7906 with p < 
0.0001) (Fig. 2A), and a very strong positive correlation 
was observed between the particle concentration of EV 
samples and the CD62P exposure of platelets (R2 = 0.6626, 
Spearman r = 0.8269 with p < 0.0001) (Fig. 2B) and be-
tween the sGPV content of PCs and the CD62P exposure 
of platelets (R2 = 0.8816, Spearman r = 0.9253 with p < 
0.0001) (Fig. 2C).
Discussion
For a few decades, PCs have been prepared with PAS 
together with some plasma. Initially only plasma-con-
taining PCs were favored due to better functionality 
(estimated by corrected count increments and bleed-
ing) compared to only PAS-containing PCs [29]. The 
disadvantages of plasma-containing PCs include in-
creased incidence of adverse transfusion-related reac-
tions, mainly allergic reactions, but possibly also trans-
fusion-related acute lung injury and ABO-mismatched 
hemolysis [26]. Currently, approximately 30% of the 
volume of PAS-containing PCs still contains plasma to 
maintain platelet functionality [30], but the develop-
ment of PASs has resulted in a notable improvement of 
platelet quality and functionality, leading to experi-
mentations with decreased content of plasma in PCs 
with PASs [31]. At the moment, PAS-E is considered to 
be the best PAS developed, having similar platelet func-
tionality to the PCs with plasma in terms of corrected 
count increment [29], and it has even been hypothe-
sized whether with the addition of further components 
such as glucose [30], the advantage of plasma could be 
surpassed in favor of the PAS-only PCs. The driving 
force behind reducing the plasma content in PCs is the 
potential decline in the incidence of adverse transfu-
sion-related reactions. Additionally, the leftover plas-
ma could be utilized for fractionation to produce other 
transfusable products [26].
All common PASs contain NaCl and acetate [26]. 
NaCl is added in varying amounts to adjust PC osmolar-
ity, and acetate is added for two reasons: firstly, to pro-
vide an alternative energy source in addition to glucose, 
as it reduces lactate production and consequently influ-
ences the pH of the PC; secondly, during the enzymatic 
processing of acetate, carbon dioxide is formed, which 
further reacts with water to form bicarbonate providing 
increased buffer capacity to PCs [32]. Most PASs also 
contain citrate as an anticoagulant, which provides yet 
another energy source and added buffer capacity [26, 
33]. Furthermore, PAS-E contains phosphate, potas-
sium, and magnesium, whereas PAS-B does not [26]. 
Phosphate is added to PCs for improved buffer capacity 
and to stimulate platelet glycolysis [34]. PASs with dif-
ferent compositions have been extensively tested, and 
addition of potassium and magnesium has been con-
nected to decreased cytokine [35] and lactate [36, 37] 
production as well as decreased CD62P [37, 38] and 
phosphatidylserine [38] exposure of platelets. Our re-
sults on time-dependent platelet activation are in line 
with these previous findings as based on the three as-
sessed platelet activation markers (CD62P exposure of 
platelets together with sGPV and EV content of PCs), 
platelets in PAS-B PCs were more activated than PAS-E 
PC platelets on d5, the last day when PC could be trans-
fused to patients. A significant increase in the activation 
state of the PAS-B platelets was detected with all three 
activation markers at d5 sampling. For PAS-E PCs a sig-
nificant increase in sGPV content and EV particle con-
centration was observed on d5 as well, whereas a sig-
nificant increase in CD62P exposure was observed only 
on d8. Although it is unclear how altered PAS composi-
tion affects platelet activation, the mechanism might in-
volve membrane potassium movement and permeabil-
ity [39]. Similarly to CD62P and sGPV, a time-depen-
dent increase in EV concentration in PCs was observed, 
in line with previously published results [40, 41]. Based 
on the current data, EV concentration correlated well 
with the sGPV content and the CD62P exposure of 
platelets, indicating that EV concentration could be 
used to indicate platelet activation in PCs.
As shown previously, determination of both the 
CD62P exposure of platelets and the sGPV content in 
PCs were sensitive and reproducible methods to detect 
platelet activation [6, 27]. As an additional advantage of 
these methods, the maximum extent for both parame-
ters can be determined, which helps to estimate the 
platelet activation state by giving either a relative or an 
absolute [42] boundary value (for CD62P and sGPV, re-
spectively). Contrary to CD62P and sGPV measure-
ments, it is not possible to generate an accurate control 
for a maximum EV production as different agonists pro-
duce varying amounts of platelet-derived EVs [23]. Al-
though current PC manufacturing processes ensure 
minimal cell contamination, EVs from erythrocytes, 
platelets, and leukocytes are present in PCs already due 
to the plasma component of the PCs, as shown in this 
study and by others [14]. It is difficult to determine 
whether the platelet-derived EVs are produced due to 
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aging-related platelet activation, as a result of interac-
tion of buffy coat components during storage, or even 
due to an apoptosis-like process [43]. The interaction of 
buffy coat EVs and platelets might explain the platelet 
activation to some degree [44] and consequently the 
high variation in the particle concentration of EV sam-
ples from PCs especially seen in the d8 samples. Addi-
tionally, considering the variance in donors [45, 46], 
current EV sample preparation methods [47], and the 
lack of standardized and accurate EV quantification 
methods [48–50], it must be stressed that although EV 
concentration seems to be a potential marker of platelet 
activation, significant development and standardization 
will be needed before the current methods can be re-
placed to determine platelet activation state in PCs. The 
authors would like to underline that EVs could still be 
used as a complementary platelet activation marker to 
CD62P and sGPV.
In addition to EV concentration being a marker for 
platelet activation similarly to CD62P or sGPV, EVs 
could also provide qualitative information of PC aging 
and possibly even functionality. Besides influencing the 
size [23, 51] and the molecular cargo [23, 24, 52] of pro-
duced EVs, platelet activating conditions have been 
shown to affect the subsequent function of produced 
EVs [53], and future studies could concentrate on the 
qualitative information provided by PC-derived EVs. 
In the current study, we observed a time-dependent in-
crease in the size distribution of particles in the EV sam-
ples from platelets stored in PAS-B. Since platelet acti-
vation was influenced by PAS composition, it may also 
have an influence on the produced EVs. Another pos-
sible explanation for the altered size could be an arte-
factual clumping of EVs, which has been shown previ-
ously [54]. However, the effect was only subtle com-
pared to the size of for instance EV doublets and without 
a corresponding decline in the particle concentration, 
so formation of stickier EVs is unlikely to explain the 
current results. A change in the EV population in the 
PC, reflected by size change, could also have functional 
effects upon transfusion [55]. To understand the poten-
tial effects of EVs in storage lesion, adverse transfusion-
related reactions, or immunomodulatory functions in 
general, it will be necessary to carefully examine the 
molecular composition of EV populations by lipido-
mics, proteomics, or metabolomics [56–58]. Moreover, 
characterizing the PC-derived EVs could also be a step 
towards personalized transfusion treatments, where 
patients could be targeted to receive PCs that would 
best suit their needs [45, 46], e.g., PCs that have more 
procoagulant potency in the case of severe bleeding. By 
doing this, the utilization of PCs could be optimized, 
leading to less wasted PCs and hopefully to transfusions 
with less adverse transfusion-related reactions.
In conclusion, EVs may be a useful tool in the quality 
control of PCs in the future, and the molecular character-
ization of EVs could provide more information about the 
state and usability of the PCs, ultimately benefitting pa-
tients receiving transfusions.
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A B S T R A C T
Platelets are collected for transfusion to patients with diﬀerent haematological disorders, and for logistical
reasons, platelets are stored as concentrates. Despite carefully controlled conditions, platelets become activated
during storage, and platelet concentrates (PlaCs) may cause adverse inﬂammatory reactions in recipients. The
time-dependent changes in the lipidome of clinical PlaCs, platelets isolated from PlaCs, and extracellular vesicles
(EVs) thereof were examined by mass spectrometry. The relative amount of arachidonic acid containing gly-
cerophospholipids, especially those in the phosphatidylethanolamine and phosphatidylserine classes during
storage, but the relative amount of other polyunsaturated fatty acid containing glycerophospholipids remained
stable in all sample types. These changes were not directly translated to lipid mediator (LM) proﬁle since the
levels of arachidonic acid-derived proinﬂammatory LMs were not speciﬁcally elevated. Instead, several mono-
hydroxy pathway markers and functionally relevant LMs, both proinﬂammatory and proresolving, were detected
in the PlaCs and the EVs, and some representatives of both kind clearly accumulated during storage. By Western
blot, the key enzymes of these pathways were shown to be present in platelets, and in many cases, EVs. Since the
EVs were enriched in the fatty acid precursors of LMs in their (phospholipid) membranes, harboured LM-pro-
ducing enzymes, contained the related monohydroxy pathway markers, and secreted the ﬁnal LM products,
PlaC-derived EVs could participate in the regulation of inﬂammation and healing, and thereby aid the platelets
in exerting their essential physiological functions.
1. Introduction
Besides being structural components and the means for storing en-
ergy, fatty acids and membrane lipids play signiﬁcant roles in cell
signalling pathways [1–3]. For platelets, membrane lipids are a pre-
requisite for optimal functioning and therefore, their membrane lipi-
dome is under constant enzymatic remodelling and regulation [4].
Glycerophospholipid (GPL)-derived polyunsaturated fatty acids
(PUFAs) such as arachidonic acid (20:4n-6, AA), eicosapentaenoic acid
(20:5n-3, EPA), n-3 docosapentaenoic acid (22:5n-3, DPA), and
docosahexaenoic acid (22:6n-3, DHA) are used to produce lipid med-
iators (LMs), which play vital roles in the diﬀerent phases of in-
ﬂammation, including the resolution and healing process [5–8]. In
contrast to the well-characterized, time-dependent platelet GPL al-
terations and related mechanisms [9–12], the role of LMs in platelets is
incompletely understood. Speciﬁc LMs, such as thromboxane (Tx)A2,
prostaglandin (PG)D2 and PGE2, have well known functions in platelets
[13–15], but the biological actions of the recently discovered pro-
resolving LMs, such as resolvins (Rvs), protectins and maresins, remain
of interest [16–19] in both platelets and their extracellular vesicles
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(EVs).
Platelet concentrates (PlaC) are widely used in clinical settings to
treat patients with thrombocytopenia (low platelet count), to replace
platelets in case of massive bleeding and to prevent bleeding in patients
with cancer, malignant blood diseases, or other malfunctions of plate-
lets. The lifespan of a platelet in the circulation is typically 8 to 10 days
[20], and currently, the storage time of clinical PlaCs is 5 to 7 days
[21]. In addition to replenishing the patient's platelet count to a hae-
mostatically functional level, clinical PlaCs may contribute to the
overall immunological status of a patient, as platelets communicate
with and modulate other cells involved in immunological reactions
[15,22–27].
One way of cell communication is mediated through the secretion of
EVs, which are protein-, lipid-, carbohydrate-, nucleic acid-, and me-
tabolite-containing lipid bilayered particles produced by most cells
[28,29]. Platelets are sensitive cells that are activated in multiple ways
including mechanical stress [30], chemical agonists [31], and ageing
[32]. When activated, platelets produce EVs with an activation-de-
pendent composition [33,34]. During storage, platelet activation and
the concentration of EVs increase in the PlaC [35–37], which may aﬀect
the recipient's transfusion response. The molecular mechanisms un-
derlying adverse transfusion responses, such as allergic and febrile
nonhemolytic reactions, are still poorly understood [38]. Analogously,
the increasing numbers of EVs in ageing erythrocyte concentrates have
been associated with a proinﬂammatory host response [39].
During ageing, at least two types of phospholipid-related alterations
occur in platelets within the PlaC: following the depletion of ATP,
membrane phospholipid asymmetry cannot be maintained by lipid
translocating enzymes and is eventually lost [40], which is an event tied
to EV formation [41]. In addition to the defective control of transbi-
layer lipid distribution, lipid peroxidation and EV secretion cause losses
of phospholipid content [12,42]. As the acyl chains of membrane GPLs
may be cleaved and converted to LMs, it is important to investigate the
abundance of the molecular species within the diﬀerent GPL classes
along with the enzymes required for LM biosynthesis. Depending on the
presence of precursor PUFAs and the enzymes that modify them, the
resulting downstream LMs exhibit proinﬂammatory properties, pro-
resolving properties, or have dual functions [7,43,44]. Depending on
these functions, LMs are generally categorized as proinﬂammatory
mediators or specialized proresolving mediators (SPMs). SPMs have
been shown to modulate the resolution, i.e., the active dampening
phase of inﬂammation, in several disease models [5,45,46]. It has been
demonstrated that only pico to nanomolar concentrations of SPMs are
required to exert their eﬀects on cellular functions [47], and the recent
technological development has now enabled the discovery of novel SPM
structures. As PlaC lipids may have an impact on the immunological
cells of a patient receiving the clinical PlaC, it is crucial to comprehend
the time-dependent LM alterations in the platelets and EVs of the
clinical PlaCs by studying i) how the shifts in the GPL proﬁles are
translated to the LM proﬁle, ii) whether certain LMs or their pathway
markers are transported in EVs or platelets, and iii) to what extent the
LMs originated from platelets or their EVs inﬂuence the surrounding
cells. By solving these questions, we can begin to elucidate the lipid-
mediated eﬀects of PlaC transfusion from an immunological perspec-
tive.
In the current study, time-dependent alterations in GPL composition
during the storage of clinical PlaCs were investigated from three sample
types: PlaCs as a whole, platelets, and PlaC-derived EV samples. Second,
the presence of speciﬁc enzymes required for LM production was ver-
iﬁed. Furthermore, the LMs of the PlaCs and EVs were proﬁled to un-
ravel whether certain LMs become more prevalent as a function of time.
2. Materials and methods
2.1. Sample preparation
In total, ﬁve standard leukocyte-reduced clinical-grade PlaCs, each
derived from four buﬀy coats of ABO RhD-matched whole blood do-
nations, were obtained from the Finnish Red Cross Blood Service
(Helsinki, Finland) and handled anonymously, as accepted by the
Finnish Supervisory Authority for Welfare and Health (Valvira,
Finland).
Sterile sampling was done using 50 mL syringes (Henke-Sass, Wolf
GmbH, Tuttlingen, Germany) and 18-gauge needles (Terumo, Tokyo,
Japan). Before sampling, the contents of the storage bag's tube were
emptied into the storage bag, and the PlaC was mixed by gently turning
it from side to side 5 times. This procedure was repeated 3 times to
obtain a representative sample. After extracting 20 mL of sample via the
storage bag's tube, the tube was resealed. The sampling days (d) were
d1, d2, d5, and d8 counted from blood donation (d0), where d1 was the
production day of a PlaC. The d1 sampling was performed within 2 h
after the PlaCs were available from the production line, approximately
at 3 p.m., but the d2–d8 samplings were performed at 9 a.m. PlaCs were
stored at 22 °C under constant horizontal agitation and subjected to
standard quality control of the Finnish Red Cross Blood Service (visual
inspection of PlaC, and determination of glucose concentration, lactate
concentration, potassium concentration, pCO2, pO2, pH, and residual
leukocyte count). Additionally, microbiological cultures were prepared
from the PlaCs after the ﬁnal sampling day to exclude possible micro-
bial contamination (data not shown).
Aliquots of 250 μL of untreated PlaC were snap frozen and placed
under argon gas to store the lipids. The PlaC samples were stored at
−70 °C until the analysis. A total of 17 mL of PlaC was used to prepare
an EV sample. To prevent platelet activation, Anticoagulant Citrate
Dextrose Solution pH Eur Solution A (Terumo BCT, Lakewood, CO,
USA) and Apyrase (Sigma-Aldrich, St. Louis, MO, USA) were added at
ﬁnal concentrations of 4.25% v/v and 2 U/mL, respectively, and the
PlaCs were diluted 1:4 with phosphate-buﬀered saline (PBS (Thermo
Fisher Scientiﬁc, Waltham, MA, USA)). The diluted PlaCs were cen-
trifuged at 650 × g at RT for 7 min (Eppendorf centrifuge 5810R,
(Eppendorf, Hamburg, Germany)) without braking, and the pelleted
platelets were placed under argon and snap frozen. The supernatant
was centrifuged at 1560 × g at RT for 20 min (Eppendorf centrifuge
5810R), and the platelet content of the supernatant was reduced to
1 × 106 platelets/mL, as conﬁrmed with Coulter Cell counter T-540
(Beckman Coulter). To extract the whole EV population from the PlaC,
the supernatant was ultracentrifuged at 100000 × g at 4 °C for 1 h
(MLA-50 rotor, k-factor 92 (Beckman Coulter)). The supernatant was
carefully decanted and the remaining supernatant was removed with a
pipette, after which the EV pellet was resuspended into 200 μL of PBS
and divided into two aliquots of 90 μL for lipid analysis and a 20 μL
aliquot for Nanoparticle Tracking Analysis (NTA) in Protein LoBind
tubes (Eppendorf). Immediately after preparing the aliquots, samples
were snap frozen, placed under argon and stored at −70 °C until lipid
analysis.
2.2. Nanoparticle Tracking Analysis
The particle number and size distribution of the particles in the EV
samples were analysed with NTA instrument LM14C equipped with a
violet (405 nm, 70 mW) laser (Malvern Instruments Ltd., Malvern, UK)
and an sCMOS camera (Hamamatsu photonics K.K., Hamamatsu,
Japan) at controlled temperature of 22.0 °C and camera level 14 using
Nanosight software 3.0 (Malvern Instruments Ltd.). EV samples were
diluted 1:1000, 1:2000, 1:5000 and 1:10000 with ﬁltered (0.2 μm) PBS
on d1, d2, d5 and d8 samples, respectively, and three videos of 90 s
were recorded from samples, mixing the sample manually between
measurements. Data were analysed with NanoSight NTA 3.0 software
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using a detection threshold 5 and a gain of 10.
2.3. EV characterization with Amnis imaging ﬂow cytometer
EV samples were carboxyﬂuorescein succinimidyl ester (CFSE)-la-
belled using 20 μM CFSE diluted from 5 mM CFSE in DMSO and further
in D-PBS. 100 μL of EV samples, 150 μL PBS, and 250 μL 20 μM CFSE
were incubated for 15 min in the dark at +37C. Samples were puriﬁed
using SEC prepared as in [48], and fractions 8 and 9 were collected and
used for the analysis. CFSE positive EVs were analysed using excitation
laser 488 in 12 channel Amnis® ImageStream®X Mark II (EMD Milli-
pore) imaging ﬂow cytometer. Samples were acquired at 60 × magni-
ﬁcation with low ﬂow rate/high sensitivity. The integrated software
INSPIRE® (EMD Millipore) was used for data collection. The instrument
and INSPIRE software were set up as follows: channels 01 and Ch9
(bright ﬁeld, BF), Ch06 (scattering channel), plus ﬂuorescence channel
Ch02 were activated for signal detection. Single colour controls were
used for compensation and unlabeled EVs were used to determine the
auto ﬂuorescence. Buﬀer with and without CFSE molecules were used
to determine the background noise. Compensated data ﬁles were ana-
lysed using image-based algorithms available in the IDEAS® statistical
analysis software package (version 6.2.188.0).
2.4. Western blotting
To ensure suﬃcient sample material for Western blot analysis, a
separate sampling was conducted, where the sampling volume from
PlaC was increased to 50 mL. Samples were collected from two PlaCs on
d1 and d8, and sample collection and processing were conducted si-
milarly as above. One tablet of cOmplete Mini EDTA-free Protease
Inhibitor Cocktail (Roche, Basel, Switzerland) was dissolved into
1.5 mL of PBS, and a volume equal to 1/6 of the sample volume was
added to samples before determining the protein content using the
Pierce BCA Protein Assay Kit (Thermo Fisher Scientiﬁc). The samples
containing 25 μg of protein for each well were prepared together with
4× Laemmli sample buﬀer (Bio-Rad, Hercules, CA, USA) containing
10% 2-mercaptoethanol (Sigma-Aldrich) and boiled for 5 min. Then
samples were loaded onto Mini-PROTEAN TGX Stain-Free protein gels
with a 4–20% gradient (Bio-Rad) in biological duplicates together with
Precision Protein Plus WesternC Blotting Standard (Bio-Rad). Gels were
run for 50 min at 170 V in 1× Tris/Glycine/SDS Buﬀer (Bio-Rad), and
proteins were blotted for 20 min with 1.3 A up to 25 V using a semi-dry
blotting machine Trans-Blot Turbo (Bio-Rad), 1× Transfer Buﬀer (Bio-
Rad), including 20% methanol (Merck), and Trans-Blot Turbo Mini
Nitrocellulose Transfer Packs (Bio-Rad), where the original 0.2 μm ni-
trocellulose membrane was replaced with a 0.45 μm nitrocellulose
membrane (Bio-Rad). Transfer of the proteins was conﬁrmed by ima-
ging gels and membranes using the ChemiDoc Touch Imaging System
(Bio-Rad), followed by 1 hour blocking of the membrane at room
temperature with 6% fat-free milk powder solution (Valio, Helsinki,
Finland) prepared in 1× Tris buﬀer (Sigma-Aldrich) containing 0.05%
Tween 20 (Sigma-Aldrich).
Antibodies against 12-Lipoxygenase ((12-LOX) Novus Biologicals,
Littleton, CO, USA, clone 1C3), 15-Lipoxygenase 1 ((15-LOX1) Novus
Biologicals, clone 3G8), 15-Lipoxygenase 2 ((15-LOX2) Novus
Biologicals, clone 4A7), Apolipoprotein (Apo)A1 (Medix Biochemica,
Espoo, Finland, product 100264), ApoB (Medix Biochemica, product
100261), CD9 (Becton Dickinson, Franklin Lakes, NJ, USA, clone M-
L13), CD41 (Beckman Coulter, clone sz22), CD63 (Becton Dickinson,
clone H5C6), Cyclooxygenase (COX)1 (Thermo Fisher Scientiﬁc,
Waltham, MA, USA, clone AS70), COX2 (Thermo Fisher Scientiﬁc,
clone AS66), Cytochrome p450 (CYP) 1A1 (Novus Biologicals, clone
6G5), CYP2J2 (Novus Biologicals, clone 2D10), CYP5A1 (Novus
Biologicals, clone OTI2C1), cytosolic Phospholipase A2 ((cPLA2) Santa
Cruz Biotechnology, Inc., Dallas, TX, USA, clone sc-454), and secretory
Phospholipase A2 ((sPLA2), Abcam plc, Cambridge, UK, ab23705) were
diluted 1:200 (15-LOX1, 15-LOX2 and CYP2J2), 1:250 (CD9 and CD63),
1:500 (COX1, COX2, and cPLA2), 1:1000 (ApoA1, ApoB, CYP1A1,
CYP5A1, and sPLA2), 1:2000 (12-LOX), or 1:10000 (CD41) in 1 × Tris
buﬀer containing 2% milk and 0.05% Tween 20 and incubated over-
night. The membranes were ﬁrst rinsed and then washed with Tris
buﬀer containing 0.05% Tween 20 3 × 10 min followed by incubation
with goat anti-mouse or anti-rabbit IgG (H + L)-HRP conjugates sec-
ondary antibodies (Bio-Rad), containing Precision Protein StrepTactin-
HRP Conjugate (Bio-Rad) diluted 1:3000 and 1:10000, respectively, to
Tris buﬀer containing 2% milk and 0.05% Tween 20. After incubation,
the membranes were ﬁrst rinsed and then washed 2 × 10 min in Tris
buﬀer containing 0.05% Tween 20 and 10 min in Tris buﬀer, followed
by the addition of 1 mL of Amersham ECL Western Blotting Detection
Reagents (GE Healthcare, Chicago, IL, USA) per membrane, mixed 1:1
as instructed. After a 1-minute incubation at room temperature, the
chemiluminescence of the membranes was captured using a ChemiDoc
Touch Imaging System.
2.5. Phospholipid analysis
Phospholipids of the PlaC, platelet, and EV samples were analysed
as reported previously [49]. Brieﬂy, total lipids were extracted using
Folch extraction [50], and the lipid extracts, in chloroform:methanol
(1:2 v:v, both LiChrosolv® (Merck, Darmstadt, Germany)), spiked with
internal standards (phosphatidylcholine (PC) 28:2, PC 40:2, PC 44:2;
phosphatidylethanolamine (PE) 28:0, phosphatidylserine (PS) 28:0, and
sphingomyelin (SM) 17:0 (Avanti Polar Lipids Inc., Alabaster, AL,
USA)) and supplemented with 1% NH4OH (Surprapur®, Merck), were
infused into an electrospray ionization source of triple quadrupole mass
spectrometer (MS) Agilent 6490 Triple Quad LC/MS with iFunnel
technology (Agilent Technologies, Santa Clara, CA, USA) using a ﬂow
rate of 10 μL/min, an ion source temperature of 250 °C, instrument
collision energies of 5–45 eV depending on the lipid class, and nitrogen
as the nebulizing (20 psi) and drying gas (11 μL/min at 250 °C).
After the MS+ or MS− scan survey, the GPL and SM species were
detected using MS/MS scans speciﬁc to a given GPL class: m/z 184 for
PC and SM, neutral loss scans of 141 amu for PE, and 185 amu for PS
[51]. PE plasmalogen (PEp) species were analysed from the MS− scan
after veriﬁcation from fragment-speciﬁc scans for the vinyl ether chains
at the sn-1 position (e.g., m/z 364, 390, and 392 for 16:0p, 18:1p, and
18:0p, respectively [52]). The resulting spectra were processed using
MassHunter Workstation Qualitative Analysis Software (Agilent Tech-
nologies, Inc.), and the quantiﬁcation of individual GPL species was
conducted using free software called Lipid Mass Spectrum Analysis [53]
through comparison of the sample peak intensities to the internal and
external standards (PE 37:4 and PS 37:4 (Avanti Polar Lipids)) with
known concentrations. The results were determined and expressed as
molar percentages (mol%) calculated separately for each GPL class. To
keep technical variation at a minimum, the average relative con-
centration of a GPL species had to exceed 0.5 mol% across all sample
types and time points within a given GPL class to be included in the
quantiﬁcation, and for PEp species, the 5 most abundant PEp species
were analysed. For bar graph visualization, thr GPL species abundance
threshold was set to> 1 mol% (after normalizing data to 100 mol%,
when species contributing< 0.5 mol% were deducted) in every sample
type studied.
2.6. Fatty acid analysis
Fatty acids of PlaC were identiﬁed and quantiﬁed from trans-
methylated lipid extracts as described previously [49]. Samples (d1 and
d8) were extracted using Folch extraction [50], evaporated into dryness
under a nitrogen gas stream, and transmethylated [54] by heating the
samples in 1% H2SO4 (Sigma-Aldrich) in methanol (LiChrosolv®,
Merck) at a temperature of 96 °C under a nitrogen atmosphere for
120 min. The formed fatty acid methyl esters (FAMEs) were recovered
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with hexane (LiChrosolv®, Merck) in two steps, dried overnight in an-
hydrous Na2SO4 (EMSURE®, Merck), and analysed using a gas chro-
matograph (Shimadzu GC-2010 Plus, Kyoto, Japan) equipped with an
auto injector (AOC-20i), a ﬂame ionization detector (FID), and a ZB-
wax capillary column (30 m, 0.25 mm ID, 0.25 μm ﬁlm, Phenomenex,
Torrance, CA, USA). FAME identiﬁcation was based on the retention
time and the use of authentic standard mixtures of known composition
and conﬁrmatory recordings of mass spectra (GC-2010 Plus with GCMS-
QP2010 Ultra, Shimadzu, equipped with a similar column as in the GC-
FID system). Quantiﬁcations were based on FID responses, which were
corrected according to the theoretical response factors [55] and cali-
brations with quantitative FAME standards (Supelco, Bellefonte, PA,
USA). Fatty acid proportions were calculated as mol%, and fatty acids
were marked using the following abbreviations: [carbon number]:
[number of double bonds] n-[position of the ﬁrst double bond calcu-
lated from the methyl end] (e.g., 22:6n-3 for DHA). Phospholipid al-
kenyl chains were detected as dimethyl acetals (DMAs).
2.7. Lipid mediator proﬁling
PlaC and EV samples were thawed on ice and 4 volumes of ice-cold
methanol (Thermo Fisher Scientiﬁc) containing internal standards (d8-
5S-hydroxyeicosatetraenoic acid (HETE), d5-RvD2, d5-lipoxin (LX)A4,
d4-PGE2, d4-leukotriene (LT)B4, d5-LTC4, d5-LTD4, and d5-LTE4; 500 pg
each (Cayman Chemical) was added to the sample. LMs were extracted
and identiﬁed as described previously [8,56,57]. Brieﬂy, the samples in
methanol were incubated for 45 min at−20 °C for protein precipitation
and centrifuged at 1900 × g at 4 °C for 10 min. The methanol content
of the supernatant was evaporated to<1 mL using a nitrogen gas
stream, and the LMs were extracted with an automated Extra-Hera
system (Biotage, Uppsala, Sweden) employing solid-phase extraction as
described previously [8]. LMs were eluted with methyl formate
(Thermo Fisher Scientiﬁc) and methanol (for sulﬁdo-conjugates). The
samples were concentrated and injected into a liquid chromatography-
tandem mass spectrometry (LC-MS/MS) system (LC-20AD HPLC (Shi-
madzu, Kyoto, Japan) and an SIL-20AC autoinjector (Shimadzu) paired
with QTrap 6500+ (ABSciex, Framingham, MA, USA)). LMs were
identiﬁed with multiple reaction monitoring by identifying the parent
(Q1) and daughter (Q3) ions in both negative and positive (for sulﬁdo-
conjugates) ionization modes [8,56,57]. Each LM was identiﬁed using
previously published criteria [8,57] by matching the retention time of
the authentic and synthetic standards (from Cayman Chemical, pre-
pared in house or provided by Charles N. Serhan, Harvard Medical
School, Boston, MA, USA) and identifying at least 6 diagnostic ions
from the MS/MS spectra (Supplementary Fig. 1). For the chiral analysis
of monohydroxy pathway markers, the methyl formate fraction was
extracted as described above. Chiral LC-MS/MS was conducted for
platelet PlaC samples at days 5 and 8 as previously described [58].
2.8. Statistical analysis
Statistical signiﬁcance was determined using Friedman's test with
Dunn's multiple comparison test, and p-values ≤ 0.05 were considered
signiﬁcant. Statistical analysis was performed using GraphPad Prism
v7.02 (GraphPad Software Inc., La Jolla, CA, USA).
Principal component analysis (PCA) was conducted and visualized
using the free online tool MetaboAnalyst [59]. For analysis, all quan-
tiﬁable phospholipid classes, sample types, and sample days were im-
ported as mol% excluding species with mol% < 0.5. In data input for
MetaboAnalyst, features with> 25%, missing values were removed
and missing values were estimated using Bayesian PCA. The imported
data were log transformed and auto scaled (mean centred and divided
by the square root of each variable) for the analysis.
3. Results
3.1. Extracellular vesicles accumulate to the platelet concentrate during
storage
During storage, the particle concentration in the EV samples in-
creased signiﬁcantly (p= 0.0087) from a median of 7.5 × 109 parti-
cles/mL in the d1 sample to 2.7 × 1010 particles/mL in the d8 sample
(Fig. 1a). Despite the increased particle concentration, the particle size
of EV samples remained unchanged throughout storage, with 60% of
the particles being 100–200 nm (Fig. 1b). In total, 71% of CFSE parti-
cles of the EV sample expressed CD41 (data not shown).
3.2. Storage alters the glycerophospholipid composition of platelet
concentrates
Mass spectrometry of PC, PE, and PS species compositions in PlaCs,
platelets, and EV samples revealed a set of storage time-dependent
changes, which were common for all the sample types. Although the
relative fatty acid proﬁle of PlaC remained stable during the storage in
many aspects, a slight decrease in paired comparisons of the relative
amount of AA (and its precursor linoleic acid, 18:2n-6) was observed
(data with medians in Supplementary Fig. 2). While a time-dependent
accumulation in the relative amount of GPLs containing 38:4, the major
source of AA, was observed especially in the PE, PEp, and PS species
from the PlaC, platelets and EV samples, only modest changes in the
Fig. 1. Concentration (A) and size distribution (B) of particles in the extracellular vesicle samples on day (d)1, d2, d5, and d8. In Fig. A, each dot represents an
averaged result of three replicate measurements of a single extracellular vesicle sample, and bars represent median with interquartile range. In Fig. B, columns
represent median and bars interquartile range. n = 5, **p≤ 0.01 using Friedman's test with Dunn's multiple comparisons test.
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relative amounts of GPL species serving as the source of n-3 PUFAs,
EPA, DPA and DHA were found.
In the PC species from PlaCs, platelets, and EV samples, a consistent
and statistically signiﬁcant increase in the relative amount of species
32:0 and 38:4 was detected, while the relative amount of species 34:2
decreased with increasing storage time (Fig. 2). In the EV samples, 38:4
and 40:5 were the only polyunsaturated PC species having a statistically
signiﬁcant increase in the relative amount in contrary to other poly-
unsaturated PC species with signiﬁcant change in the relative amount.
The general time-dependent decrease in the relative amount of poly-
unsaturated PC species was reﬂected as a respective relative increase in
the monounsaturated PC species. In general, the relative PC species
proﬁles of the d8 EV samples were very similar to the corresponding
proﬁles of the PlaCs, whereas the relative PC species proﬁles of platelets
were notably diﬀerent compared to these two.
Regarding PE, the relative levels of a minor species, 34:1, con-
sistently declined in all sample types. Quantitatively, the most im-
portant PE species, 38:4, showed remarkable and statistically sig-
niﬁcant relative accumulation in the d5 and d8 EV samples, and the
relative amount was also signiﬁcantly increased in d8 platelets (Fig. 3).
Overall more PE species variation was observed in the EV samples than
in the PlaCs or platelets, which was also applicable for PEp species, a
prominent AA source. Initially PEp species 38:5 and 38:6 together
comprised 50% of total PEp, but on d8 the PEp proﬁle resembled more
of PlaC and platelets, as the relative amount of PEp species 36:4 and
38:4 increased signiﬁcantly, together reaching 66% of total PEp (Sup-
plementary Fig. 3).
In the PS species, the only statistically signiﬁcant change common to
all sample types was the relative increase in the most prominent PS
species, 38:4 (Fig. 4). In the EV samples, the relative amount of the
rather short polyunsaturated species (e.g., 36:4 and 36:5) decreased
signiﬁcantly with time, similarly to the trend observed for the PE spe-
cies.
In the PCA score plot, the PlaC and platelet samples were clustered,
forming two clearly deﬁned populations with uniform phospholipid
species composition (Fig. 5), whereas the EV samples were dispersed
wider, showing a concentrate age -dependent, large variation in phos-
pholipid species composition when all quantiﬁed phospholipid classes
(Figs. 2–4, Supplementary Figs. 3–6) were included in the analysis. The
three diﬀerent populations did not overlap with each other when 95%
Fig. 2. Variation in the relative abundance of phosphatidylcholine (PC) species in the platelet concentrates, platelets, and extracellular vesicles on day (d)1, d2, d5,
and d8. Columns represent median and bars interquartile range. n = 5; **p≤ 0.01, *p≤ 0.05 using Friedman's test with Dunn's multiple comparisons test.
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conﬁdence intervals were visualized.
3.3. Enzymes linked to lipid mediator biosynthesis are expressed and active
in platelet concentrates
Next, Western blot analysis was performed to prove the presence of
LOX, COX, CYP and PLA2 species in the samples isolated from PlaCs.
From lipoxygenases, 12-LOX, and 15-LOX2 were detected in all the
sample types in both d1 and d8 samples, whereas 15-LOX1 was less
prominent in the samples. Additionally, cyclooxygenases COX1 and
COX2 were detected in PlaC and EV samples, but only COX1 was de-
tected in platelets. From the analysed CYP species, only CYP2J2 and
CYP5A1, also known as the thromboxane synthase, were detected in all
the sample types, as CYP1A1 was detected only in PlaCs and EV sam-
ples. From PLA2 species, cPLA2 was detected in all the sample types, but
sPLA2 was present only in platelets and EV samples (Fig. 6a, for original
images of membranes, see Supplementary Figs. 7–11).
As controls, ApoA1, ApoB, CD9, CD41, and CD63 were also detected
in the samples. ApoA1 and ApoB levels were detected to show the
presence of HDL and LDL, normal plasma components in PlaCs. No
change in the levels of the apolipoprotein intensities was observed
between the d1 and d8 samples. CD41, a platelet membrane marker
prominently present also in platelet-derived EVs, was equally present in
the d1 and d8 samples from the PlaCs and platelets, but in the EV
samples the level of CD41 markedly increased from the d1 samples to
d8 samples similarly to the common EV marker CD9, (also known to
reside on platelet surfaces). The increased intensities of the CD41 and
CD9 bands were paralleled with the increased intensities in the d8
bands of the enzymes 12-LOX, COX1, CYP1A1, CYP5A1, and cPLA2.
The expression of the EV marker CD63 in the EV samples remained
stable at both time points (Fig. 6a).
When investigating the chirality of the monohydroxy pathway
markers resulting from the enzymatic processing of GPLs, a clear ten-
dency towards either the R or S conﬁguration was observed, as the
relative abundance of the dominant conﬁguration was>80%. The
majority of the 13 monohydroxy pathway markers analysed were in the
S conﬁguration, and only in the case of 4 monohydroxy pathway
markers (13-hydroxydocosahexaenoic acid (HDHA), 13-
Fig. 3. Variation in the relative abundance of phosphatidylethanolamine (PE) species in the platelet concentrates, platelets, and extracellular vesicles on day (d)1, d2,
d5, and d8. Columns represent median and bars interquartile range. n = 5; **p≤ 0.01, *p≤ 0.05 using Friedman's test with Dunn's multiple comparisons test.
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hydroxydocosapentaenoic acid (HDPA), 11-hydroxyeicosapentaenoic
acid (HEPE), and 11-HETE) R was the dominant conﬁguration (ex-
amples in Fig. 6b).
3.4. Lipid mediators accumulate in platelet concentrates during storage
Gas chromatography conﬁrmed that the major precursors for LM
production in PlaC were AA, DHA, dihomo-γ-linoleic acid (20:3n-6),
EPA, n-3 DPA, and adrenic acid (22:4n-6), contributing to 8%, 1.5%,
1.2%, 0.75%, 0.55%, and 0.35% of all acyl and alkenyl chains, re-
spectively. PlaC samples contained three times the amount of AA and
dihomo-γ-linoleic acid, the major n-6 PUFA precursors for proin-
ﬂammatory LMs, compared to n-3 PUFAs EPA, DPA and DHA (data
with medians in Supplementary Fig. 2).
Numerous LMs and their pathway markers were identiﬁed from the
PlaCs and EV samples: In the PlaCs, several bioactive metabolites of AA,
EPA, n-3 DPA, and DHA, both SPMs and proinﬂammatory mediators
were detected (Fig. 7, Supplementary Table 1). The content of some
LMs (e.g., sulﬁdo-conjugate LTE4) remained unchanged, whereas cer-
tain LMs and pathway markers, such as AA-derived TxB2, PGD2, PGE2,
and 15-epi-LXA4, EPA-derived RvE2, and DHA-derived RvD4, RvD5,
17R-RvD1, 17R-RvD3, PDX, 7R,Δ12-trans-diHDHA, and 4S,14S-
diHDHA, showed a statistically signiﬁcant, time-dependent accumula-
tion during storage (Fig. 7, Supplementary Table 1). The most notable
accumulation in SPMs was of 17R-RvD1, where an almost 100-fold
increase was detected (median from 2.7 to 209.5 pg/2 × 108 platelets,
p= 0.0001). In the case of TxB2, which is the hydrolysed form of the
most prevalent and extremely short-lived proinﬂammatory mediator
from platelets, TxA2, an over 10-fold increase was observed during
storage (median from 34.4 to 407.1 pg/2 × 108 platelets, p= 0.0003),
but the absolute amount of TxB2 was higher than that of 17R-RvD1.
Additionally, the levels of monohydroxy pathway markers derived from
AA, EPA, n-3 DPA, and DHA metabolomes drastically accumulated in
the PlaC samples (Supplementary Table 1).
The EV samples contained, to a large extent, the same LMs as the
PlaCs, but they were present in lower amounts due to the minute
amount of material in the EV samples. Nonetheless, EV samples con-
tained some LMs (RvD3, MaR1, n-3-DPA, and RvE3) that were not
detected in PlaCs (Supplementary Tables 1 and 2). The amount of the
AA-derived TxB2 and PGD2 remained stable in the EV samples during
storage, but the dual-function LM, PGE2 and the AA-derived mono-
hydroxy pathway marker 12-HETE showed statistically signiﬁcant,
Fig. 4. Variation in the relative abundance of phosphatidylserine (PS) species in the platelet concentrates, platelets, and extracellular vesicles on day (d)1, d2, d5, and
d8. Columns represent median and bars interquartile range. n = 5; **p≤ 0.01, *p≤ 0.05 using Friedman's test with Dunn's multiple comparisons test.
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time-dependent accumulation during storage (p= 0.0044 on d8 for
both). From SPMs, 17R-RvD1 was the only LM detected with statisti-
cally signiﬁcant (p= 0.0066) accumulation during storage along with
the several monohydroxy pathway markers, such as EPA-derived 18-
HEPE, n-3 DPA-derived 14-HDPA, and DHA-derived 14-HDHA and 17-
HDHA (Fig. 8, Supplementary Table 2).
4. Discussion
Currently, diﬀerent molecular indicators are employed in the de-
termination of platelet activation [35]. Since EVs are produced as a
result of cell activation [60], they have also been suggested to serve as a
measure of platelet activation [36,37,61]. Presently, it is demanding to
create EV particle number-based quality criteria for platelets because
the EV quantiﬁcation methods are still not accurate or reproducible
enough and they lack standardization [62–64]. Furthermore, a low
number of EVs is thought to be constitutively formed by platelets
during storage [32,33], as also shown by our results. Therefore, for
developing improved EV-based indicators of platelet activation, the
composition, rather than the quantity of EVs deserves further in-
vestigation. As demonstrated by our group and others, the platelet EV
protein composition is platelet condition-dependent [33,65]. Therefore,
the acquisition of compositional data may also help elucidate the role of
platelet EVs in intercellular communication i.e., immunomodulation
and the underlying molecular mechanisms.
From the perspective of EVs, their fundamental property is the
surrounding membrane bilayer derived from the membranes of the
parent cell. The time-dependent alterations in the GPL composition of
clinical-grade PlaCs, their platelets, and EVs have been studied pre-
viously [10,11], and our lipidome data of platelets and EVs are com-
parable to these results: a clear diﬀerence in the relative GPL proﬁles
between the platelets and EV samples during the ﬁrst 2 days of storage
was observed. Later, at d5 and d8, however, the lipidomes of platelets
and EV samples resembled each other in many aspects. An important
and consistent ﬁnding in our study was the relative increase in the AA-
containing species 38:4 found especially in PE, PEp, and PS from the
PlaC, platelet and EV samples. However, based on the fatty acid ana-
lysis of PlaCs, only minor relative changes in the total fatty acid pool
were observed. For example, a slight decrease in the relative amount of
AA was observed during storage. In platelets and EV samples, the re-
lative amount of highly unsaturated GPL species (such as 38:6, 38:7,
40:6, 40:7, which have DHA as their main PUFA component) remained
constant during PlaC storage. Cell membranes are subject of a constant
compositional modiﬁcation as several factors inﬂuence GPL composi-
tion, which is consequently transferred to the EVs produced from the
membranes of those cells. Factors contributing speciﬁcally to the PC
proﬁles include de novo Kennedy and remodelling Lands pathways
which both incorporate fatty acids into cell membranes [66]. It has
been suggested that the Lands pathway impacts the natural GPL proﬁle
especially by incorporating free AA, which as high concentrations
promotes apoptosis [67], into the cell membrane GPLs. Notable con-
tributors to the PC proﬁle are also the exchange of plasma phospholi-
pids with platelets [68] and the presence of lipoproteins in the samples,
which was proven by Western blot. Thus, some of the changes in the
Fig. 5. Visualization of principal component analysis of phospholipid composition in the platelet concentrates, platelets, and extracellular vesicles. All quantiﬁed
phospholipid species were used as loadings. Samples were assigned codes consisting of the sample type (PlaC/Platelets/EV), platelet concentrate number (1–5), and
the sampling day (d1, d2, d5, or d8); shaded areas represent 95% conﬁdence intervals.
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Fig. 7. Lipid mediators and pathway markers accumulate in the platelet concentrates during storage. Samples were collected on day (d)1, d2, d5, and d8 post the
preparation of the concentrates. Results are expressed as pg/2.0 × 108 platelets; n = 5 per group. ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05 vs. day 1 using Friedman's
test with Dunn's multiple comparisons test. HDHA, hydroxydocosahexaenoic acid; HETE, hydroxyeicosatetraenoic acid; LX, lipoxin; PG, prostaglandin; Rv, resolvin;
Tx, thromboxane.
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relative proﬁle of PC species of the PlaCs and EV samples are likely due
to lipoproteins, which are known to be rich in PC, especially PC 34:2,
34:1, 36:2, and 36:4, together contributing to 66% of the total PC
species [69]. As the particle number in the EV samples was small during
the ﬁrst days, the contribution of lipoproteins in the relative PC proﬁle
should not be underestimated. However, since lipoproteins carry very
little PE, PEp, and PS, the time-dependent elevation of 38:4 in those
lipid classes in the PlaC and EVs are ﬁrm ﬁndings of changes in the EV
lipidome. Importantly, the d1-2 EV samples contained elevated levels of
relatively short and highly unsaturated PE, PEp, and PS species, the
kind of GPL species known to have high eﬄux propensity [70], which
likely promotes their exit from the plasma membranes with EVs bud-
ding at early timepoints. Consequently, the relative amount of GPL
species with high eﬄux propensity decreased in the later EV samples, as
they had been consumed already. Other possible factors having an
impact on the GPL proﬁle include the loss of lipid bilayer asymmetry
[40], lipid peroxidation [42], or an altered rate of EV formation [12].
When we assessed the molecular mechanisms of LM production, a
large repertoire of enzymes involved in the biosynthesis of LMs from
the cleavage of acyl chains from GPLs (e.g., sPLA2, cPLA2) into the
oxygenation of free fatty acids (12-LOX, 15-LOX) was identiﬁed in all
the samples examined (PlaC, platelet, EV samples). Previously, the
presence of several key enzymes has been reported in platelets [71–77],
and the enzyme activity of 15-LOX has been demonstrated in neutrophil
EVs [78]. It is important to highlight the presence of these enzymes
related to LM biosynthesis in the PlaC-derived EVs, since these results
indicate that EVs contain the enzymatic machinery required for LM
production. The analysis of monohydroxy pathway marker chirality
proved that pathway markers of PlaC are speciﬁc products of enzymatic
modiﬁcation rather than a result of auto-oxidation, because enzymes
have a clear tendency to produce molecules with a speciﬁc conﬁgura-
tion. For instance, the observed production of various LMs with the R
Fig. 8. Lipid mediators and monohydroxy pathway markers accumulate in the extracellular vesicles of platelet concentrate during storage. Samples were collected on
day (d)1, d2, d5, and d8 post the preparation of platelet products. Results are expressed as pg/2.0 × 108 platelets; n = 5 per group. ***p≤ 0.001, **p≤ 0.01,
*p≤ 0.05 vs. day 1 using Friedman's test with Dunn's multiple comparisons test. HDHA, hydroxydocosahexaenoic acid; HDPA, hydroxydocosapentaenoic acid;
HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; PG, prostaglandin; Rv, resolvin.
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conﬁguration, such as 17R-RvD1 and 15-epi-LXA4, was consistent with
the expression of CYP enzymes in the EV samples (isoforms CYP1A1
and CYP2J2), which insert a hydroxyl group mainly into the R position
[79]. Overall, knowledge on the roles of the diﬀerent CYP isoforms in
the biosynthesis of SPMs is lacking; hence, the relationships between
the CYP isoforms and the produced SPMs are unclear [75]. Further-
more, COX1 and COX2 enzymes were present in both PlaC and EV
samples. A recent study demonstrated endogenous acetylation me-
chanism for COX2 that increases 15-epi-LXA4 formation [80] and may
have played a role in the biosynthesis of this SPM with the R conﬁg-
uration described in our study. Additionally, sPLA2 and cPLA2, which
are required for the remodelling of the GPL membrane, were found
from both PlaC and EV samples. The PLA2 enzymes may also free es-
teriﬁed monohydroxy fatty acids from the GPL membrane enabling
quick downstream synthesis of LM synthesis [81]. In all, these results
indicate that the detected enzymes can be active and contribute to the
composition of the lipid cargo of PlaC EVs. It is important to ac-
knowledge that, to some extent, LMs might also be produced in cells via
active enzymatic hydroxylation and delivered into EVs. Although en-
zyme activity was not measured directly, the chirality analysis of the
monohydroxy pathway markers indicates that PlaCs contain active
enzyme machinery.
Although there are previous reports on the GPL composition of
platelets during storage, no systematic studies exist regarding the mo-
lecular mechanisms of LM production or LMs themselves in ageing
platelets. In this study, we investigated the LM proﬁles of PlaCs and EV
samples and we observed a clear, time-dependent increase in the
monohydroxy pathway markers, proinﬂammatory LMs, and most im-
portantly, SPMs. Overall, the eﬀects of proinﬂammatory LMs on platelet
function have been investigated more than the role of SPMs, possibly
due to larger amounts of these mediators. Until now, only mono-
hydroxy pathway markers, but not their bioactive downstream pro-
ducts, SPMs, have been identiﬁed from EVs derived from inﬂammatory
exudates [82]. This might be due to the low amounts of SPMs present in
EVs, which was also observed in this study: in contrast to PlaCs, EV
samples mainly contained monohydroxy pathway markers and enzymes
required for the biosynthesis of LMs as cargo and only minor amounts
of bioactive LMs.
The activation of platelets has been reported to induce the pro-
duction of TxA2 [83], and we also observed a drastic accumulation of
TxB2, the inactive metabolite of bioactive TxA2, with a half-life of 30 s.
Although the accumulation of inactive TxB2 in the PlaCs may bear no
immunological relevance upon transfusion from a clinical perspective,
it remains a measurable indicator of TxA2 and platelet activation [84].
One interesting ﬁnding related to the heterogenic cell interactions and
the contribution of an ample AA source for TxA2, active COX1 or the
activation of inducible COX2 is in cancer, where aspirin-mediated in-
hibition of platelet COX1 is beneﬁcial for patients [85]. As expected, in
addition to TxB2, the amount of other AA metabolites, both mono-
hydroxy pathway markers and LMs, was greatly increased as a function
of time. Although PGD2 and PGE2 have reportedly opposite eﬀects on
platelet aggregation [15], the increased amount of AA metabolite
content of the PlaC and EV samples overall indicates the potential to
push the state of surrounding cells towards a more inﬂammatory phe-
notype. In addition to the increased levels of proinﬂammatory LMs, we
found that the levels of several SPMs increased during storage, espe-
cially 17R-RvD1, which accumulated in both PlaCs and EV samples.
Based on our ﬁndings, alterations in the GPL and fatty acid proﬁles
are not directly translated to LM precursor proﬁles: even though the
relative amount of AA and dihomo-γ-linoleic acid remained stable and
were three times more abundant than n-3 PUFAs EPA, DPA, and DHA,
such a diﬀerence was undetected with the downstream molecules, such
as 12-LOX products. This may be partially explained by the enzyme
activity and preference towards diﬀerent PUFAs, which have been
shown with COX [86,87], but is likely to be applicable to other enzymes
as well. On the other hand, relative changes in the species proﬁles of
diﬀerent GPL classes are observed, which might make certain PUFAs
more available for enzymatic processing, as enzymes have substrate
preference also for certain the GPL molecular species [70,88]. Even
when these aspects are accounted for, the relationship between GPL and
LM proﬁles is non-arithmetic, which can be especially seen in the EVs:
as the particle number in the EV samples increased approximately 3-
fold from d1 to d8 and the relative PUFA composition of GPL species
remained virtually unchanged, enhanced enzymatic activity would be
required to produce the observed eﬀect, even 30-fold increase in
monohydroxy pathway markers. However, the LM analysis was limited
by the amount of material available and the limits of sensitivity of the
equipment; therefore, the results should be interpreted cautiously. Al-
though we discovered some LMs unique to EV samples indicating that
enzymatic processing took place in EVs, there is a need for direct stu-
dies addressing whether EVs actively produce monohydroxy pathway
markers and LMs or whether they are speciﬁcally packaged into EVs for
transportation.
Taken together, our ﬁndings indicate that PlaCs and EVs have the
potential to moderate the inﬂammatory status of surrounding cells to-
wards a proinﬂammatory or resolving direction. Our current results
imply that at diﬀerent phases of inﬂammation, the monohydroxy
compounds of EVs may reinforce the impact of platelet LM deposits
[13,18,19], as EVs in circulation contain monohydroxy compounds and
the enzymatic machinery required to convert them to bioactive LMs. In
addition, monohydroxy chains could be esteriﬁed into membrane GPLs
to promote fast LM biosynthesis [81,89]. Considering that SPMs are
bioactive at pico to nanomolar concentrations [47], EVs could be re-
garded as ﬁrst aid kits [90]; when required, the enzymes present in EVs
could convert monohydroxy fatty acids to functional SPMs to rapidly
inﬂuence the surrounding cells e.g., platelets [17], macrophages [91],
neutrophils [92], and endothelial cells [93]. Further studies are re-
quired to elucidate whether the detected enzymes are active in platelet
EVs and how the residual leukocytes and their EVs in PlaCs contribute
to LM production. Additionally, the detailed signalling that activates
the enzymatic conversion of monohydroxy pathway markers to bioac-
tive LMs and the enzymatic preferences to diﬀerent PUFAs remain to be
determined. LMs have previously been shown to play a pivotal role in
the interaction of platelets with immune cells, particularly neutrophils,
or their EVs [76,94–99], underlining the importance of studying LMs
and SPMs.
Circulating platelets in the human body are constantly replenished,
meaning that at any given time only a fraction of the platelet popula-
tion is comprised of aged platelets, which may also contribute to the
total EV population in plasma. Thus, the EVs in stored PlaCs, which are
more coeval, cannot be compared directly to the platelets and EVs in
plasma. As PlaCs are sealed products, nothing is added or removed from
them after preparation. Platelets, whether alive or dysfunctional, stay in
the PlaCs, whereas dysfunctional and ageing platelets are removed from
the circulation. Moreover, lipoproteins and other cell types, such as
leukocytes, remain in the PlaC product throughout storage. The de-
tection of enzymes involved in LM production was conducted using
highly speciﬁc antibodies, and in addition to known platelet enzymes,
we detected enzymes that are typically not associated with platelets
(COX2 and 15-LOX1) but rather with leukocytes. Another indication of
leukocyte contamination was the detection of PDX [100]. To what ex-
tent other residual cells, e.g., leukocytes and their EVs, contribute to the
detected enzymes, and furthermore, enzymatic activity, remains un-
known. Additionally, the instructions for blood donors dictate that as-
pirin should not be consumed, but we cannot exclude the possibility of
aspirin intake. Thus, it is possible that COX acetylated by aspirin to-
gether with residual leukocytes and their EVs may have contributed to
the biosynthesis of SPMs with the R conﬁguration [6]. All these factors
contribute to the lipidome; therefore, the results are not directly com-
parable to the lipidome of pure platelet population or platelet EVs, but
rather represent the lipidome of clinical-grade PlaC transfused to pa-
tients.
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Considering the time-dependent compositional changes from the
perspective of clinical transfusions, the d5 PlaCs were fairly similar
with the d1 PlaCs in terms of their EV content, GPL composition, and
LM proﬁle. Major compositional changes were observed only after
8 days of storage, with signiﬁcantly increased EV content, a large var-
iation in GPL content, and signiﬁcant accumulation of LMs to both
PlaCs and EVs. These observations indicate that clinical PlaCs remain
stable for the duration of the current storage time of up to d5 from the
perspective of the metabolipidome.
In conclusion, this study examined the biosynthesis pathway of LMs
covering the membrane GPL precursor, enzymes, and bioactive end
products in clinical-grade PlaCs and, more interestingly, in PlaC EVs.
We demonstrated storage time-dependent variation in the relative
abundance of GPL species, the sources of precursor PUFAs utilized in
LM synthesis. Furthermore, we conﬁrmed the presence and activity of
the enzymatic machinery required for the biosynthesis of LMs, and ﬁ-
nally, we identiﬁed and quantiﬁed the bioactive metabolomes derived
from AA, EPA, n-3 DPA, and DHA in whole PlaC and EV samples that
have not been described previously. In addition to shedding light on the
mechanisms of the intercellular signalling, the current study adds an-
other level of complexity to platelet-mediated interactions, as we de-
monstrated that platelet age contributes to the composition of EVs. The
detection of monohydroxy pathway markers and proresolving LMs in
platelets and EVs, especially the detection of LMs unique to EVs, is of
great importance and suggests that EVs may strengthen platelet-medi-
ated cell communication with immune cells. The data given here prove
that PlaC-derived EVs possess the machinery to mediate powerful lipid-
dependent functions in inﬂammation. Platelet function in diﬀerent
phases of inﬂammation and healing requires further studies, including
how platelets employ the lipid machinery via EVs, and to which cells/
LM receptors platelet-derived EV-borne LMs are ultimately targeted.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbalip.2019.03.011.
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IV
The original questionnaire sent to groups working with EVs (Study I)

1. Are you currently using reference materials in your MV studies? 
 
[  ] Yes (choose one: synthetic/biological/both) 
[  ] No 
 
2. I am interested to use biological reference materials with 
 
[  ] Atomic Force Microscopy 
[  ] Dynamic Light Scattering / Nanoparticle Tracking Analysis 
[  ] Electron Microscopy 
[  ] Flow Cytometry 
[  ] Functional assays 
[  ] Omics 
[  ] PCR-based techniques 
[  ] Resistive Pulse Sensing 
[  ] Western blot 
 
3. Mark the minimum required biochemical resemblance to MVs 
 
[  ] Phospholipid membrane 
[  ] Phospholipid membrane + proteins 
[  ] Phospholipid membrane + proteins + genomic material 
 
4. Which properties of reference material are most important to you (please 
rank 1-6, the most important is 6) 
 
[  ] Biochemical composition 
[  ] Monodispersity (size distribution) 
[  ] Price 
[  ] Refractive index 
[  ] Safety 
[  ] Stability 
[  ] Other: _________________________________________ 
 
5. Would you use a plant virus or marine bacteria as a reference material? 
 
[  ] Yes 
[  ] No, because ____________ 
 
6. General comments and suggestions regarding the biological reference 
materials: 
 
ACADEMIC DISSERTATIONS FROM THE 
FINNISH RED CROSS BLOOD SERVICE 
 
 
1. Nevanlinna, H.R. Factors affecting maternal Rh immunisation. Helsinki 
1953 
 
2. Ikkala, Eero. Haemophilia. A study of its laboratory, clinical, genetic 
and social aspects based on known haemophiliacs in Finland. Helsinki 1960. 
 
3. Vuopio, Pekka. Red Cell enzymes in anemia. Helsinki 1963. 
 
4. Pyörälä, Kalevi. Determinants of the clotting factor response to 
warfarin in the rat. Helsinki 1965. 
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